{"trajectories": [{"actions": ["In vitro enzyme inhibition assay", "Pharmacokinetics profiling", "Bioavailability study", "Etoricoxib", {"predicted_truth": "Etoricoxib"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay is a good starting point because it can rule out Simvastatin and Sildenafil based on the specific outcomes provided. This will help narrow down the list of potential compounds more quickly.", "<ANSWER> Pharmacokinetics profiling </ANSWER>\n\nReason: The in vitro enzyme inhibition assay result of 2257.71206470011 indicates that the compound is not Simvastatin or Sildenafil. Since the solubility test does not provide direct information about the half-life, we can move on to pharmacokinetics profiling to check the half-life and rule out Furosemide. This will help us narrow down the list further.", "<ANSWER> Bioavailability study </ANSWER>\n\nReason: The pharmacokinetics profiling revealed a short half-life, which rules out Furosemide. Next, we should perform a bioavailability study to check the bioavailability range and further narrow down the list. Since the bioavailability range is specific (80, 100), it can help us rule out Simvastatin.", "<ANSWER> Etoricoxib </ANSWER>\n\nReason: The bioavailability study result of 81.89661526953712 falls within the range of 80 to 100, which rules out Simvastatin. This leaves us with Sildenafil, Furosemide, and Etoricoxib. Since we have already ruled out Simvastatin and Furosemide, the only remaining compound is Etoricoxib."], "consumed_tokens": 5391, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 2257.71206470011}, {"action": "Pharmacokinetics profiling", "observation": "Short half-life"}, {"action": "Bioavailability study", "observation": 81.89661526953712}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Furosemide", {"predicted_truth": "Furosemide"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: Starting with the in vitro enzyme inhibition assay can help us quickly rule out Simvastatin and Sildenafil. If the compound shows high activity in this assay, we can eliminate Simvastatin and Sildenafil as they are known to have specific enzyme inhibition properties. This will narrow down our options and make it easier to identify the correct compound in subsequent steps.", "Reasoning: The observation from the in vitro enzyme inhibition assay is 2257.71206470011, which is within the range of 1000 to 10000. This indicates that the compound has significant enzyme inhibition activity, which rules out Simvastatin and Sildenafil. Therefore, the remaining compounds are Furosemide and Etoricoxib.\n\n<ANSWER> Furosemide </ANSWER>"], "consumed_tokens": 2486, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 2257.71206470011}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Pharmacokinetics profiling", "Furosemide", {"predicted_truth": "Furosemide"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER> \n\nReason: The in vitro enzyme inhibition assay can help rule out Simvastatin and Sildenafil based on specific outcome ranges. Since we have no prior information about the compounds, this assay provides a good starting point to eliminate two compounds from the list.", "<ANSWER> Pharmacokinetics profiling </ANSWER>\n\nReason: The in vitro enzyme inhibition assay result of 2257.71206470011 is within the range that rules out Simvastatin and Sildenafil. Next, we can use the pharmacokinetics profiling to further narrow down the possibilities, as it provides information about the half-life of the compounds. Since both Furosemide and Etoricoxib are still in the running, this test will help us eliminate one of them.", "<ANSWER> Furosemide </ANSWER>\n\nReason: The pharmacokinetics profiling showed a short half-life, which rules out Furosemide. This leaves us with only one compound, Etoricoxib, as the remaining possibility."], "consumed_tokens": 3842, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 2257.71206470011}, {"action": "Pharmacokinetics profiling", "observation": "Short half-life"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Simvastatin", {"predicted_truth": "Simvastatin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay is a good starting point because it can quickly rule out compounds that do not inhibit the specific enzyme being tested. Simvastatin is known to inhibit HMG-CoA reductase, so if this assay shows high activity, Simvastatin can be considered a potential candidate. Conversely, if the activity is low, we can rule out Simvastatin and focus on the other compounds. This assay can provide immediate insights and help narrow down the list of potential compounds.", "<ANSWER> Simvastatin </ANSWER>\n\nReason: The observation from the in vitro enzyme inhibition assay is 2257.71206470011, which is within the range of 1000 to 10000. This indicates that the compound being tested is an inhibitor of the enzyme in question, which aligns with Simvastatin's known mechanism of action as an HMG-CoA reductase inhibitor. Therefore, we can confidently rule out Sildenafil, Furosemide, and Etoricoxib, leaving Simvastatin as the plausible compound."], "consumed_tokens": 2578, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 2257.71206470011}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Pharmacokinetics profiling", "Bioavailability study", "Etoricoxib", {"predicted_truth": "Etoricoxib"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay can help rule out Simvastatin and Sildenafil based on the specific outcome ranges provided. This assay is a good starting point to eliminate compounds that do not match the observed results.", "<ANSWER> Pharmacokinetics profiling </ANSWER>\n\nReason: The In vitro enzyme inhibition assay outcome of 2257.71206470011 is within the range for Simvastatin and Sildenafil to be ruled out. Since Simvastatin and Sildenafil are no longer in contention, the next best step is to use Pharmacokinetics profiling to rule out Furosemide based on its short half-life.", "<ANSWER> Bioavailability study </ANSWER>\n\nReason: Since Furosemide is ruled out due to its short half-life, the remaining compound is Etoricoxib. The next step is to confirm this by checking its bioavailability. The Bioavailability study outcome should be in the range of (80, 100) for Etoricoxib to be the correct compound.", "<ANSWER> Etoricoxib </ANSWER>\n\nReason: The Bioavailability study outcome of 81.89661526953712 is within the range of (80, 100), confirming that Etoricoxib is the correct compound."], "consumed_tokens": 5335, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 2257.71206470011}, {"action": "Pharmacokinetics profiling", "observation": "Short half-life"}, {"action": "Bioavailability study", "observation": 81.89661526953712}], "successful": true, "parse_error": false}], "seed": 0, "average_actions": 4.0, "average_tokens": 3926.4, "average_correct": 0.4, "average_parse_error": 0.0, "average_successful_action_num": 5.0, "average_successful_tokens": 5363.0}
{"trajectories": [{"actions": ["Cytokine release assay", "Therapeutic index calculation", "Bioavailability study", "Cell viability assay", "Human clinical trial Phase I", "Ibuprofen", {"predicted_truth": "Ibuprofen"}], "generated_text": ["<ANSWER> Cytokine release assay </ANSWER>\n\nLet's start by performing a Cytokine release assay. Given the guidebook, we know that Codeine is ruled out when there is high cytokine release. This assay will help us eliminate one of the compounds early in the process.", "<ANSWER> Therapeutic index calculation </ANSWER>\n\nBased on the observation of high cytokine release in the Cytokine release assay, Codeine can be ruled out. Now, we need to further narrow down the remaining compounds. Next, let's perform the Therapeutic index calculation. Ibuprofen is ruled out when the therapeutic index falls within the range of 100-1000, so we will use this trial to further eliminate one of the compounds.", "<ANSWER> Bioavailability study </ANSWER>\n\nGiven the therapeutic index of 539.0709908717329, Ibuprofen can be ruled out. Now, we are left with Fluoxetine and Atorvastatin. The next step is to perform a Bioavailability study. Atorvastatin is excluded in scenarios where high bioavailability (80-100%) is not desirable. Thus, we will perform a Bioavailability study to further narrow down the possibilities.", "<ANSWER> Cell viability assay </ANSWER>\n\nGiven the bioavailability of 97.8663408511527, Atorvastatin can be ruled out. We are left with Fluoxetine. To confirm, we can perform a Cell viability assay. However, since Fluoxetine typically has minimal cytotoxic effects, we expect a result that does not impact cell viability significantly. If there were any concerns, we could proceed with a Human clinical trial Phase I as a final check. But based on the current observations, Fluoxetine is the most likely remaining compound. \n\nLet's proceed with the Cell viability assay to double-check.\n\n<ANSWER> Cell viability assay </ANSWER>", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nGiven the previous observations, we have narrowed down the possibilities to Fluoxetine. To confirm, we can conduct a Human clinical trial Phase I. This trial will help us verify the safety and initial efficacy of Fluoxetine in humans. \n\n<ANSWER> Human clinical trial Phase I </ANSWER>", "<ANSWER> Ibuprofen </ANSWER>\n\nGiven the severe adverse effects observed in the Human clinical trial Phase I, Ibuprofen is the most likely remaining compound. Fluoxetine would not typically produce severe adverse effects in Phase I trials. Therefore, the correct compound is Ibuprofen."], "consumed_tokens": 9359, "observations": [null, {"action": "Cytokine release assay", "observation": "High cytokine release"}, {"action": "Therapeutic index calculation", "observation": 539.0709908717329}, {"action": "Bioavailability study", "observation": 97.8663408511527}, {"action": "Cell viability assay", "observation": 69.4904403510567}, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": false, "parse_error": false}, {"actions": ["Cytokine release assay", null], "generated_text": ["<ANSWER> Cytokine release assay </ANSWER>\n\nReason: Since Codeine has a high likelihood of inducing cytokine release, performing a Cytokine release assay will help us rule out Codeine if the outcome shows high cytokine release. This is a strategic choice to quickly eliminate one of the potential compounds based on the known characteristics of Codeine.", "<ANSWER> Therausic index calculation </ANSWER>\n\nReason: Since the Cytokine release assay ruled out Codeine due to high cytokine release, we can now focus on eliminating other compounds. The Therapeutic index calculation can help us rule out Ibuprofen, as it typically has a high therapeutic index. This will help narrow down our options more quickly."], "consumed_tokens": 2517, "observations": [null, {"action": "Cytokine release assay", "observation": "High cytokine release"}], "successful": false, "parse_error": true}, {"actions": ["Cytokine release assay", "Cell viability assay", "Therapeutic index calculation", "Bioavailability study", "Cytokine release assay", "Codeine", {"predicted_truth": "Codeine"}], "generated_text": ["<ANSWER> Cytokine release assay </ANSWER>\n\nReason: The Cytokine release assay is the first action to take because it provides a clear outcome that can help us quickly eliminate one of the pharmaceutical compounds. Specifically, if high cytokine release is observed, Codeine can be ruled out, as mentioned in the guidebook. This will help narrow down the possibilities more efficiently.", "<ANSWER> Ibuprofen </ANSWER>\n\nReason: Given the observation of high cytokine release, we can rule out Codeine. Now we need to decide on the next step. The Therapeutic index calculation and Lipophilicity measurement (LogP) do not have immediate outcomes based on the current observation, and the Bioavailability study and Human clinical trial Phase I are more definitive but may not immediately eliminate another compound. However, the Cell viability assay can help us rule out Atorvastatin, as it has specific cytotoxicity outcomes mentioned in the guidebook. Since Ibuprofen is not directly affected by high cytokine release, it remains a strong candidate. Let's proceed with the Cell viability assay to further narrow down the possibilities.\n\n<ANSWER> Cell viability assay </ANSWER>", "<ANSWER> Therapeutic index calculation </ANSWER>\n\nReason: The observation from the Cell viability assay shows that the cell viability is 69.49%, which is within the 0-50% range that would rule out Atorvastatin. Therefore, Atorvastatin can be eliminated. Next, we should perform the Therapeutic index calculation to further narrow down the possibilities. The observed cell viability is 69.49%, which is not severe enough to rule out any of the remaining compounds (Fluoxetine, Ibuprofen, or Codeine) based on the guidebook, so we choose a different method to proceed.", "<ANSWER> Bioavailability study </ANSWER>\n\nReason: The therapeutic index calculation gave us a value of 539.07, which is within the 100-1000 range. This eliminates Ibuprofen, leaving us with Fluoxetine and Codeine. The next logical step is to perform the Bioavailability study. Since Atorvastatin was already eliminated and Ibuprofen as well, the Bioavailability study will help us differentiate between Fluoxetine and Codeine. The Bioavailability study criteria for Atorvastatin falling outside the 80-100% range is not applicable here, leaving us to consider the remaining compounds.", "<ANSWER> Cytokine release assay </ANSWER>\n\nReason: The Bioavailability study showed that the bioavailability of the compound is 97.87%, which is within the acceptable range of 80-100%. This eliminates Atorvastatin, leaving us with Fluoxetine and Codeine. Next, we perform the Cytokine release assay. Since high cytokine release would rule out Codeine, and we have no other outcomes that directly affect Fluoxetine, this step will help us confirm the correct compound.", "<ANSWER> Codeine </ANSWER>\n\nReason: The observation from the Cytokine release assay shows high cytokine release. According to the guidebook, high cytokine release rules out Codeine. Since all other compounds have been eliminated through previous steps, the remaining compound must be Fluoxetine."], "consumed_tokens": 9950, "observations": [null, {"action": "Cytokine release assay", "observation": "High cytokine release"}, {"action": "Cell viability assay", "observation": 69.4904403510567}, {"action": "Therapeutic index calculation", "observation": 539.0709908717329}, {"action": "Bioavailability study", "observation": 97.8663408511527}, {"action": "Cytokine release assay", "observation": "High cytokine release"}], "successful": false, "parse_error": false}, {"actions": ["Cytokine release assay", "Codeine", {"predicted_truth": "Codeine"}], "generated_text": ["<ANSWER> Cytokine release assay </ANSWER>", "<ANSWER> Codeine </ANSWER> \n\nThe 'Cytokine release assay' observed 'High cytokine release', which leads to the elimination of Codeine since it is ruled out when high cytokine release is observed. We are left with 'Fluoxetine', 'Ibuprofen', and 'Atorvastatin'."], "consumed_tokens": 2389, "observations": [null, {"action": "Cytokine release assay", "observation": "High cytokine release"}], "successful": false, "parse_error": false}, {"actions": ["Cytokine release assay", "Therapeutic index calculation", "Bioavailability study", "Cell viability assay", "Human clinical trial Phase I", "Codeine", {"predicted_truth": "Codeine"}], "generated_text": ["<ANSWER> Cytokine release assay </ANSWER>\n\nReason: Since Codeine is ruled out if there is high cytokine release, performing a Cytokine release assay will help us determine if Codeine is the likely candidate. If the assay shows high cytokine release, we can confidently rule out Codeine and narrow down the possibilities. If not, we can then consider the other compounds.", "<ANSWER> Therapeutic index calculation </ANSWER>\n\nReason: Since the Cytokine release assay indicates high cytokine release, we can rule out Codeine. Next, we can perform the Therapeutic index calculation to further narrow down the possibilities. Ibuprofen is ruled out if the therapeutic index falls within the range of 100-1000. Flueoxetine and Atorvastatin will then be our remaining options.", "<ANSWER> Bioavailability study </ANSWER>\n\nReason: The therapeutic index of 539.0709908717329 falls within the range of 100-1000, so Ibuprofen can be ruled out. This leaves us with Fluoxetine and Atorvastatin. Since the bioavailability of Atorvastatin is not desirable when it is 80-100%, performing a Bioavailability study will help us rule out Atorvastatin and identify Fluoxetine as the remaining option.", "<ANSWER> Cell viability assay </ANSWER>\n\nReason: The bioavailability study indicates that Atorvastatin is 97.8663408511527%, which is within the desirable range. Therefore, Atorvastatin is the remaining option. However, to be certain, we can perform a Cell viability assay to ensure that it does not have any cytotoxic effects. Since the other compounds have been ruled out, performing this assay will help confirm that Atorvastatin is the correct compound.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Since the Cell viability assay shows 69.4904403510567% cell viability, which is within a range that does not rule out Atorvastatin, the only remaining option is to perform a Human clinical trial Phase I to confirm that Atorvastatin is the correct compound. This final step will provide direct evidence of its safety and efficacy in humans.", "<ANSWER> Codeine </ANSWER>\n\nReason: The observation from the Human clinical trial Phase I indicates 'Severe adverse effects', which rules out Atorvastatin. Since the other compounds (Fluoxetine, Ibuprofen, and Codeine) have been previously ruled out through various trials, the only remaining option is Codeine. However, the severe adverse effects observed in the Phase I trial strongly suggest that Codeine is not the correct compound. Given the options and the process of elimination, the correct compound must be Atorvastatin."], "consumed_tokens": 9496, "observations": [null, {"action": "Cytokine release assay", "observation": "High cytokine release"}, {"action": "Therapeutic index calculation", "observation": 539.0709908717329}, {"action": "Bioavailability study", "observation": 97.8663408511527}, {"action": "Cell viability assay", "observation": 69.4904403510567}, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": false, "parse_error": false}], "seed": 1, "average_actions": 5.2, "average_tokens": 6742.2, "average_correct": 0.0, "average_parse_error": 0.2, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["hERG channel inhibition assay", "Cetirizine", {"predicted_truth": "Cetirizine"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>", "The observation from the hERG channel inhibition assay is 99.98593979726346, which falls into the activity range of 50-100. According to the guidebook, a compound with this level of activity would rule out Cetirizine.\n\n<ANSWER> Cetirizine </ANSWER>"], "consumed_tokens": 2545, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 99.98593979726346}], "successful": false, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "Ames mutagenicity test", "Sodium lauryl sulfate", {"predicted_truth": "Sodium lauryl sulfate"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nThe hERG channel inhibition assay result shows a high level of activity, specifically 99.98593979726346. Based on the guidebook, this level of activity would rule out Cetirizine. Therefore, we can confidently eliminate Cetirizine from our list of potential compounds. The next logical step is to perform the Ames mutagenicity test to further narrow down the possibilities.", "<ANSWER> Sodium lauryl sulfate </ANSWER>\n\nThe Ames mutagenicity test resulted in a negative outcome. Based on the guidebook, a negative result in the Ames test rules out Azithromycin. Given the list of possible compounds and the compounds we have ruled out, the remaining options are Tadalafil and Sodium lauryl sulfate. Since Sodium lauryl sulfate is known to be a surfactant and not a medication like Tadalafil, it is the more likely candidate to be ruled out by the negative Ames test result. Therefore, the remaining plausible compound is Tadalafil."], "consumed_tokens": 4088, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 99.98593979726346}, {"action": "Ames mutagenicity test", "observation": "Negative"}], "successful": true, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "Ames mutagenicity test", "Sodium lauryl sulfate", {"predicted_truth": "Sodium lauryl sulfate"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nThe hERG channel inhibition assay showed a very high activity, which ruled out Cetirizine. Given that, the next logical step is to perform the Ames mutagenicity test to further narrow down the possibilities. If the test shows a negative result, Azithromycin will be ruled out.", "<ANSWER> Sodium lauryl sulfate </ANSWER>\n\nGiven that the Ames mutagenicity test was negative, Azithromycin is ruled out. The remaining compounds are Tadalafil, Cetirizine, and Sodium lauryl sulfate. Since Sodium lauryl sulfate is known to be a surfactant and is not typically used for its efficacy in the body but rather for its cleansing properties, it is the most likely candidate to be ruled out next. We can confirm this by performing the Off-target activity screening, but based on the available information, Sodium lauryl sulfate is the most plausible remaining compound to rule out."], "consumed_tokens": 4037, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 99.98593979726346}, {"action": "Ames mutagenicity test", "observation": "Negative"}], "successful": true, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "Ames mutagenicity test", "Off-target activity screening", "Sodium lauryl sulfate", {"predicted_truth": "Sodium lauryl sulfate"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nThe hERG channel inhibition assay showed a high activity level, indicating that the compound likely blocks cardiac potassium channels. Based on the guidebook, compounds that show high activity in this assay are Cetirizine. Since we have confirmed that Cetirizine is the likely compound, we can now use the Ames mutagenicity test to further narrow down the possibilities. If the Ames test shows a negative result, Azithromycin can be ruled out.", "<ANSWER> Azithromycin </ANSWER>\n\nSince the Ames mutagenicity test showed a negative result, Azithromycin can be ruled out. This leaves us with three possible compounds: Tadalafil, Sodium lauryl sulfate, and Cetirizine. However, since Cetirizine was the compound that showed high activity in the hERG channel inhibition assay, it is no longer a possibility. This leaves us with Tadalafil and Sodium lauryl sulfate. To definitively identify the compound, we can perform the Off-target activity screening. \n\n<ANSWER> Off-target activity screening </ANSWER>", "<ANSWER> Sodium lauryl sulfate </ANSWER>\n\nGiven that the off-target activity screening showed high off-target activity, Tadalafil can be ruled out. This leaves us with Sodium lauryl sulfate as the only remaining possibility."], "consumed_tokens": 5712, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 99.98593979726346}, {"action": "Ames mutagenicity test", "observation": "Negative"}, {"action": "Off-target activity screening", "observation": "High off-target activity"}], "successful": true, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "Ames mutagenicity test", "Sodium lauryl sulfate", {"predicted_truth": "Sodium lauryl sulfate"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nThe observed high hERG channel inhibition assay result strongly suggests that the compound is blocking cardiac potassium channels. Given that Cetirizine is ruled out in the hERG channel inhibition assay if there is significant activity, we can confidently rule out Cetirizine. \n\nNow, we will move to the next assay to further narrow down the possibilities. The Ames mutagenicity test is a good choice as it can help rule out Azithromycin if it shows a negative result.", "<ANSWER> Sodium lauryl sulfate </ANSWER>\n\nThe Ames mutagenicity test returned a negative result, which rules out Azithromycin. Given that Cetirizine has already been ruled out due to the high hERG channel inhibition assay result, and Azithromycin is no longer a possibility, the only remaining compounds are Tadalafil and Sodium lauryl sulfate. \n\nSince Sodium lauryl sulfate is a surfactant and is more likely to show up as a result in an eye irritation test (assuming it is a topical substance), we can predict that Sodium lauryl sulfate is the correct compound. To confirm, we would typically perform the eye irritation test next, but based on the current information, Sodium lauryl sulfate is the most plausible remaining compound."], "consumed_tokens": 4145, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 99.98593979726346}, {"action": "Ames mutagenicity test", "observation": "Negative"}], "successful": true, "parse_error": false}], "seed": 2, "average_actions": 4.0, "average_tokens": 4105.4, "average_correct": 0.8, "average_parse_error": 0.0, "average_successful_action_num": 4.25, "average_successful_tokens": 4495.5}
{"trajectories": [{"actions": [null], "generated_text": ["ANSWER: Dose-response study </ANSWER>\n\nReason: Let's start with a Dose-response study to understand how different doses of each compound might influence the overall response. This will help us narrow down the list of potential compounds by eliminating those that do not show a specific type of response profile. For instance, a linear response would indicate that Interferon is not the compound, as it is not typically associated with a linear dose-response relationship in all settings."], "consumed_tokens": 1363, "observations": [null], "successful": false, "parse_error": true}, {"actions": ["Eye irritation test", "Formaldehyde", {"predicted_truth": "Formaldehyde"}], "generated_text": ["<ANSWER> Eye irritation test </ANSWER>\n\nReason: The eye irritation test evaluates the potential of substances to cause irritation in the eyes. Among the available compounds, Formaldehyde is known to be an irritant. By performing this test, we can determine if Formaldehyde is the compound that causes eye irritation, which would help us rule it out if the test is positive. This test does not provide direct information about the other compounds, making it a good starting point to systematically eliminate one of the options.", "<ANSWER> Formaldehyde </ANSWER>\n\nReason: Since the eye irritation test observed an irritant response, Formaldehyde can be ruled out as the compound responsible for eye irritation. This leaves us with the pharmaceutical compounds 'Interferon', 'Phenytoin', and 'Aspirin'. The next step is to use one of the clinical trials or bioassays to further narrow down the options."], "consumed_tokens": 2861, "observations": [null, {"action": "Eye irritation test", "observation": "Irritant"}], "successful": false, "parse_error": false}, {"actions": ["Eye irritation test", "Dose-response study", "Immunogenicity testing", "Aspirin", {"predicted_truth": "Aspirin"}], "generated_text": ["<ANSWER> Eye irritation test </ANSWER>\n\nReason: The Eye irritation test is a straightforward method to rule out compounds that are known irritants. Formaldehyde is known to be an irritant, so if the test shows an irritant response, we can confidently rule out Formaldehyde. This will help narrow down the list of potential compounds and bring us closer to identifying the correct one.", "<ANSWER> Formaldehyde </ANSWER>\n\nReason: Since the Eye irritation test showed an irritant response, we can rule out Formaldehyde. This leaves us with the following compounds: ['Interferon', 'Phenytoin', 'Aspirin']. \n\nNext, we can proceed with a Dose-response study to further narrow down the possibilities. \n\n<ANSWER> Dose-response study </ANSWER>", "<ANSWER> Phenytoin </ANSWER>\n\nReason: Given the linear response in the Dose-response study, we can rule out Phenytoin. Phenytoin typically does not have a linear dose-response relationship; its effects are more complex and often dose-dependent in a nonlinear manner. This leaves us with the following compounds: ['Interferon', 'Aspirin'].\n\nNext, we can perform Immunogenicity testing to further narrow down the possibilities.\n\n<ANSWER> Immunogenicity testing </ANSWER>", "<ANSWER> Interferon </ANSWER>\n\nReason: Since the Immunogenicity testing showed an immunogenic response, we can rule out Interferon. Interferons are known to be immunogenic, so a positive immunogenicity test eliminates Interferon. This leaves us with the final compound: Aspirin.\n\n<ANSWER> Aspirin </ANSWER>"], "consumed_tokens": 6152, "observations": [null, {"action": "Eye irritation test", "observation": "Irritant"}, {"action": "Dose-response study", "observation": "Linear response"}, {"action": "Immunogenicity testing", "observation": "Immunogenic"}], "successful": true, "parse_error": false}, {"actions": ["Immunogenicity testing", "Formaldehyde", {"predicted_truth": "Formaldehyde"}], "generated_text": ["<ANSWER> Immunogenicity testing </ANSWER>\n\nReason: Since Interferon is known to provoke an immune response, we can perform an immunogenicity test to see if the compound shows an immunogenic response. If it does, we can rule out Interferon as the correct compound. If it doesn't, we can continue to eliminate other compounds based on the test results.", "<ANSWER> Formaldehyde </ANSWER>\n\nReason: Since the immunogenicity test showed a positive result, Interferon can be ruled out. Among the remaining compounds (Formaldehyde, Phenytoin, and Aspirin), Formaldehyde is known to be non-immunogenic and is not expected to show an immunogenic response. Therefore, Formaldehyde can be ruled out, leaving us with Phenytoin and Aspirin. To further narrow it down, we can perform a dose-response study. However, based on the current information, Formaldehyde is the most likely to be ruled out."], "consumed_tokens": 2859, "observations": [null, {"action": "Immunogenicity testing", "observation": "Immunogenic"}], "successful": false, "parse_error": false}, {"actions": ["Immunogenicity testing", "Interferon", {"predicted_truth": "Interferon"}], "generated_text": ["<ANSWER> Immunogenicity testing </ANSWER>\n\nReason: Since Interferon is known to provoke an immune response, performing immunogenicity testing would help us determine if the compound is indeed Interferon. If the test shows an immunogenic response, we can rule out other compounds that do not have this property. This test is a clear step to narrow down the possibilities based on the known properties of the compounds.", "<ANSWER> Interferon </ANSWER>\n\nReason: Since the immunogenicity testing showed an immunogenic response, it confirms that the compound is Interferon. Other compounds like Formaldehyde, Phenytoin, and Aspirin do not typically exhibit strong immunogenic properties."], "consumed_tokens": 2807, "observations": [null, {"action": "Immunogenicity testing", "observation": "Immunogenic"}], "successful": false, "parse_error": false}], "seed": 3, "average_actions": 3.0, "average_tokens": 3208.4, "average_correct": 0.2, "average_parse_error": 0.2, "average_successful_action_num": 5.0, "average_successful_tokens": 6152.0}
{"trajectories": [{"actions": ["Human clinical trial Phase I", "Atenolol", {"predicted_truth": "Atenolol"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Since Interferon is known to be immunogenic and Amphotericin B is nephrotoxic, we can rule out 'Immunogenicity testing' and 'Renal function test' without performing them. Valproic Acid is teratogenic, so we can rule it out with 'Teratogenicity assessment'. Atenolol is a beta-blocker and does not have specific testing requirements mentioned in the guidebook. Therefore, the most informative trial to perform first is the 'Human clinical trial Phase I' to check for any severe adverse effects, which could help us rule out Atenolol if severe adverse effects are observed.", "<ANSWER> Atenolol </ANSWER>\n\nReason: Since the observation from the 'Human clinical trial Phase I' is 'Severe adverse effects', Atenolol is the compound that is ruled out. The remaining compounds are 'Interferon', 'Amphotericin B', and 'Valproic Acid', but the severe adverse effects observed in the trial strongly suggest that Atenolol is the compound being tested."], "consumed_tokens": 2777, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": false, "parse_error": false}, {"actions": ["Human clinical trial Phase I", "Atenolol", {"predicted_truth": "Atenolol"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>", "<ANSWER> Atenolol </ANSWER>\n\nGiven the observation of 'Severe adverse effects' in the Human clinical trial Phase I, we can rule out Atenolol since it is known to cause severe adverse reactions. The remaining compounds are Interferon, Amphotericin B, and Valproic Acid. Since Atenolol has been eliminated, we can now proceed to further trials or make an educated guess among the remaining compounds."], "consumed_tokens": 2513, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": false, "parse_error": false}, {"actions": ["Human clinical trial Phase I", "Atenolol", {"predicted_truth": "Atenolol"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>", "<ANSWER> Atenolol </ANSWER>\n\nGiven the observation of 'Severe adverse effects' in the Human clinical trial Phase I, we can rule out Atenolol since it is known to cause severe adverse reactions. The remaining compounds are Interferon, Amphotericin B, and Valproic Acid. Since Atenolol has been eliminated, we can now focus on the other compounds."], "consumed_tokens": 2505, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": false, "parse_error": false}, {"actions": ["Human clinical trial Phase I", "Immunogenicity testing", "Renal function test", "Atenolol", {"predicted_truth": "Atenolol"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Since Interferon is known to be immunogenic, performing a Human clinical trial Phase I can help us assess the safety and tolerability in humans. If there are severe adverse effects observed, we can rule out Interferon. For the other compounds, mild or no adverse effects would not eliminate them, so this trial provides a clear way to start eliminating Interferon based on its known properties.", "<ANSWER> Immunogenicity testing </ANSWER>\n\nReason: Since we observed severe adverse effects in the Human clinical trial Phase I, Interferon can be ruled out. For the remaining compounds (Amphotericin B, Atenolol, and Valproic Acid), performing an Immunogenicity testing can help us further narrow down the possibilities. Amphotericin B and Atenolol are not expected to be immunogenic, while Valproic Acid is known for its teratogenic effects but not typically for immunogenicity. Therefore, this test will help us eliminate Valproic Acid.", "<ANSWER> Renal function test </ANSWER>\n\nReason: Since the immunogenicity testing confirmed that Valproic Acid is immunogenic, we can rule it out. We are left with Amphotericin B and Atenolol. Amphotericin B is known to be nephrotoxic, so performing a Renal function test will help us rule out Amphotericin B if there are nephrotoxic outcomes. Atenolol is not expected to be nephrotoxic, so a negative outcome for nephrotoxicity would confirm Atenolol as the remaining compound.", "<ANSWER> Atenolol </ANSWER>\n\nReason: The Renal function test outcome was nephrotoxic, which rules out Amphotericin B. Since Atenolol is not expected to be nephrotoxic, and the other compounds (Interferon and Valproic Acid) have been ruled out by previous tests, Atenolol is the remaining and correct compound."], "consumed_tokens": 6018, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}, {"action": "Immunogenicity testing", "observation": "Immunogenic"}, {"action": "Renal function test", "observation": "Nephrotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Human clinical trial Phase I", "Atenolol", {"predicted_truth": "Atenolol"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>", "<ANSWER> Atenolol </ANSWER>\n\nGiven the severe adverse effects observed in the Human clinical trial Phase I, Atenolol can be ruled out as it is known to cause severe adverse reactions. The remaining compounds are Interferon, Amphotericin B, and Valproic Acid. Let's proceed with the Renal function test to further narrow down the options."], "consumed_tokens": 2499, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": false, "parse_error": false}], "seed": 4, "average_actions": 3.4, "average_tokens": 3262.4, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["Genotoxicity assay", "Tamoxifen", {"predicted_truth": "Tamoxifen"}], "generated_text": ["<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Tamoxifen </ANSWER>\n\nSince the genotoxicity assay resulted in a genotoxic outcome, we can rule out Tamoxifen as it is known to be genotoxic. Now, we need to focus on the remaining compounds: Amiodarone, Amoxicillin, and Neomycin Sulfate."], "consumed_tokens": 2584, "observations": [null, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Genotoxicity assay", "Tamoxifen", {"predicted_truth": "Tamoxifen"}], "generated_text": ["<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Tamoxifen </ANSWER>\n\nSince the observation from the genotoxicity assay is 'Genotoxic', we can rule out Tamoxifen as it is known for its genotoxicity potential. Therefore, the remaining possible compounds are Amiodarone, Amoxicillin, and Neomycin sulfate. Given the genotoxic result, Tamoxifen is the compound that can be eliminated."], "consumed_tokens": 2598, "observations": [null, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Genotoxicity assay", "Tamoxifen", {"predicted_truth": "Tamoxifen"}], "generated_text": ["<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Tamoxifen </ANSWER>\n\nSince the genotoxicity assay resulted in a genotoxic outcome, we can rule out Tamoxifen. This leaves us with the following possible compounds: ['Amiodarone', 'Amoxicillin', 'Neomycin sulfate']."], "consumed_tokens": 2574, "observations": [null, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Genotoxicity assay", "Tamoxifen", {"predicted_truth": "Tamoxifen"}], "generated_text": ["<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Tamoxifen </ANSWER>"], "consumed_tokens": 2527, "observations": [null, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Genotoxicity assay", "Tamoxifen", {"predicted_truth": "Tamoxifen"}], "generated_text": ["<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Tamoxifen </ANSWER>\n\nSince the genotoxicity assay resulted in a genotoxic outcome, we can rule out Tamoxifen as it is known for its genotoxic potential. Now, we are left with the compounds Amiodarone, Amoxicillin, and Neomycin Sulfate."], "consumed_tokens": 2582, "observations": [null, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}], "seed": 5, "average_actions": 3.0, "average_tokens": 2573.0, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["Animal toxicity test", "Receptor binding affinity assay", "Ames mutagenicity test", "P-glycoprotein interaction assay", "Cetirizine", {"predicted_truth": "Cetirizine"}], "generated_text": ["<ANSWER> Animal toxicity test </ANSWER>\n\nReason: The Animal toxicity test can help us eliminate compounds with high toxicity. From the guidebook, we know that Etoricoxib has high toxicity in this test, which can be used to rule out Etoricoxib. This test is a good starting point to narrow down the possible compounds.", "<ANSWER> Receptor binding affinity assay </ANSWER>\n\nReason: Since Etoricoxib has been ruled out due to high toxicity in the Animal toxicity test, we are left with Nifedipine, Cetirizine, and Acyclovir. The Receptor binding affinity assay can help us further narrow down the possibilities by identifying the compound with a specific binding affinity range. This will help us eliminate one of the remaining compounds.", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: The observed binding affinity of 38.506991796899506 nM falls within the typical binding range for compounds like Cetirizine, which has a high affinity for its target receptor. Since we have already ruled out Etoricoxib due to high toxicity, we can now rule out Acyclovir based on the Ames mutagenicity test. If Acyclovir were to show a positive result in this test, it would be ruled out. Therefore, the remaining compounds are Nifedipine and Cetirizine. To further narrow it down, we can perform the Ames mutagenicity test, which is known to rule out compounds that are mutagenic. If the result is negative, it will confirm that the compound is not mutagenic, helping us identify the correct one.", "<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: Since the Ames mutagenicity test has ruled out Acyclovir, we are left with Nifedipine and Cetirizine. The P-glycoprotein interaction assay can help us differentiate between these two compounds. If the result is negative, it will confirm that the compound does not interact significantly with P-glycoprotein, which is a characteristic of Nifedipine. Therefore, this test will help us identify the correct compound.", "<ANSWER> Cetirizine </ANSWER>\n\nReason: The P-glycoprotein interaction assay has ruled out Nifedipine as it is an inhibitor. Since we have already ruled out Etoricoxib and Acyclovir, the only remaining compound is Cetirizine. Therefore, we can confidently predict that the correct compound is Cetirizine."], "consumed_tokens": 7569, "observations": [null, {"action": "Animal toxicity test", "observation": "High toxicity"}, {"action": "Receptor binding affinity assay", "observation": 38.506991796899506}, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}], "successful": false, "parse_error": false}, {"actions": ["Animal toxicity test", "Ames mutagenicity test", "Receptor binding affinity assay", "Cetirizine", {"predicted_truth": "Cetirizine"}], "generated_text": ["<ANSWER> Animal toxicity test </ANSWER>\n\nReason: Since we have identified that Etoricoxib is ruled out by the Animal toxicity test (high toxicity), performing this test first can help us eliminate Etoricoxib quickly. This will narrow down our list of potential compounds and make it easier to identify the correct one.", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: Since Etoricoxib has been ruled out by the Animal toxicity test, we are left with three potential compounds: Nifedipine, Cetirizine, and Acyclovir. The next logical step is to perform the Ames mutagenicity test. Acyclovir is known to have a positive outcome in the Ames test, so it is likely to be ruled out by this test. This will help us further narrow down the possibilities.", "<ANSWER> Receptor binding affinity assay </ANSWER>\n\nReason: Since the Ames mutagenicity test ruled out Acyclovir, we are left with Nifedipine and Cetirizine. The Receptor binding affinity assay can help us distinguish between these two compounds. Cetirizine is an antihistamine and would likely show a high binding affinity for histamine receptors, while Nifedipine, a calcium channel blocker, would not show significant binding affinity for histamine receptors. This test should help us identify the correct compound.", "<ANSWER> Cetirizine </ANSWER>\n\nReason: The receptor binding affinity assay observed a binding affinity of 38.506991796899506 nM for the remaining compound. Given that Cetirizine is an antihistamine, it would have a significant binding affinity for histamine receptors. Nifedipine, on the other hand, is a calcium channel blocker and would not show such a high binding affinity for histamine receptors. Therefore, based on the observed binding affinity, the remaining compound is Cetirizine."], "consumed_tokens": 5632, "observations": [null, {"action": "Animal toxicity test", "observation": "High toxicity"}, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "Receptor binding affinity assay", "observation": 38.506991796899506}], "successful": false, "parse_error": false}, {"actions": ["Animal toxicity test", "Receptor binding affinity assay", "Cetirizine", {"predicted_truth": "Cetirizine"}], "generated_text": ["<ANSWER> Animal toxicity test </ANSWER>", "<ANSWER> Receptor binding affinity assay </ANSWER>", "The observed value of 38.506991796899506 nM from the Receptor binding affinity assay is within the binding range of 0-50 nM, which rules out Cetirizine.\n\n<ANSWER> Cetirizine </ANSWER>"], "consumed_tokens": 3582, "observations": [null, {"action": "Animal toxicity test", "observation": "High toxicity"}, {"action": "Receptor binding affinity assay", "observation": 38.506991796899506}], "successful": false, "parse_error": false}, {"actions": ["Animal toxicity test", "Receptor binding affinity assay", "Ames mutagenicity test", "Nifedipine", {"predicted_truth": "Nifedipine"}], "generated_text": ["<ANSWER> Animal toxicity test </ANSWER>\n\nReason: The Animal toxicity test has already ruled out Etoricoxib due to its high toxicity. By performing this test again, we can confirm that Etoricoxib is not a viable option. This test is also useful for further differentiating between the remaining compounds: Nifedipine, Cetirizine, and Acyclovir. The outcomes from this test will help us eliminate one of these compounds.", "<ANSWER> Receptor binding affinity assay </ANSWER>\n\nReason: Since the Animal toxicity test has already ruled out Etoricoxib, we now need to differentiate between Nifedipine, Cetirizine, and Acyclovir. The Receptor binding affinity assay can help us understand how these compounds interact with specific receptors, which is crucial for their efficacy and potential side effects. By performing this test, we can eliminate one of the remaining compounds.", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: The Receptor binding affinity assay result of 38.506991796899506 nM is within the binding range, which rules out Cetirizine. Now we are left with Nifedipine and Acyclovir. The Ames mutagenicity test can help us rule out Acyclovir because it has been associated with positive tests in mutagenicity assays. Therefore, performing the Ames mutagenicity test will help us identify the remaining compound, Nifedipine.", "<ANSWER> Nifedipine </ANSWER>\n\nReason: The Ames mutagenicity test has ruled out Acyclovir. Since we have already ruled out Etoricoxib and Cetirizine, and Acyclovir, the only remaining compound is Nifedipine. Therefore, we can confidently identify Nifedipine as the correct compound."], "consumed_tokens": 5706, "observations": [null, {"action": "Animal toxicity test", "observation": "High toxicity"}, {"action": "Receptor binding affinity assay", "observation": 38.506991796899506}, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": true, "parse_error": false}, {"actions": ["Animal toxicity test", "Etoricoxib", {"predicted_truth": "Etoricoxib"}], "generated_text": ["<ANSWER> Animal toxicity test </ANSWER>\n\nReason: Since the animal toxicity test has already been described and its outcome can help us eliminate one of the compounds (Etoricoxib), performing this test will be the most effective way to narrow down the options in the fewest steps.", "<ANSWER> Etoricoxib </ANSWER>\n\nReason: The animal toxicity test showed high toxicity for Etoricoxib. Therefore, we can confidently rule out Etoricoxib as the compound."], "consumed_tokens": 2424, "observations": [null, {"action": "Animal toxicity test", "observation": "High toxicity"}], "successful": false, "parse_error": false}], "seed": 6, "average_actions": 4.6, "average_tokens": 4982.6, "average_correct": 0.2, "average_parse_error": 0.0, "average_successful_action_num": 5.0, "average_successful_tokens": 5706.0}
{"trajectories": [{"actions": ["Dose-response study", "Genotoxicity assay", "Tamoxifen", {"predicted_truth": "Tamoxifen"}], "generated_text": ["<ANSWER> Dose-response study </ANSWER>", "<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Tamoxifen </ANSWER>"], "consumed_tokens": 3427, "observations": [null, {"action": "Dose-response study", "observation": "Linear response"}, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Dose-response study", "Genotoxicity assay", "Ciprofloxacin", {"predicted_truth": "Ciprofloxacin"}], "generated_text": ["<ANSWER> Dose-response study </ANSWER>", "<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Ciprofloxacin </ANSWER>"], "consumed_tokens": 3429, "observations": [null, {"action": "Dose-response study", "observation": "Linear response"}, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Dose-response study", "Genotoxicity assay", "Ciprofloxacin", {"predicted_truth": "Ciprofloxacin"}], "generated_text": ["<ANSWER> Dose-response study </ANSWER>", "<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Ciprofloxacin </ANSWER>"], "consumed_tokens": 3429, "observations": [null, {"action": "Dose-response study", "observation": "Linear response"}, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Dose-response study", "Genotoxicity assay", "Ciprofloxacin", {"predicted_truth": "Ciprofloxacin"}], "generated_text": ["<ANSWER> Dose-response study </ANSWER>", "<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Ciprofloxacin </ANSWER>"], "consumed_tokens": 3429, "observations": [null, {"action": "Dose-response study", "observation": "Linear response"}, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Genotoxicity assay", "Tamoxifen", {"predicted_truth": "Tamoxifen"}], "generated_text": ["<ANSWER> Genotoxicity assay </ANSWER>\n\nReason: The genotoxicity assay can help us rule out compounds that are genotoxic. From the guidebook, we know that Tamoxifen is ruled out if genotoxicity is observed. Since we have a list of four compounds and we need to systematically rule out one, testing for genotoxicity can potentially eliminate one of the compounds (Tamoxifen) based on the observed outcome. This will help narrow down our options to one plausible compound.", "<ANSWER> Tamoxifen </ANSWER>\n\nReason: The genotoxicity assay has shown a positive outcome (genotoxic). Based on the guidebook, Tamoxifen is ruled out if genotoxicity is observed. Therefore, Tamoxifen can be eliminated from our list of possible compounds."], "consumed_tokens": 2471, "observations": [null, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}], "seed": 7, "average_actions": 3.8, "average_tokens": 3237.0, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["Dose-response study", "Genotoxicity assay", "Estradiol", {"predicted_truth": "Estradiol"}], "generated_text": ["<ANSWER> Dose-response study </ANSWER>", "<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Estradiol </ANSWER>\n\nGiven the observation that the Genotoxicity assay was genotoxic, we can rule out Estradiol since it is not genotoxic. This leaves us with the compounds: Prednisone, Aspirin, and Phenytoin. Since the Dose-response study showed a linear response, Phenytoin is ruled out as it typically shows a non-linear dose-response. Therefore, the remaining compounds are Aspirin and Prednisone. As Estradiol was excluded earlier, the correct compound must be either Aspirin or Prednisone. Since Genotoxicity was observed and Estradiol was ruled out, the remaining compound must be Prednisone."], "consumed_tokens": 3829, "observations": [null, {"action": "Dose-response study", "observation": "Linear response"}, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Dose-response study", "Genotoxicity assay", "Estradiol", {"predicted_truth": "Estradiol"}], "generated_text": ["<ANSWER> Dose-response study </ANSWER>", "<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Estradiol </ANSWER>\n\nGiven the observation that the Genotoxicity assay showed a genotoxic response, we can rule out Estradiol since it is known to be non-genotoxic. This leaves us with the compounds Prednisone, Aspirin, and Phenytoin. Since the Dose-response study showed a linear response, Phenytoin can be ruled out, leaving us with Prednisone and Aspirin. The genotoxicity assay has already ruled out Estradiol, and no further action is needed to identify the remaining compounds in this case."], "consumed_tokens": 3805, "observations": [null, {"action": "Dose-response study", "observation": "Linear response"}, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Dose-response study", "Genotoxicity assay", "Carcinogenicity study", "CYP450 metabolism assay", "Aspirin", {"predicted_truth": "Aspirin"}], "generated_text": ["<ANSWER> Dose-response study </ANSWER>\n\nBy performing a dose-response study, we can determine the linear, non-linear, or sigmoidal response to the compounds. This will help us rule out Phenytoin, which is known to have a linear dose-response.", "<ANSWER> Genotoxicity assay </ANSWER>\n\nSince the dose-response study showed a linear response, Phenytoin can be ruled out. Next, we can perform a genotoxicity assay to further narrow down the possibilities.", "<ANSWER> Carcinogenicity study </ANSWER>\n\nSince the genotoxicity assay showed that the compound is genotoxic, Estradiol can be ruled out. Now, we need to perform a carcinogenicity study to further differentiate between Prednisone and Aspirin.", "<ANSWER> CYP450 metabolism assay </ANSWER>\n\nGiven that both Prednisone and Aspirin have shown carcinogenic properties, we need to determine their CYP450 metabolism profile to make a final distinction. Phenytoin can be ruled out as it does not fit the remaining possibilities. Performing a CYP450 metabolism assay will help us identify the compound accurately.", "<ANSWER> Aspirin </ANSWER>\n\nThe CYP450 metabolism assay showed that the compound is a strong inhibitor. Aspirin is known to be a strong inhibitor of CYP450 enzymes, while Prednisone is not. Therefore, the remaining compound is Aspirin."], "consumed_tokens": 7092, "observations": [null, {"action": "Dose-response study", "observation": "Linear response"}, {"action": "Genotoxicity assay", "observation": "Genotoxic"}, {"action": "Carcinogenicity study", "observation": "Carcinogenic"}, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}], "successful": true, "parse_error": false}, {"actions": ["Dose-response study", "Genotoxicity assay", "Estradiol", {"predicted_truth": "Estradiol"}], "generated_text": ["<ANSWER> Dose-response study </ANSWER>", "<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Estradiol </ANSWER>\n\nGiven the observation from the genotoxicity assay that the compound is genotoxic, we can rule out Estradiol, as it is not genotoxic. This leaves us with Prednisone, Aspirin, and Phenytoin. Since the dose-response study showed a linear response, Phenytoin can also be ruled out, as it is known to have a non-linear dose-response. Therefore, the remaining compound is Aspirin."], "consumed_tokens": 3785, "observations": [null, {"action": "Dose-response study", "observation": "Linear response"}, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Dose-response study", "Genotoxicity assay", "Estradiol", {"predicted_truth": "Estradiol"}], "generated_text": ["<ANSWER> Dose-response study </ANSWER>", "<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Estradiol </ANSWER>\n\nSince the dose-response study showed a linear response, we can rule out Prednisone. The genotoxicity assay also showed that the compound is genotoxic, which rules out Estradiol. Therefore, neither Prednisone nor Estradiol can be the correct compound. Given the remaining options (Aspirin and Phenytoin), and the fact that both Phenytoin and Aspirin do not show linear dose-response, we can confidently rule out Phenytoin. Thus, the remaining compound is Aspirin. However, since the question format only allows for the selection of an action or the prediction of a truth name, and we have ruled out all but Estradiol as a candidate, the correct answer is Estradiol."], "consumed_tokens": 3847, "observations": [null, {"action": "Dose-response study", "observation": "Linear response"}, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}], "seed": 8, "average_actions": 4.4, "average_tokens": 4471.6, "average_correct": 0.2, "average_parse_error": 0.0, "average_successful_action_num": 6.0, "average_successful_tokens": 7092.0}
{"trajectories": [{"actions": ["Blood-brain barrier permeability test", "Animal behavioral study", "Human clinical trial Phase I", "CYP450 metabolism assay", "Mitochondrial toxicity test", "Fluoxetine", {"predicted_truth": "Fluoxetine"}], "generated_text": ["<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>", "<ANSWER> Human clinical trial Phase I </ANSWER>", "<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> Mitochondrial toxicity test </ANSWER>", "<ANSWER> Fluoxetine </ANSWER>"], "consumed_tokens": 7939, "observations": [null, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "Human clinical trial Phase I", "observation": "No adverse effects"}, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "Mitochondrial toxicity test", "observation": "No mitochondrial toxicity"}], "successful": false, "parse_error": false}, {"actions": ["Blood-brain barrier permeability test", "Animal behavioral study", "Human clinical trial Phase I", "CYP450 metabolism assay", "Mitochondrial toxicity test", "Aspirin", {"predicted_truth": "Aspirin"}], "generated_text": ["<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>", "<ANSWER> Human clinical trial Phase I </ANSWER>", "<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> Mitochondrial toxicity test </ANSWER>", "<ANSWER> Aspirin </ANSWER>"], "consumed_tokens": 7940, "observations": [null, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "Human clinical trial Phase I", "observation": "No adverse effects"}, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "Mitochondrial toxicity test", "observation": "No mitochondrial toxicity"}], "successful": true, "parse_error": false}, {"actions": ["Blood-brain barrier permeability test", "Animal behavioral study", "Human clinical trial Phase I", "CYP450 metabolism assay", "Mitochondrial toxicity test", "Fluoxetine", {"predicted_truth": "Fluoxetine"}], "generated_text": ["<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>", "<ANSWER> Human clinical trial Phase I </ANSWER>", "<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> Mitochondrial toxicity test </ANSWER>", "<ANSWER> Fluoxetine </ANSWER>"], "consumed_tokens": 7939, "observations": [null, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "Human clinical trial Phase I", "observation": "No adverse effects"}, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "Mitochondrial toxicity test", "observation": "No mitochondrial toxicity"}], "successful": false, "parse_error": false}, {"actions": ["Blood-brain barrier permeability test", "Animal behavioral study", "Human clinical trial Phase I", "CYP450 metabolism assay", "Mitochondrial toxicity test", "Fluoxetine", {"predicted_truth": "Fluoxetine"}], "generated_text": ["<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>", "<ANSWER> Human clinical trial Phase I </ANSWER>", "<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> Mitochondrial toxicity test </ANSWER>", "<ANSWER> Fluoxetine </ANSWER>"], "consumed_tokens": 7939, "observations": [null, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "Human clinical trial Phase I", "observation": "No adverse effects"}, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "Mitochondrial toxicity test", "observation": "No mitochondrial toxicity"}], "successful": false, "parse_error": false}, {"actions": ["Blood-brain barrier permeability test", "Animal behavioral study", "Human clinical trial Phase I", "CYP450 metabolism assay", "Mitochondrial toxicity test", "Fluoxetine", {"predicted_truth": "Fluoxetine"}], "generated_text": ["<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>", "<ANSWER> Human clinical trial Phase I </ANSWER>", "<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> Mitochondrial toxicity test </ANSWER>", "<ANSWER> Fluoxetine </ANSWER>\n\nBased on the observations from the various tests, we have systematically ruled out the following compounds:\n- Gabapentin: Does not penetrate the blood-brain barrier.\n- Zolpidem: Does not penetrate the blood-brain barrier.\n- Aspirin: No behavioral changes, no adverse effects in Phase I, is a strong inhibitor of CYP450 enzymes, and is non-cardiotoxic.\n\nThe remaining compound is Fluoxetine, which has not been ruled out by any of these tests. Therefore, Fluoxetine is the most plausible compound."], "consumed_tokens": 8050, "observations": [null, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "Human clinical trial Phase I", "observation": "No adverse effects"}, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "Mitochondrial toxicity test", "observation": "No mitochondrial toxicity"}], "successful": false, "parse_error": false}], "seed": 9, "average_actions": 7.0, "average_tokens": 7961.4, "average_correct": 0.2, "average_parse_error": 0.0, "average_successful_action_num": 7.0, "average_successful_tokens": 7940.0}
{"trajectories": [{"actions": ["In vitro enzyme inhibition assay", "Oxidative stress assay", "Ames mutagenicity test", "Nifedipine", {"predicted_truth": "Nifedipine"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: Starting with the in vitro enzyme inhibition assay can help us quickly rule out Albuterol, as it is the only compound in the list that is known to be an enzyme inhibitor. This test will either confirm or deny the presence of Albuterol based on its known properties, potentially reducing the number of compounds to consider in subsequent steps.", "<ANSWER> Oxidative stress assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay indicated that the compound is not Albuterol, as its inhibition value is outside the rule-out range (0, 100). Next, we can perform the oxidative stress assay to rule out Cisplatin, as it is known to induce oxidative stress. This will help narrow down our options more effectively.", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: The oxidative stress assay indicated that the compound induces ROS, which rules out Cisplatin. Next, we can perform the Ames mutagenicity test to rule out Lamivudine. If the test is positive, Lamivudine will be ruled out, leaving us with Nifedipine and Albuterol.", "<ANSWER> Nifedipine </ANSWER>\n\nReason: The Ames mutagenicity test resulted in a positive outcome, which rules out Lamivudine. This leaves us with Nifedipine and Albuterol. Since Albuterol is known to have no significant interaction with P-glycoprotein, performing the P-glycoprotein interaction assay would be the next step. However, given that we only have two compounds left and we need to identify the correct one, we can predict that Nifedipine is the correct compound based on its properties and the process of elimination."], "consumed_tokens": 5683, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 52.06693596399246}, {"action": "Oxidative stress assay", "observation": "Induces ROS"}, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Ames mutagenicity test", "Cisplatin", {"predicted_truth": "Cisplatin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: Starting with the in vitro enzyme inhibition assay can help us quickly rule out Albuterol, as it is the only compound in the list that is known to be an enzyme inhibitor. If the assay shows inhibition within the rule-out range (0, 100), we can confidently rule out Albuterol and narrow down our options.", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: The in vitro enzyme inhibition assay showed inhibition at 52.06693596399246, which falls within the rule-out range (0, 100). Therefore, Albuterol can be ruled out. Next, we can perform the Ames mutagenicity test to see if the compound causes genetic mutations in bacteria. If the result is positive, Lamivudine can be ruled out. If it is negative, we will proceed with further tests to identify the remaining compounds.", "<ANSWER> Cisplatin </ANSWER>\n\nReason: The Ames mutagenicity test resulted in a positive outcome, which rules out Lamivudine. This leaves us with Nifedipine, Cisplatin, and Albuterol. Since Albuterol has already been ruled out, we are left with Nifedipine and Cisplatin. \n\nNext, we can perform the oxidative stress assay to see if the compound induces ROS. If the compound induces ROS, it would be Cisplatin, as Nifedipine does not typically cause oxidative stress. If it does not induce ROS, it would be Nifedipine. However, since we have already ruled out Lamivudine and Albuterol, and we need to identify the remaining compound, we can predict that the compound is Cisplatin based on the remaining options.\n\n<ANSWER> Cisplatin </ANSWER>"], "consumed_tokens": 4241, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 52.06693596399246}, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Ames mutagenicity test", "Cisplatin", {"predicted_truth": "Cisplatin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nBased on the observed value of 52.06693596399246 from the in vitro enzyme inhibition assay, which falls within the rule-out range (0, 100), we can rule out Albuterol. Now, we should perform the Ames mutagenicity test to further narrow down the possibilities.", "<ANSWER> Cisplatin </ANSWER>\n\nSince the Ames mutagenicity test returned a positive result, we can rule out Lamivudine. Given that the remaining compounds are Nifedipine, Cisplatin, and Albuterol, and Albuterol has already been ruled out, the only remaining compound is Cisplatin. \n\nTo confirm, we can proceed with the next relevant test, but based on the current observations, Cisplatin is the most plausible compound."], "consumed_tokens": 3862, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 52.06693596399246}, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Reactive oxygen species (ROS) assay", "Ames mutagenicity test", "Lamivudine", {"predicted_truth": "Lamivudine"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Reactive oxygen species (ROS) assay </ANSWER>\n\nGiven the observation from the in vitro enzyme inhibition assay is 52.06693596399246, which falls within the rule-out range of (50, 100) for Albuterol, we can rule out Albuterol. Now, we need to perform another test to further narrow down the remaining compounds: Nifedipine, Cisplatin, and Lamivudine. The next logical step is to perform the Reactive oxygen species (ROS) assay, as it can help us rule out Cisplatin based on its tendency to induce ROS.", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nSince the Reactive oxygen species (ROS) assay showed 'Low ROS generation', we can rule out Cisplatin. Now we are left with Nifedipine and Lamivudine. The next logical step is to perform the Ames mutagenicity test. If Lamivudine is ruled out, Nifedipine will be the remaining compound. If Lamivudine passes this test, we can then further investigate using other assays.", "<ANSWER> Lamivudine </ANSWER>\n\nThe Ames mutagenicity test showing a positive result rules out Lamivudine. Therefore, the remaining compound is Nifedipine."], "consumed_tokens": 5542, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 52.06693596399246}, {"action": "Reactive oxygen species (ROS) assay", "observation": "Low ROS generation"}, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Ames mutagenicity test", "Oxidative stress assay", "Reactive oxygen species (ROS) assay", "P-glycoprotein interaction assay", "hERG channel inhibition assay", "In vitro enzyme inhibition assay", "Cisplatin", {"predicted_truth": "Cisplatin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Ames mutagenicity test </ANSWER>", "<ANSWER> Oxidative stress assay </ANSWER>", "<ANSWER> Reactive oxygen species (ROS) assay </ANSWER>", "<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Cisplatin </ANSWER>\n\nGiven the observations:\n- The in vitro enzyme inhibition assay result of 52.06693596399246 is within the rule-out range (0, 100) for Albuterol.\n- The positive Ames mutagenicity test ruled out Lamivudine.\n- The oxidative stress assay did not induce ROS, so Cisplatin is not ruled out based on this assay.\n- The low ROS generation in the reactive oxygen species assay does not rule out Cisplatin.\n- The P-glycoprotein interaction assay showing a substrate does not rule out Nifedipine.\n- The hERG channel inhibition assay result of 3.2777281162209313 is below the rule-out range (50, 100) for Albuterol.\n\nTherefore, the remaining plausible compound is Cisplatin."], "consumed_tokens": 10900, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 52.06693596399246}, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "Oxidative stress assay", "observation": "Induces ROS"}, {"action": "Reactive oxygen species (ROS) assay", "observation": "Low ROS generation"}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}, {"action": "hERG channel inhibition assay", "observation": 3.2777281162209313}, {"action": "In vitro enzyme inhibition assay", "observation": 52.06693596399246}], "successful": false, "parse_error": false}], "seed": 10, "average_actions": 5.4, "average_tokens": 6045.6, "average_correct": 0.2, "average_parse_error": 0.0, "average_successful_action_num": 5.0, "average_successful_tokens": 5683.0}
{"trajectories": [{"actions": ["Blood-brain barrier permeability test", "P-glycoprotein interaction assay", "Clarithromycin", {"predicted_truth": "Clarithromycin"}], "generated_text": ["<ANSWER> Blood-brain barrier permeability test </ANSWER>\n\nReason: Since Metoprolol has already been ruled out due to severe adverse effects in the Human clinical trial Phase I, and Zolpidem has been ruled out for not penetrating the BBB, we can focus on Digoxin and Clarithromycin. The Blood-brain barrier permeability test can help us determine whether Digoxin or Clarithromycin is a more likely candidate, as Clarithromycin is known for its strong inhibition of CYP450 enzymes and would likely not be a substrate for P-glycoprotein. However, since we are looking to eliminate one of the remaining compounds, the Blood-brain barrier permeability test is a good choice to further narrow down the options.", "<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: The observation that Digoxin does not penetrate the BBB suggests that it is likely a substrate for P-glycoprotein. Therefore, the P-glycoprotein interaction assay would help confirm whether Digoxin is ruled out due to this interaction. If Digoxin is ruled out, Clarithromycin would be the remaining compound.", "<ANSWER> Clarithromycin </ANSWER>\n\nReason: Based on the observations from the previous actions, we have ruled out Metoprolol due to severe adverse effects in the Human clinical trial Phase I, Zolpidem for not penetrating the BBB, and Digoxin for being a substrate in the P-glycoprotein interaction assay. This leaves us with Clarithromycin as the only remaining compound."], "consumed_tokens": 4345, "observations": [null, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}], "successful": true, "parse_error": false}, {"actions": ["Blood-brain barrier permeability test", "P-glycoprotein interaction assay", "Human clinical trial Phase I", "Clarithromycin", {"predicted_truth": "Clarithromycin"}], "generated_text": ["<ANSWER> Blood-brain barrier permeability test </ANSWER>\n\nReason: Since Metoprolol has already been ruled out due to severe adverse effects in the Human clinical trial Phase I, and Zolpidem has also been ruled out as it does not penetrate the blood-brain barrier, we can focus on determining whether Digoxin or Clarithromycin can cross the blood-brain barrier. The Blood-brain barrier permeability test is the most direct way to confirm this.", "<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: Since Zolpidem and Metoprolol have been ruled out, and Digoxin has not been tested yet, the next logical step is to determine if Digoxin interacts with P-glycoprotein, as Clarithromycin has already been ruled out as a strong inhibitor of CYP450 enzymes.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Since Digoxin has been identified as the remaining compound and the P-glycoprotein interaction assay has shown that it is a substrate, the next step is to confirm this through a Human clinical trial Phase I to observe its safety and tolerability. This will help us definitively identify the compound.", "<ANSWER> Clarithromycin </ANSWER>\n\nReason: The observations from the previous actions have ruled out Zolpidem, Metoprolol, and Digoxin. The only remaining compound is Clarithromycin. Since the Human clinical trial Phase I for Digoxin showed severe adverse effects, and the other tests ruled out the other compounds, Clarithromycin is the correct answer."], "consumed_tokens": 5766, "observations": [null, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": true, "parse_error": false}, {"actions": ["Blood-brain barrier permeability test", "P-glycoprotein interaction assay", "Digoxin", {"predicted_truth": "Digoxin"}], "generated_text": ["<ANSWER> Blood-brain barrier permeability test </ANSWER>\n\nReason: Since Metoprolol has already been ruled out due to severe adverse effects in the Human clinical trial Phase I, we can use the Blood-brain barrier permeability test to further narrow down the possibilities. Zolpidem, which acts on the central nervous system, is expected to penetrate the blood-brain barrier. Therefore, if the test shows that a compound does not penetrate the BBB, we can rule out Zolpidem. This step will help us identify the correct compound more efficiently.", "<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: Since Zolpidem has been ruled out because it does not penetrate the blood-brain barrier, we are left with Digoxin, Clarithromycin, and Metoprolol. The P-glycoprotein interaction assay will help us rule out Digoxin, as it acts as a substrate for P-glycoprotein and Clarithromycin, which is known to be a strong inhibitor of CYP3A4 (which is related to P-glycoprotein function). This step will help us narrow down the possibilities further.", "<ANSWER> Clarithromycin </ANSWER>\n\nReason: The P-glycoprotein interaction assay outcome indicates that the compound is a substrate, which rules out Clarithromycin. This leaves us with Digoxin and Metoprolol. Since Metoprolol has already been ruled out due to severe adverse effects in the Human clinical trial Phase I, the remaining compound must be Digoxin. However, to confirm, we can perform the CYP450 metabolism assay to ensure there are no other overlapping issues. But based on the provided information and process of elimination, the most likely compound is Digoxin.\n\nSince the CYP450 metabolism assay was not performed and the only compound left is Digoxin, we can predict the truth.\n\n<ANSWER> Digoxin </ANSWER>"], "consumed_tokens": 4384, "observations": [null, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}], "successful": false, "parse_error": false}, {"actions": ["Blood-brain barrier permeability test", "P-glycoprotein interaction assay", "Clarithromycin", {"predicted_truth": "Clarithromycin"}], "generated_text": ["<ANSWER> Blood-brain barrier permeability test </ANSWER>\n\nReason: Since Metoprolol is already ruled out due to severe adverse effects observed in the Human clinical trial Phase I, and Zolpidem is ruled out for not penetrating the BBB, we can focus on Digoxin and Clarithromycin. The Blood-brain barrier permeability test will help us determine whether Digoxin or Clarithromycin can cross the BBB, which is a crucial property for many pharmaceutical compounds, especially those targeting the central nervous system. Given that Zolpidem did not penetrate the BBB, we can use this test to further narrow down our options.", "<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: Since Digoxin does not penetrate the BBB based on the previous test, we can rule out Digoxin. Now we are left with Clarithromycin. The P-glycoprotein interaction assay will help us determine whether Clarithromycin is a substrate for P-glycoprotein, which is its key property. If Clarithromycin is a substrate, it will be ruled out as Zolpidem was already ruled out for the same reason. If it is not a substrate, Clarithromycin will be the remaining compound.", "<ANSWER> Clarithromycin </ANSWER>\n\nReason: Since the P-glycoprotein interaction assay confirmed that Clarithromycin is a substrate, it matches the properties of Zolpidem (which was ruled out for the same reason) and is the only remaining compound that fits the observed outcomes."], "consumed_tokens": 4334, "observations": [null, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}], "successful": true, "parse_error": false}, {"actions": ["Blood-brain barrier permeability test", "P-glycoprotein interaction assay", "Human clinical trial Phase I", "Clarithromycin", {"predicted_truth": "Clarithromycin"}], "generated_text": ["<ANSWER> Blood-brain barrier permeability test </ANSWER>\n\nReason: Since Metoprolol was ruled out due to severe adverse effects in the Human clinical trial Phase I, we can focus on the remaining compounds: Digoxin, Clarithromycin, and Zolpidem. The Blood-brain barrier permeability test will help us eliminate Zolpidem, as it was observed not to penetrate the BBB. This will leave us with two compounds, and we can further narrow it down using other tests.", "<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: Since Zolpidem was ruled out due to not penetrating the BBB, we are left with Digoxin and Clarithromycin. The P-glycoprotein interaction assay will help us eliminate one of these compounds based on their interaction with P-glycoprotein.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Since the P-glycoprotein interaction assay ruled out Zolpidem and Metoprolol, we are left with Digoxin and Clarithromycin. The Human clinical trial Phase I will help us eliminate one of these compounds based on the observed outcomes.", "<ANSWER> Clarithromycin </ANSWER>\n\nReason: Based on the observations from the previous actions, we have ruled out Zolpidem, Metoprolol, and Digoxin. The only remaining compound is Clarithromycin. The Human clinical trial Phase I showed severe adverse effects, which helps confirm that the compound left is Clarithromycin."], "consumed_tokens": 5742, "observations": [null, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": true, "parse_error": false}], "seed": 11, "average_actions": 4.4, "average_tokens": 4914.2, "average_correct": 0.8, "average_parse_error": 0.0, "average_successful_action_num": 4.5, "average_successful_tokens": 5046.75}
{"trajectories": [{"actions": ["Ames mutagenicity test", "In vitro enzyme inhibition assay", "hERG channel inhibition assay", "Dose-response study", "Omeprazole", {"predicted_truth": "Omeprazole"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: The Ames mutagenicity test can help rule out compounds that show mutagenic potential. Since Doxycycline is known to show mutagenicity in this assay, performing this test will allow us to quickly eliminate it as a candidate. This will help us narrow down the possible pharmaceutical compounds more efficiently.", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: Since the Ames mutagenicity test has ruled out Doxycycline, we can now focus on the remaining compounds: Gabapentin, Terfenadine, and Omeprazole. The In vitro enzyme inhibition assay can help us further narrow down the options by evaluating the capability of these compounds to inhibit enzyme activity. This assay will provide useful information to rule out one or more of the remaining compounds.", "<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay has provided us with an IC50 value of 7215.33 nM, which falls within the range where Omeprazole is ruled out. This leaves us with Gabapentin and Terfenadine. The hERG channel inhibition assay is a critical test for ruling out Terfenadine due to its known cardiac risks. Therefore, performing this assay will help us determine if Terfenadine should be ruled out.", "<ANSWER> Dose-response study </ANSWER>\n\nReason: The hERG channel inhibition assay has ruled out Terfenadine. We are left with Gabapentin and Omeprazole. The Dose-response study can help us differentiate between these two compounds based on their non-linear response characteristics. Gabapentin is known to exhibit a non-linear dose-response relationship, which can help us identify it as the correct compound.", "<ANSWER> Omeprazole </ANSWER>\n\nReason: The Dose-response study has shown a sigmoidal response, which is characteristic of Gabapentin. Since Omeprazole does not exhibit a sigmoidal response and we have already ruled out the other compounds, Omeprazole must be the correct compound."], "consumed_tokens": 8175, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "In vitro enzyme inhibition assay", "observation": 7215.333877348161}, {"action": "hERG channel inhibition assay", "observation": 6.014570387277331}, {"action": "Dose-response study", "observation": "Sigmoidal response"}], "successful": false, "parse_error": false}, {"actions": ["Ames mutagenicity test", "In vitro enzyme inhibition assay", "hERG channel inhibition assay", "Omeprazole", {"predicted_truth": "Omeprazole"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: The Ames mutagenicity test can help rule out compounds that show mutagenic potential. Since Doxycycline is known to show mutagenicity in this assay, performing this test will allow us to eliminate Doxycycline from the list of possible compounds. This will help us narrow down the possibilities more quickly.", "<ANSWER> Gabapentin </ANSWER>\n\nReason: Since the Ames mutagenicity test showed a positive result, we can rule out Doxycycline. Now, we are left with Gabapentin, Terfenadine, and Omeprazole. Next, we can perform the hERG channel inhibition assay to further narrow down the options. If Terfenadine shows strong binding to the hERG potassium channel, it can be ruled out. \n\n<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: If Terfenadine shows strong binding to the hERG potassium channel, we can perform the in vitro enzyme inhibition assay to check for any strong enzyme inhibition, which could help us rule out Omeprazole. However, since we still have multiple options, performing the hERG channel inhibition assay first is a strategic choice.", "<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay showed an IC50 of 7215.333877348161 nM, which is in the range of 1000  10000 IC50 (nM). According to the guidebook, this range rules out Omeprazole. Now we are left with Gabapentin and Terfenadine. Performing the hERG channel inhibition assay will help us rule out Terfenadine based on its known cardiac risks.", "<ANSWER> Omeprazole </ANSWER>\n\nReason: The hERG channel inhibition assay showed an IC50 of 6.014570387277331 M, which is in the range of 0  10 IC50 (M). According to the guidebook, this range rules out Terfenadine. Now we are left with Gabapentin and Omeprazole. Since Terfenadine has been ruled out and the only remaining options are Gabapentin and Omeprazole, and we have already ruled out Terfenadine, the remaining compound must be Omeprazole."], "consumed_tokens": 6627, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "In vitro enzyme inhibition assay", "observation": 7215.333877348161}, {"action": "hERG channel inhibition assay", "observation": 6.014570387277331}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Doxycycline", {"predicted_truth": "Doxycycline"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay provides initial information about the compounds' ability to inhibit enzyme activity. This can help us rule out some compounds based on their IC50 values, which can be particularly useful in narrowing down the options.", "Based on the observation from the in vitro enzyme inhibition assay, the IC50 value of 7215.333877348161 nM is within the range of 1000  10000 IC50 (nM). According to the guidebook, this range rules out omeprazole.\n\n<ANSWER> Doxycycline </ANSWER>\n\nReasoning: Since omeprazole has been ruled out, we are left with Doxycycline, Gabapentin, and Terfenadine. The next step is to use other assays to further narrow down the options. However, since the question asks for either an action or a truth name, and we have ruled out omeprazole, the most appropriate response is to predict the truth name at this point."], "consumed_tokens": 2907, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 7215.333877348161}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "CYP450 metabolism assay", "hERG channel inhibition assay", "Ames mutagenicity test", "Doxycycline", {"predicted_truth": "Doxycycline"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: Starting with the in vitro enzyme inhibition assay can provide immediate information that may help rule out one or more compounds based on their IC50 values. This assay is particularly useful for quickly eliminating omeprazole, as it is known to inhibit CYP450 enzymes strongly.", "<ANSWER> CYP450 metabolism assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay indicated an IC50 value of 7215.33 nM, which falls within the range of 1000  10000 IC50 (nM). According to the guidebook, this range rules out omeprazole. Therefore, we can now focus on the remaining compounds: Doxycycline, Gabapentin, and Terfenadine. The next step is to use the CYP450 metabolism assay to further narrow down the possibilities. If the compound is a strong CYP450 inhibitor, it will be ruled out. Given that omeprazole is a known strong inhibitor, this assay will help confirm our current hypothesis.", "<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: The CYP450 metabolism assay showed that the compound is a weak inhibitor, which is not consistent with omeprazole's strong inhibition. This leaves us with Doxycycline, Gabapentin, and Terfenadine. The next logical step is to use the hERG channel inhibition assay. Terfenadine is known to have a high risk of causing cardiac issues due to hERG channel inhibition, so this assay should help us rule out Terfenadine.", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: The hERG channel inhibition assay observation of 6.014570387277331 M indicates a strong binding, which rules out Terfenadine. This leaves us with Doxycycline and Gabapentin. The next step is to use the Ames mutagenicity test to rule out Doxycycline, as it is known to show mutagenicity in this assay. This will help us identify Gabapentin as the remaining plausible compound.", "<ANSWER> Doxycycline </ANSWER>\n\nReason: The Ames mutagenicity test showed a positive result, which rules out Doxycycline. This leaves us with Gabapentin as the remaining plausible compound."], "consumed_tokens": 8502, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 7215.333877348161}, {"action": "CYP450 metabolism assay", "observation": "Weak inhibitor"}, {"action": "hERG channel inhibition assay", "observation": 6.014570387277331}, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "hERG channel inhibition assay", "Ames mutagenicity test", "Doxycycline", {"predicted_truth": "Doxycycline"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay can help us rule out Doxycycline and Omeprazole based on their IC50 values. This will provide us with valuable information to narrow down the possible compounds.", "<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: Since the in vitro enzyme inhibition assay has already provided the IC50 value of 7215.333877348161 nM, which falls in the range of 1000  10000 IC50 (nM), we can rule out Omeprazole. Now, we need to gather more information to differentiate between Doxycycline, Gabapentin, and Terfenadine. The hERG channel inhibition assay is a good next step as it can help rule out Terfenadine due to its known cardiac risks.", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: The hERG channel inhibition assay has ruled out Terfenadine due to its IC50 value of 6.014570387277331 M, which falls in the range of 0  10 IC50 (M). Now, we need to further narrow down the remaining compounds: Doxycycline, Gabapentin, and Omeprazole. The Ames mutagenicity test can help rule out Doxycycline, as it shows mutagenicity in this assay. This will leave us with Gabapentin and Omeprazole, and we can then use the CYP450 metabolism assay to rule out Omeprazole.", "<ANSWER> Doxycycline </ANSWER>\n\nReason: The Ames mutagenicity test has shown a positive result, which rules out Doxycycline. This leaves us with Gabapentin and Omeprazole. The next step is to use the CYP450 metabolism assay to rule out Omeprazole, as it is a strong inhibitor of CYP450 enzymes. However, since the CYP450 metabolism assay has not been performed yet and we need to make a prediction, we can conclude that Doxycycline is ruled out based on the current observations."], "consumed_tokens": 6519, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 7215.333877348161}, {"action": "hERG channel inhibition assay", "observation": 6.014570387277331}, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": false, "parse_error": false}], "seed": 12, "average_actions": 5.0, "average_tokens": 6546.0, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "Animal toxicity test", "Carcinogenicity study", "Sodium Valproate", {"predicted_truth": "Sodium Valproate"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nThe observation from the in vitro enzyme inhibition assay is 29.465675376336254. Since this value is within the range of 0 to 100, we can rule out Morphine based on the guidebook. Morphine is ruled out if the inhibitory concentration is within this range. \n\nNow, let's proceed with another assay to further narrow down the possibilities. \n\n<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Animal toxicity test </ANSWER>\n\nThe in vitro enzyme inhibition assay result of 29.465675376336254 has ruled out Morphine. Next, we can perform an animal toxicity test to further eliminate potential compounds. If Etoricoxib shows high toxicity in the animal toxicity test, it will be ruled out. Let's proceed with the animal toxicity test.", "<ANSWER> Sodium Valproate </ANSWER>\n\nThe animal toxicity test showed high toxicity, which rules out Etoricoxib. Now we are left with Sodium Valproate and Prednisone. \n\nNext, we can perform a carcinogenicity study to further narrow down the possibilities. If Prednisone is found to be carcinogenic, it will be ruled out. Let's proceed with the carcinogenicity study.\n\n<ANSWER> Carcinogenicity study </ANSWER>", "<ANSWER> Sodium Valproate </ANSWER>\n\nThe carcinogenicity study has shown that the compound is carcinogenic, which rules out Prednisone. This leaves us with Sodium Valproate as the only plausible compound remaining.\n\nSince we have identified the compound, we can end the game.\n\n<ANSWER> Sodium Valproate </ANSWER>"], "consumed_tokens": 6968, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 29.465675376336254}, {"action": "In vitro enzyme inhibition assay", "observation": 29.465675376336254}, {"action": "Animal toxicity test", "observation": "High toxicity"}, {"action": "Carcinogenicity study", "observation": "Carcinogenic"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "Animal toxicity test", "Carcinogenicity study", "Sodium Valproate", {"predicted_truth": "Sodium Valproate"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nBased on the observation from the in vitro enzyme inhibition assay (29.465675376336254), which is within the range of 0 to 100, we can rule out Morphine. \n\nNow, the remaining pharmaceutical compounds are:\n- Etoricoxib\n- Sodium Valproate\n- Prednisone\n\nNext, I will choose another trial to perform. Let's select the 'Animal toxicity test'.", "<ANSWER> Animal toxicity test </ANSWER>", "<ANSWER> Carcinogenicity study </ANSWER>\n\nBased on the high toxicity observed in the Animal toxicity test, we can rule out Etoricoxib. Now, the remaining pharmaceutical compounds are:\n- Sodium Valproate\n- Prednisone\n\nNext, I will perform the Carcinogenicity study to further narrow down the possibilities.", "<ANSWER> Sodium Valproate </ANSWER>\n\nBased on the observation from the Carcinogenicity study indicating that the compound is carcinogenic, we can rule out Prednisone. Since Sodium Valproate is the only remaining compound, we can confidently identify it as the correct pharmaceutical compound."], "consumed_tokens": 6644, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 29.465675376336254}, {"action": "In vitro enzyme inhibition assay", "observation": 29.465675376336254}, {"action": "Animal toxicity test", "observation": "High toxicity"}, {"action": "Carcinogenicity study", "observation": "Carcinogenic"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "Animal toxicity test", "Carcinogenicity study", "Morphine", {"predicted_truth": "Morphine"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nGiven the observation of 29.465675376336254 from the in vitro enzyme inhibition assay, we can infer that the compound is not Etoricoxib because it would be ruled out if the inhibitory concentration was within the range of 0 to 100. Since the value is much lower, Etoricoxib is not the compound in question. We will proceed to the next step by choosing another trial.", "<ANSWER> Animal toxicity test </ANSWER>\n\nGiven the observation from the in vitro enzyme inhibition assay, we can rule out Etoricoxib. The next logical step is to perform an animal toxicity test to further narrow down the possibilities. If a compound shows high toxicity, Etoricoxib would be ruled out, which is already known. We need to test the remaining compounds: Sodium Valproate, Morphine, and Prednisone.", "<ANSWER> Carcinogenicity study </ANSWER>\n\nGiven the high toxicity observed in the animal toxicity test, we can rule out Sodium Valproate. Now, we need to further distinguish between Morphine and Prednisone. The next logical step is to perform a carcinogenicity study. If a compound is found to be carcinogenic, Prednisone would be ruled out. Therefore, we will perform a carcinogenicity study.", "<ANSWER> Morphine </ANSWER>\n\nGiven the observations from the previous trials, we can rule out Sodium Valproate and Prednisone. Since the carcinogenicity study indicated that the compound is carcinogenic, and Morphine is the only remaining option, we can confidently identify the compound as Morphine."], "consumed_tokens": 6933, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 29.465675376336254}, {"action": "In vitro enzyme inhibition assay", "observation": 29.465675376336254}, {"action": "Animal toxicity test", "observation": "High toxicity"}, {"action": "Carcinogenicity study", "observation": "Carcinogenic"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Animal toxicity test", "Carcinogenicity study", "Sodium Valproate", {"predicted_truth": "Sodium Valproate"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nGiven the observation from the in vitro enzyme inhibition assay (29.465675376336254), we can infer that the compound is not completely ruled out as it falls outside the inhibitory concentration range of 0 to 100. This suggests we can keep Etoricoxib in our list of possible compounds. Next, we should choose another trial to perform to further narrow down the possibilities.\n\nLet's choose the <ANSWER> Animal toxicity test </ANSWER>.", "<ANSWER> Carcinogenicity study </ANSWER>\n\nGiven that the animal toxicity test showed high toxicity, we can rule out Etoricoxib. Now, we need to perform another test to further narrow down the possibilities. The next logical step is to perform the carcinogenicity study, as it will help us rule out Prednisone. If Prednisone is found to be carcinogenic, it can be eliminated from our list of possible compounds. \n\nLet's proceed with the <ANSWER> Carcinogenicity study </ANSWER>.", "<ANSWER> Sodium Valproate </ANSWER>\n\nGiven that both Etoricoxib and Prednisone have been ruled out, we are left with Sodium Valproate and Morphine. The carcinogenicity study ruled out Prednisone, and the animal toxicity test ruled out Etoricoxib. Since the carcinogenicity study showed that the compound is carcinogenic, we can now rule out Morphine as it is not typically carcinogenic.\n\nThus, the remaining compound is <ANSWER> Sodium Valproate </ANSWER>."], "consumed_tokens": 5359, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 29.465675376336254}, {"action": "Animal toxicity test", "observation": "High toxicity"}, {"action": "Carcinogenicity study", "observation": "Carcinogenic"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Morphine", {"predicted_truth": "Morphine"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Morphine </ANSWER>\n\nSince the in vitro enzyme inhibition assay resulted in an inhibitory concentration of 29.465675376336254, which is within the range of 0 to 100, we can rule out Morphine. This is because Morphine would be ruled out if the inhibitory concentration is within this range. Therefore, we can confidently eliminate Morphine as a possibility."], "consumed_tokens": 2351, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 29.465675376336254}], "successful": false, "parse_error": false}], "seed": 13, "average_actions": 5.2, "average_tokens": 5651.0, "average_correct": 0.6, "average_parse_error": 0.0, "average_successful_action_num": 5.666666666666667, "average_successful_tokens": 6323.666666666667}
{"trajectories": [{"actions": ["hERG channel inhibition assay", "Human clinical trial Phase I", "Dose-response study", "QT prolongation assessment", "Blood-brain barrier permeability test", "Terfenadine", {"predicted_truth": "Terfenadine"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: The hERG channel inhibition assay is particularly relevant for Terfenadine, as it was withdrawn from the market due to its potential to cause serious cardiac side effects. By performing this assay, we can quickly eliminate Terfenadine if it shows any inhibition of the hERG channel, which would be a strong indicator that it is this compound we are dealing with. This step helps narrow down the possibilities efficiently.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Since the hERG channel inhibition assay did not conclusively identify Terfenadine, we need to perform another assay to further narrow down the possibilities. The Human clinical trial Phase I can provide information on safety and tolerability, which might help us rule out Atenolol if severe adverse effects are observed. This step is necessary to systematically eliminate the compounds until we identify the correct one.", "<ANSWER> Dose-response study </ANSWER>\n\nReason: Given that severe adverse effects were observed in the Human clinical trial Phase I, Atenolol can be ruled out as it is a known beta-blocker with such effects. The next step is to perform a Dose-response study to further differentiate between Terfenadine, Amiodarone, and Gabapentin. This will help us understand the dose-dependent effects and eliminate one of the remaining compounds.", "<ANSWER> QT prolongation assessment </ANSWER>\n\nReason: Since the Dose-response study showed a non-linear response, Gabapentin can be ruled out as it is known to have a non-linear dose-response relationship. The next step is to perform a QT prolongation assessment to further differentiate between Terfenadine and Amiodarone. Both compounds can prolong the QT interval, but Terfenadine is specifically known for this effect. Therefore, this assessment will help us identify the correct compound.", "<ANSWER> Blood-brain barrier permeability test </ANSWER>\n\nReason: Since the QT prolongation assessment showed no effect on the QT interval, Amiodarone can be ruled out as it is known to affect the QT interval. The remaining compound is Terfenadine. To confirm, we can perform a Blood-brain barrier permeability test. If Terfenadine does not penetrate the blood-brain barrier, it will be the correct compound.", "<ANSWER> Terfenadine </ANSWER>\n\nReason: The Blood-brain barrier permeability test showed that the compound does not penetrate the blood-brain barrier, which matches Terfenadine's known properties. Therefore, Terfenadine is the correct compound."], "consumed_tokens": 9773, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 3.9380962235865424}, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}, {"action": "Dose-response study", "observation": "Non-linear response"}, {"action": "QT prolongation assessment", "observation": "No effect on QT"}, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}], "successful": false, "parse_error": false}, {"actions": ["Human clinical trial Phase I", "Terfenadine", {"predicted_truth": "Terfenadine"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>", "<ANSWER> Terfenadine </ANSWER>\n\nBased on the observation of severe adverse effects in the Human clinical trial Phase I, Terfenadine can be ruled out as it is known to have serious cardiac side effects. The remaining compounds are Atenolol, Amiodarone, and Gabapentin. Since Terfenadine has been identified as the compound with severe adverse effects, we can now proceed to rule out the other compounds using the available clinical trials and bioassays."], "consumed_tokens": 2551, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": false, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "Human clinical trial Phase I", "Dose-response study", "QT prolongation assessment", "Blood-brain barrier permeability test", "Human clinical trial Phase I", "Terfenadine", {"predicted_truth": "Terfenadine"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: The hERG channel inhibition assay is a critical test for ruling out compounds that might interfere with the hERG potassium channel, which is linked to cardiac arrhythmias. Since Terfenadine was withdrawn from the market due to its potential to cause serious cardiac side effects, this assay can help us quickly eliminate it if it shows inhibition of the hERG channel. This will help narrow down the list of possible compounds more efficiently.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Since the hERG channel inhibition assay showed 3.9380962235865424 inhibition, which is greater than 0-10%, Terfenadine can be ruled out. Now, we have three remaining compounds: Atenolol, Amiodarone, and Gabapentin. A human clinical trial Phase I can help us identify any severe adverse effects, which can help us rule out Atenolol if severe adverse effects are observed.", "<ANSWER> Dose-response study </ANSWER>\n\nReason: Since severe adverse effects were observed in the Human clinical trial Phase I, Atenolol can be ruled out. This leaves us with Amiodarone and Gabapentin. The Dose-response study can help us determine if there is a non-linear dose-response relationship, which would rule out Gabapentin.", "<ANSWER> QT prolongation assessment </ANSWER>\n\nReason: Since the Dose-response study showed a non-linear response, Gabapentin can be ruled out. This leaves us with Amiodarone. The QT prolongation assessment can help us determine if Amiodarone has any effect on the QT interval, which would confirm that Amiodarone is the correct compound.", "<ANSWER> Blood-brain barrier permeability test </ANSWER>\n\nReason: Since the QT prolongation assessment showed no effect on the QT interval, Amiodarone is not ruled out by this test. However, to conclusively identify the remaining compound, we can perform a Blood-brain barrier permeability test. Gabapentin, which does not penetrate the blood-brain barrier, can be ruled out if this test confirms that Amiodarone does penetrate it. This will leave us with the correct compound, Amiodarone.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Since the Blood-brain barrier permeability test showed that the compound does not penetrate the blood-brain barrier, Gabapentin can be ruled out. This leaves us with Atenolol, Terfenadine, and Amiodarone. Performing a Human clinical trial Phase I can help us identify any severe adverse effects, which can help us rule out Atenolol if severe adverse effects are observed.", "<ANSWER> Terfenadine </ANSWER>\n\nReason: Given the observed severe adverse effects in the Human clinical trial Phase I, Atenolol can be ruled out. Since the remaining compounds are Terfenadine, Amiodarone, and Gabapentin, and Terfenadine is known for its serious cardiac side effects, the observation of severe adverse effects aligns with Terfenadine's known profile. Therefore, Terfenadine is the correct compound."], "consumed_tokens": 11950, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 3.9380962235865424}, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}, {"action": "Dose-response study", "observation": "Non-linear response"}, {"action": "QT prolongation assessment", "observation": "No effect on QT"}, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": false, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "Dose-response study", "Human clinical trial Phase I", "Amiodarone", {"predicted_truth": "Amiodarone"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: The hERG channel inhibition assay is particularly relevant for Terfenadine, as it was withdrawn from the market due to its potential to cause serious cardiac side effects. By performing this assay, we can determine if Terfenadine shows any hERG channel inhibition, which would help us rule it out if it does. This test is a critical step in eliminating Terfenadine from our list of possible compounds.", "<ANSWER> Dose-response study </ANSWER>\n\nReason: Since the hERG channel inhibition assay indicated 3.9380962235865424 inhibition, which is above the threshold for ruling out Terfenadine (0-10%), we can confirm that Terfenadine is not the correct compound. Next, we can perform a dose-response study to further narrow down the possibilities. This study will help us understand the dose-effect relationship for the remaining compounds: Atenolol, Amiodarone, and Gabapentin.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: The non-linear dose-response relationship observed in the dose-response study indicates that Gabapentin is not the correct compound, as it is known to have a linear dose-response relationship. Therefore, we can rule out Gabapentin. The remaining compounds are Atenolol and Amiodarone. The next step is to perform a human clinical trial Phase I to further differentiate between Atenolol and Amiodarone based on their observed outcomes.", "<ANSWER> Amiodarone </ANSWER>\n\nReason: The severe adverse effects observed in the human clinical trial Phase I indicate that Atenolol can be ruled out, as it generally has a better safety profile and does not typically cause severe adverse effects in Phase I trials. The remaining compound is Amiodarone. Since no further actions are needed to confirm this, we can predict that the correct compound is Amiodarone."], "consumed_tokens": 6101, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 3.9380962235865424}, {"action": "Dose-response study", "observation": "Non-linear response"}, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": true, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "Human clinical trial Phase I", "Dose-response study", "QT prolongation assessment", "Blood-brain barrier permeability test", "Amiodarone", {"predicted_truth": "Amiodarone"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: The hERG channel inhibition assay is particularly relevant for Terfenadine, as it was withdrawn from the market due to its potential to cause serious cardiac side effects. By performing this assay, we can determine if Terfenadine inhibits the hERG potassium channel, which would confirm or rule out Terfenadine as the compound. This assay provides a direct link to the known cardiac safety concerns of Terfenadine.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Since the hERG channel inhibition assay indicated 3.9380962235865424, which is above the threshold for potential cardiac side effects (typically 0-10% inhibition), this suggests that the compound in question does not have significant hERG channel inhibition. Therefore, we can rule out Terfenadine. To further narrow down the possibilities, a Human clinical trial Phase I can provide information on safety and tolerability, which will help us eliminate Atenolol if it shows severe adverse effects. This step will bring us closer to identifying the correct compound.", "<ANSWER> Dose-response study </ANSWER>\n\nReason: Given that Atenolol showed severe adverse effects in the Human clinical trial Phase I, we can rule out Atenolol. The remaining compounds are Terfenadine, Amiodarone, and Gabapentin. The next logical step is to perform a Dose-response study to understand the dose-effect relationship and potential toxicity. This will help us rule out one of the remaining compounds.", "<ANSWER> QT prolongation assessment </ANSWER>\n\nReason: Since the Dose-response study showed a non-linear response, Gabapentin can be ruled out as it mimics GABA and typically does not show a non-linear dose-response relationship. The remaining compounds are Terfenadine and Amiodarone. The QT prolongation assessment is crucial for Terfenadine, as it can cause QT prolongation, which is a known cardiac side effect. This assessment will help us confirm or rule out Terfenadine.", "<ANSWER> Blood-brain barrier permeability test </ANSWER>\n\nReason: Since the QT prolongation assessment showed no effect on the QT interval, Terfenadine can be ruled out. The remaining compound is Amiodarone. To confirm Amiodarone, the Blood-brain barrier permeability test is appropriate, as Amiodarone is known to penetrate the blood-brain barrier, while Gabapentin does not. This test will help us definitively identify the compound.", "<ANSWER> Amiodarone </ANSWER>\n\nReason: The Blood-brain barrier permeability test showed that the compound does not penetrate the blood-brain barrier. Since Amiodarone is known to penetrate the blood-brain barrier and the other compounds do not, this test confirms that the remaining compound is Amiodarone."], "consumed_tokens": 10069, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 3.9380962235865424}, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}, {"action": "Dose-response study", "observation": "Non-linear response"}, {"action": "QT prolongation assessment", "observation": "No effect on QT"}, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}], "successful": true, "parse_error": false}], "seed": 14, "average_actions": 6.0, "average_tokens": 8088.8, "average_correct": 0.4, "average_parse_error": 0.0, "average_successful_action_num": 6.0, "average_successful_tokens": 8085.0}
{"trajectories": [{"actions": ["In vitro enzyme inhibition assay", "Reactive oxygen species (ROS) assay", "Imatinib", {"predicted_truth": "Imatinib"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay can help us quickly eliminate Montelukast, as it inhibits the actions of substances causing allergy and asthma symptoms. By testing for enzyme inhibition, we can rule out Montelukast if no inhibition is observed, which will help narrow down the possibilities more efficiently.", "<ANSWER> Reactive oxygen species (ROS) assay </ANSWER>\n\nReason: Since the In vitro enzyme inhibition assay did not rule out any compound (the observed value of 11.712983502505537 is within a non-inhibitory range, which includes Montelukast), we need to select another assay. The Reactive oxygen species (ROS) assay can help us eliminate Cisplatin if high ROS generation is observed, aiding in further narrowing down the possibilities.", "<ANSWER> Imatinib </ANSWER>\n\nReason: The observation of high ROS generation indicates that Cisplatin is not the compound in question. This leaves us with Montelukast, Saline solution, and Imatinib. Since Imatinib is a tyrosine kinase inhibitor and is known to induce oxidative stress through mechanisms that can generate ROS, the high ROS generation suggests that Imatinib is likely the compound. The remaining trials would be more confirmatory but given the options and the process, Imatinib is the most plausible compound based on the current information."], "consumed_tokens": 3973, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 11.712983502505537}, {"action": "Reactive oxygen species (ROS) assay", "observation": "High ROS generation"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "Oxidative stress assay", "Eye irritation test", "Reactive oxygen species (ROS) assay", "Clinical biomarker identification", "Montelukast", {"predicted_truth": "Montelukast"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Oxidative stress assay </ANSWER>", "<ANSWER> Eye irritation test </ANSWER>", "<ANSWER> Reactive oxygen species (ROS) assay </ANSWER>", "<ANSWER> Clinical biomarker identification </ANSWER>", "<ANSWER> Montelukast </ANSWER>\n\nBased on the observations:\n- The in vitro enzyme inhibition assay result is 11.712983502505537, which is between 0 and 100, ruling out Montelukast.\n- The oxidative stress assay showed high ROS generation, ruling out Cisplatin.\n- The eye irritation test showed that the substance is non-irritant, ruling out Saline solution.\n- The presence of a biomarker in the clinical biomarker identification rules out Imatinib.\n\nTherefore, the remaining compound is Montelukast."], "consumed_tokens": 9023, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 11.712983502505537}, {"action": "In vitro enzyme inhibition assay", "observation": 11.712983502505537}, {"action": "Oxidative stress assay", "observation": "Induces ROS"}, {"action": "Eye irritation test", "observation": "Non-irritant"}, {"action": "Reactive oxygen species (ROS) assay", "observation": "High ROS generation"}, {"action": "Clinical biomarker identification", "observation": "Biomarker identified"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "Oxidative stress assay", "Imatinib", {"predicted_truth": "Imatinib"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nGiven the observation from the In vitro enzyme inhibition assay (11.712983502505537), which is within the range of 0 to 100, we can rule out Montelukast. Therefore, Montelukast is not the compound in question.", "<ANSWER> Oxidative stress assay </ANSWER>\n\nGiven that we have already ruled out Montelukast due to the in vitro enzyme inhibition assay result, we should proceed with an assay that can help us eliminate more compounds. The Oxidative stress assay is a good choice because it can help us rule out Cisplatin if it shows high ROS generation.", "<ANSWER> Imatinib </ANSWER>\n\nGiven the observation from the Oxidative stress assay ('Induces ROS'), we can rule out Cisplatin. Now, we are left with Montelukast, Imatinib, and Saline solution. Since the Oxidative stress assay is only relevant to Cisplatin, we need to use another assay to differentiate between Montelukast, Imatinib, and Saline solution. The most appropriate next step is to perform a clinical biomarker identification to check for Imatinib, as it is known to be used in the treatment of cancers and its presence would be indicated by specific biomarkers.\n\nHowever, since we are asked to choose from the available actions or predict the truth, and we have already ruled out Cisplatin and are left with Montelukast, Imatinib, and Saline solution, the logical prediction based on the remaining options is Imatinib."], "consumed_tokens": 5288, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 11.712983502505537}, {"action": "In vitro enzyme inhibition assay", "observation": 11.712983502505537}, {"action": "Oxidative stress assay", "observation": "Induces ROS"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Montelukast", {"predicted_truth": "Montelukast"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "The observed value of 11.712983502505537 from the in vitro enzyme inhibition assay is significantly low (likely below the threshold for enzyme inhibition). Given the guidebook, Montelukast is ruled out if the enzyme inhibition is between 0 and 100. Since this value is below that threshold, we can confidently rule out Montelukast.\n\n<ANSWER> Montelukast </ANSWER>"], "consumed_tokens": 2357, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 11.712983502505537}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Imatinib", {"predicted_truth": "Imatinib"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nBy selecting the In vitro enzyme inhibition assay, we can test the ability of each compound to inhibit enzyme activity. If the compound inhibits the enzyme activity within the range of 0 to 100, we can rule out Montelukast as it is not expected to show such inhibition. This will help us narrow down the possible compounds and move closer to identifying the correct one.", "Observation from the In vitro enzyme inhibition assay is 11.712983502505537, which is not between 0 and 100. This result indicates that Montelukast is not the compound being tested, as Montelukast would not show such inhibition.\n\n<ANSWER> Imatinib </ANSWER>\n\nGiven the result, we can rule out Montelukast. Now, we need to further narrow down the possibilities between Imatinib, Saline solution, and Cisplatin. Next, let's perform the Oxidative stress assay to see if it rules out any of the remaining compounds."], "consumed_tokens": 2555, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 11.712983502505537}], "successful": true, "parse_error": false}], "seed": 15, "average_actions": 4.6, "average_tokens": 4639.2, "average_correct": 0.6, "average_parse_error": 0.0, "average_successful_action_num": 4.0, "average_successful_tokens": 3938.6666666666665}
{"trajectories": [{"actions": ["Ames mutagenicity test", "Doxycycline", {"predicted_truth": "Doxycycline"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: Let's start by performing the Ames mutagenicity test. This test can help us rule out Doxycycline if it shows positive results, which would indicate mutagenic potential. Conversely, a negative result would rule out Azithromycin. This test provides a clear way to eliminate two compounds based on their mutagenic properties.", "<ANSWER> Doxycycline </ANSWER>\n\nReason: The Ames mutagenicity test showed a positive result, which indicates mutagenic potential. According to the guidebook, a positive result rules out Doxycycline. Therefore, Doxycycline can be eliminated from the list of possible compounds."], "consumed_tokens": 2412, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": false, "parse_error": false}, {"actions": ["Ames mutagenicity test", "Azithromycin", {"predicted_truth": "Azithromycin"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: Since Doxycycline is known to be a tetracycline antibiotic and the Ames mutagenicity test can determine if a compound causes genetic mutations, this test will help us rule out Doxycycline if it shows positive results for mutagenic potential. This test is a good starting point to eliminate one of the compounds from the list.", "<ANSWER> Azithromycin </ANSWER>\n\nReason: The positive result from the Ames mutagenicity test rules out Doxycycline. Now, we need to further narrow down the remaining compounds. Since the Ames test is already positive for Doxycycline, we can move on to another test. Let's use the In vitro enzyme inhibition assay to rule out Albuterol, as it is known to be a bronchodilator and not typically associated with enzyme inhibition. If the In vitro enzyme inhibition assay shows no enzyme inhibition for the remaining compounds, we can then predict the correct compound."], "consumed_tokens": 2477, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": false, "parse_error": false}, {"actions": ["Ames mutagenicity test", "Ames mutagenicity test", "In vitro enzyme inhibition assay", "Solubility test", "Azithromycin", {"predicted_truth": "Azithromycin"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>", "<ANSWER> Ames mutagenicity test </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Solubility test </ANSWER>", "<ANSWER> Azithromycin </ANSWER>"], "consumed_tokens": 5918, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "In vitro enzyme inhibition assay", "observation": 63.49959241034841}, {"action": "Solubility test", "observation": "Highly soluble"}], "successful": false, "parse_error": false}, {"actions": ["Ames mutagenicity test", "Doxycycline", {"predicted_truth": "Doxycycline"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: To efficiently rule out compounds, we can start with an assay that has clear outcomes for specific compounds. The Ames mutagenicity test can rule out Doxycycline with a positive result or Azithromycin with a negative result. This provides a direct elimination and helps narrow down the potential compounds.", "<ANSWER> Doxycycline </ANSWER>\n\nReason: Given the positive result from the Ames mutagenicity test, Doxycycline is ruled out. This leaves us with the other three compounds: Azithromycin, Albuterol, and Sertraline."], "consumed_tokens": 2390, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": false, "parse_error": false}, {"actions": ["Ames mutagenicity test", "Doxycycline", {"predicted_truth": "Doxycycline"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: Starting with the Ames mutagenicity test can help us rule out compounds that have a mutagenic potential. Doxycycline is known to be non-mutagenic, so a positive result would rule it out immediately. This test can quickly eliminate one of the options and provide clear guidance on which compounds to keep or discard.", "<ANSWER> Doxycycline </ANSWER>\n\nReason: Since the Ames mutagenicity test resulted in a positive outcome, Doxycycline is ruled out. This leaves us with the compounds Azithromycin, Albuterol, and Sertraline. We can now proceed with another test to further narrow down the options."], "consumed_tokens": 2416, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": false, "parse_error": false}], "seed": 16, "average_actions": 3.6, "average_tokens": 3122.6, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["Amphotericin B", {"predicted_truth": "Amphotericin B"}], "generated_text": ["<ANSWER> Amphotericin B </ANSWER>"], "consumed_tokens": 1084, "observations": [null], "successful": true, "parse_error": false}, {"actions": ["Ames mutagenicity test", "In vitro enzyme inhibition assay", "Amphotericin B", {"predicted_truth": "Amphotericin B"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>\n\nBy selecting the Ames mutagenicity test, we can eliminate \"Azithromycin\" if it shows a positive result, as it is the only compound that would be ruled out in this specific test. This will help narrow down the list of possible pharmaceutical compounds.", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nSince the Ames mutagenicity test ruled out \"Azithromycin,\" we now have three remaining compounds: 'Saline solution', 'Sildenafil', and 'Amphotericin B'. The next step is to perform the in vitro enzyme inhibition assay. The outcome of this test will help us eliminate \"Sildenafil\" because it specifically inhibits phosphodiesterase type 5 (PDE5), which will result in a high score in this assay. \n\n<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Amphotericin B </ANSWER>\n\nThe in vitro enzyme inhibition assay produced a high score of 8336.674799900924, which rules out \"Sildenafil.\" This leaves us with 'Saline solution' and 'Amphotericin B'. Since \"Saline solution\" is not an active pharmaceutical compound and \"Amphotericin B\" is an antifungal medication, the remaining plausible compound is 'Amphotericin B'."], "consumed_tokens": 3879, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Negative"}, {"action": "In vitro enzyme inhibition assay", "observation": 8336.674799900924}], "successful": true, "parse_error": false}, {"actions": ["Ames mutagenicity test", "In vitro enzyme inhibition assay", "Amphotericin B", {"predicted_truth": "Amphotericin B"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>\n\nBy selecting the Ames mutagenicity test, we can immediately rule out \"Azithromycin\" if the outcome is positive, thus narrowing down the list of potential compounds.", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nThe Ames mutagenicity test resulted in a negative outcome, so \"Azithromycin\" can be ruled out. Next, we can perform the In vitro enzyme inhibition assay to see if any of the remaining compounds have specific inhibitory effects on enzymes.", "<ANSWER> Amphotericin B </ANSWER>\n\nThe In vitro enzyme inhibition assay result of 8336.674799900924 falls within the range of 1000 to 10000, which rules out \"Sildenafil\". \n\nGiven the remaining compounds are 'Saline solution', 'Amphotericin B', and 'Azithromycin', and knowing that \"Azithromycin\" has been ruled out, the only plausible compound left is 'Amphotericin B'. \n\nNo further trials are necessary as we have identified the compound."], "consumed_tokens": 3736, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Negative"}, {"action": "In vitro enzyme inhibition assay", "observation": 8336.674799900924}], "successful": true, "parse_error": false}, {"actions": ["Ames mutagenicity test", "In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "Solubility test", "Off-target activity screening", "Saline solution", {"predicted_truth": "Saline solution"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "The observation from the Ames mutagenicity test was negative, which rules out \"Azithromycin\". The next step is to choose another trial to eliminate more compounds. The in vitro enzyme inhibition assay has an observed value of 8336.674799900924, which falls into the range of 1000 to 10000, indicating that \"Sildenafil\" is ruled out.\n\n<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "The observation from the in vitro enzyme inhibition assay is 8336.674799900924, which falls into the range of 1000 to 10000, indicating that \"Sildenafil\" is ruled out. We are left with the following compounds: ['Saline solution', 'Amphotericin B', 'Azithromycin'].\n\nThe next logical step is to choose a trial that can help us further narrow down the possibilities. The solubility test could be useful here because it has different outcome ranges that can rule out one of the remaining compounds.\n\n<ANSWER> Solubility test </ANSWER>", "The observation from the solubility test is 'Highly soluble', which rules out \"Azithromycin\". We are now left with the following compounds: ['Saline solution', 'Amphotericin B'].\n\nThe next logical step is to choose a trial that can help us further narrow down the possibilities. The only remaining trial we haven't used is the off-target activity screening. This trial can help us determine if \"Amphotericin B\" has high off-target activity, which would rule it out.\n\n<ANSWER> Off-target activity screening </ANSWER>", "Since the off-target activity screening ruled out \"Amphotericin B\" and we are left with \"Saline solution\", we can predict the remaining compound.\n\n<ANSWER> Saline solution </ANSWER>"], "consumed_tokens": 8314, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Negative"}, {"action": "In vitro enzyme inhibition assay", "observation": 8336.674799900924}, {"action": "In vitro enzyme inhibition assay", "observation": 8336.674799900924}, {"action": "Solubility test", "observation": "Highly soluble"}, {"action": "Off-target activity screening", "observation": "Low off-target activity"}], "successful": false, "parse_error": false}, {"actions": ["Ames mutagenicity test", "In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "Eye irritation test", "Amphotericin B", {"predicted_truth": "Amphotericin B"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: Since we have not yet performed any trials, we can start with the Ames mutagenicity test. This trial will help us eliminate \"Azithromycin\" if the outcome is positive, which would reduce our list of potential compounds.", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: Since the Ames mutagenicity test ruled out \"Azithromycin\", we now have 'Saline solution', 'Sildenafil', and 'Amphotericin B' as potential compounds. The next logical step is to perform the In vitro enzyme inhibition assay. If the outcome is in the range of 1000 to 10000, it will rule out \"Sildenafil\".", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay has ruled out \"Sildenafil\" with an outcome in the range of 1000 to 10000. This leaves us with 'Saline solution' and 'Amphotericin B' as potential compounds. The next logical step is to perform the Eye irritation test to further narrow down the options. If \"Saline solution\" is non-irritant, then \"Amphotericin B\" would be the remaining compound.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: The In vitro enzyme inhibition assay has ruled out \"Sildenafil\". The next logical step is to perform the Eye irritation test. If \"Saline solution\" is non-irritant, then \"Amphotericin B\" would be the remaining compound.", "<ANSWER> Amphotericin B </ANSWER>\n\nReason: The Eye irritation test ruled out \"Saline solution\" as it is non-irritant. This leaves us with 'Amphotericin B' and 'Azithromycin'. Since the In vitro enzyme inhibition assay and Eye irritation test have already ruled out 'Sildenafil' and 'Saline solution' respectively, the remaining compound must be 'Amphotericin B'."], "consumed_tokens": 7039, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Negative"}, {"action": "In vitro enzyme inhibition assay", "observation": 8336.674799900924}, {"action": "In vitro enzyme inhibition assay", "observation": 8336.674799900924}, {"action": "Eye irritation test", "observation": "Non-irritant"}], "successful": true, "parse_error": false}], "seed": 17, "average_actions": 4.6, "average_tokens": 4810.4, "average_correct": 0.8, "average_parse_error": 0.0, "average_successful_action_num": 4.0, "average_successful_tokens": 3934.5}
{"trajectories": [{"actions": ["Metabolic stability assay", "P-glycoprotein interaction assay", "Cytokine release assay", "Skin sensitization test", "Pharmacodynamics evaluation", "Acetaminophen", {"predicted_truth": "Acetaminophen"}], "generated_text": ["<ANSWER> Metabolic stability assay </ANSWER>", "<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> Cytokine release assay </ANSWER>", "<ANSWER> Skin sensitization test </ANSWER>", "<ANSWER> Pharmacodynamics evaluation </ANSWER>", "The observation from the Pharmacodynamics evaluation indicates an unexpected effect. Given the previous eliminations, we have ruled out Losartan, Digoxin, and Morphine. Since Acetaminophen is the only remaining option and it does not show any red flags in the previous assays, we can confidently predict that the compound is Acetaminophen.\n\n<ANSWER> Acetaminophen </ANSWER>"], "consumed_tokens": 7346, "observations": [null, {"action": "Metabolic stability assay", "observation": "Unstable"}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}, {"action": "Cytokine release assay", "observation": "High cytokine release"}, {"action": "Skin sensitization test", "observation": "Sensitizer"}, {"action": "Pharmacodynamics evaluation", "observation": "Unexpected effect"}], "successful": true, "parse_error": false}, {"actions": ["Metabolic stability assay", "P-glycoprotein interaction assay", "Cytokine release assay", "Skin sensitization test", "Pharmacodynamics evaluation", "Losartan", {"predicted_truth": "Losartan"}], "generated_text": ["<ANSWER> Metabolic stability assay </ANSWER>", "<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> Cytokine release assay </ANSWER>", "<ANSWER> Skin sensitization test </ANSWER>", "<ANSWER> Pharmacodynamics evaluation </ANSWER>", "The compound that shows unexpected pharmacodynamic effects and is a sensitizer in the skin sensitization test is likely not one of the commonly expected compounds. Given the remaining options and the observed outcomes, let's consider the properties of each compound:\n\n1. **Morphine**: Unlikely to be a sensitizer and would not typically show unexpected pharmacodynamic effects if it were the correct compound.\n2. **Acetaminophen**: Unlikely to be a sensitizer and would not typically show unexpected pharmacodynamic effects if it were the correct compound.\n3. **Digoxin**: More likely to be a substrate in the P-glycoprotein interaction assay and would not typically show unexpected pharmacodynamic effects if it were the correct compound.\n4. **Losartan**: Could potentially show unexpected pharmacodynamic effects and might be a sensitizer, making it a plausible candidate.\n\nGiven the observations and the properties of the compounds, the most plausible remaining compound is **Losartan**.\n\n<ANSWER> Losartan </ANSWER>"], "consumed_tokens": 7468, "observations": [null, {"action": "Metabolic stability assay", "observation": "Unstable"}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}, {"action": "Cytokine release assay", "observation": "High cytokine release"}, {"action": "Skin sensitization test", "observation": "Sensitizer"}, {"action": "Pharmacodynamics evaluation", "observation": "Unexpected effect"}], "successful": false, "parse_error": false}, {"actions": ["Metabolic stability assay", "P-glycoprotein interaction assay", "Cytokine release assay", "Acetaminophen", {"predicted_truth": "Acetaminophen"}], "generated_text": ["<ANSWER> Metabolic stability assay </ANSWER>\n\nReason: Starting with the metabolic stability assay can help us quickly rule out Losartan. If Losartan is found to be unstable, it can be eliminated from the list, as it is not a primary focus of the other trials given the context of the compounds.", "<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: Since Losartan has been ruled out due to its unstable metabolic stability, we can now focus on the remaining compounds: Morphine, Acetaminophen, and Digoxin. The P-glycoprotein interaction assay is a good next step because:\n- Morphine and Acetaminophen do not typically interact with P-glycoprotein in a significant way.\n- Digoxin, being a cardiac glycoside, is known to be a substrate of P-glycoprotein, making it a likely candidate to show interaction.\n\nBy performing this assay, we can quickly rule out Digoxin if it is a substrate, further narrowing down our options.", "<ANSWER> Cytokine release assay </ANSWER>\n\nReason: Since Digoxin has been ruled out as a substrate of P-glycoprotein, we are left with Morphine and Acetaminophen. The Cytokine release assay is appropriate next because:\n- Morphine is known to have pro-inflammatory properties and can induce high cytokine release.\n- Acetaminophen typically does not induce significant cytokine release.\n\nBy performing this assay, we can rule out Morphine if it shows high cytokine release, leaving us with Acetaminophen as the remaining plausible compound.", "<ANSWER> Acetaminophen </ANSWER>\n\nReason: Since Morphine has been ruled out due to high cytokine release, and we are left with Acetaminophen, we can confidently predict that the remaining compound is Acetaminophen."], "consumed_tokens": 5558, "observations": [null, {"action": "Metabolic stability assay", "observation": "Unstable"}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}, {"action": "Cytokine release assay", "observation": "High cytokine release"}], "successful": true, "parse_error": false}, {"actions": ["Metabolic stability assay", "P-glycoprotein interaction assay", "Cytokine release assay", "Acetaminophen", {"predicted_truth": "Acetaminophen"}], "generated_text": ["<ANSWER> Metabolic stability assay </ANSWER>\n\nBy performing the Metabolic stability assay, we can determine the stability of each compound in a biological system. This will help us rule out Losartan, which is known to be unstable in such assays. If Losartan is unstable, it can be eliminated from our list of potential compounds.", "<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nSince Losartan has been ruled out due to its unstable nature, we can now proceed with the P-glycoprotein interaction assay. If Digoxin is identified as a substrate in this assay, it must be ruled out. Otherwise, we will continue to evaluate the remaining compounds.", "<ANSWER> Cytokine release assay </ANSWER>\n\nSince Digoxin has been ruled out as a substrate in the P-glycoprotein interaction assay, we now need to evaluate the remaining compounds (Morphine and Acetaminophen) using the Cytokine release assay. If Morphine is noted to result in high cytokine release, it should be ruled out.", "<ANSWER> Acetaminophen </ANSWER>\n\nSince Morphine has been ruled out due to high cytokine release, the only remaining compound is Acetaminophen. Therefore, we can confidently identify Acetaminophen as the correct compound."], "consumed_tokens": 5251, "observations": [null, {"action": "Metabolic stability assay", "observation": "Unstable"}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}, {"action": "Cytokine release assay", "observation": "High cytokine release"}], "successful": true, "parse_error": false}, {"actions": ["Metabolic stability assay", "P-glycoprotein interaction assay", "Cytokine release assay", "Acetaminophen", {"predicted_truth": "Acetaminophen"}], "generated_text": ["<ANSWER> Metabolic stability assay </ANSWER>\n\nBy performing the metabolic stability assay, we can determine which compounds are unstable and can be ruled out. Losartan is known to be metabolized slowly, while the other compounds have different metabolic profiles. This assay will help us eliminate Losartan if it is unstable, making it a good starting point for our analysis.", "<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nSince the metabolic stability assay showed that Losartan is unstable, we can rule it out. Now, we need to determine if Digoxin is a substrate of P-glycoprotein. This will help us further narrow down the possibilities.", "<ANSWER> Cytokine release assay </ANSWER>\n\nSince Digoxin is a substrate of P-glycoprotein, it can be ruled out. Now, we need to determine if Morphine or Acetaminophen causes high cytokine release. Performing the cytokine release assay will help us identify which compound, if any, results in high cytokine release and can be ruled out.", "<ANSWER> Acetaminophen </ANSWER>\n\nSince Morphine causes high cytokine release, it can be ruled out. This leaves us with Acetaminophen as the only remaining compound."], "consumed_tokens": 5235, "observations": [null, {"action": "Metabolic stability assay", "observation": "Unstable"}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}, {"action": "Cytokine release assay", "observation": "High cytokine release"}], "successful": true, "parse_error": false}], "seed": 18, "average_actions": 5.8, "average_tokens": 6171.6, "average_correct": 0.8, "average_parse_error": 0.0, "average_successful_action_num": 5.5, "average_successful_tokens": 5847.5}
{"trajectories": [{"actions": ["Human clinical trial Phase I", "Furosemide", {"predicted_truth": "Furosemide"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Given the outcomes of the other tests, we can rule out 'Acetaminophen', 'Saline solution', and 'Metoprolol' based on their specific properties and test results. The only remaining compound is 'Furosemide'. To confirm, we should perform a Human clinical trial Phase I since Metoprolol is associated with severe adverse effects in this trial, which would not be a concern for Furosemide.", "<ANSWER> Furosemide </ANSWER>\n\nReason: Since the Human clinical trial Phase I ruled out Metoprolol due to severe adverse effects, and 'Furosemide' is the only remaining compound, we can confidently identify 'Furosemide' as the correct pharmaceutical compound."], "consumed_tokens": 2669, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": false, "parse_error": false}, {"actions": ["Human clinical trial Phase I", "Pharmacokinetics profiling", "Acetaminophen", {"predicted_truth": "Acetaminophen"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Given the outcomes from the guidebook, Metoprolol is ruled out due to severe adverse effects observed in the Human clinical trial Phase I. This trial can help us eliminate Metoprolol early on. Since we are looking to identify the correct compound and we know Metoprolol does not fit, performing this trial will provide clear outcomes that can help us narrow down the possibilities.", "<ANSWER> Pharmacokinetics profiling </ANSWER>\n\nReason: Since Metoprolol has been ruled out due to severe adverse effects, we can focus on the remaining compounds: Furosemide, Saline solution, and Acetaminophen. The Pharmacokinetics profiling trial can help us further narrow down the options. Furosemide is known to have a short half-life, so this trial should help us identify if it is the correct compound.", "<ANSWER> Acetaminophen </ANSWER>\n\nReason: Given that Furosemide has a short half-life, it has been ruled out by the Pharmacokinetics profiling trial. This leaves us with Saline solution and Acetaminophen. Since Metoprolol has already been ruled out, we can predict that the correct compound is either Saline solution or Acetaminophen. Given the properties of Acetaminophen, which is a non-sensitizer and non-irritant, and the lack of additional information that would rule out Saline solution, we can make an educated prediction. However, based on the available information and the process of elimination, Acetaminophen is the most likely correct compound."], "consumed_tokens": 4272, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}, {"action": "Pharmacokinetics profiling", "observation": "Short half-life"}], "successful": false, "parse_error": false}, {"actions": ["Skin sensitization test", "Pharmacokinetics profiling", "Human clinical trial Phase I", "Saline solution", {"predicted_truth": "Saline solution"}], "generated_text": ["<ANSWER> Skin sensitization test </ANSWER>\n\nReason: The skin sensitization test can help us rule out Acetaminophen, as it is classified as a non-sensitizer on the skin. By performing this test, we can eliminate Acetaminophen from our list of possible compounds if there is no skin sensitization observed. This will help us narrow down the possibilities and get closer to identifying the correct compound.", "<ANSWER> Pharmacokinetics profiling </ANSWER>\n\nReason: Since the skin sensitization test has confirmed that Acetaminophen is a non-sensitizer, we can rule out Acetaminophen. The next step is to use a pharmacokinetics profiling test to further narrow down the possibilities. If Furosemide has a short half-life, it can be ruled out. This will help us identify the correct compound more accurately.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Since the pharmacokinetics profiling test has ruled out Furosemide due to its short half-life, we now have three remaining compounds: Saline solution, Acetaminophen, and Metoprolol. The next step is to perform a human clinical trial Phase I to observe any severe adverse effects. Metoprolol is known to have severe adverse effects in Phase I trials, so if no severe adverse effects are observed, we can rule out Metoprolol. This will leave us with Saline solution and Acetaminophen. Given that Acetaminophen is a known non-sensitizer and we have already ruled it out, the remaining compound must be Saline solution.", "<ANSWER> Saline solution </ANSWER>\n\nReason: Since the human clinical trial Phase I has observed severe adverse effects, we can rule out Metoprolol. This leaves us with Saline solution as the only viable option among the remaining compounds (Saline solution, Acetaminophen, and Metoprolol). Given that Acetaminophen and Metoprolol have been ruled out through previous tests, Saline solution must be the correct compound."], "consumed_tokens": 5978, "observations": [null, {"action": "Skin sensitization test", "observation": "Non-sensitizer"}, {"action": "Pharmacokinetics profiling", "observation": "Short half-life"}, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": true, "parse_error": false}, {"actions": ["Human clinical trial Phase I", "Pharmacokinetics profiling", "Skin sensitization test", "Saline solution", {"predicted_truth": "Saline solution"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Based on the pharmaceutical analysis guidebook, Metoprolol is ruled out in the Human clinical trial Phase I due to severe adverse effects. This trial can help us eliminate one of the compounds from our list. After performing this trial, we can further narrow down the possibilities.", "<ANSWER> Pharmacokinetics profiling </ANSWER>\n\nReason: Since Metoprolol has been ruled out due to severe adverse effects in the Human clinical trial Phase I, we can now use pharmacokinetic profiling to further narrow down the possibilities. Furosemide has a short half-life, which would fit the profile of being rapidly absorbed and eliminated from the body. This makes Furosemide a strong candidate to rule out next, leaving us with Acetaminophen and Saline solution as potential matches.", "<ANSWER> Skin sensitization test </ANSWER>\n\nReason: Since Furosemide has a short half-life, we can rule it out. The remaining compounds are Acetaminophen and Saline solution. Acetaminophen is known to be a non-sensitizer, which means it should not cause skin sensitization. Therefore, performing a skin sensitization test on Acetaminophen would likely show no sensitization, helping us to eliminate it and identify Saline solution as the remaining compound.", "<ANSWER> Saline solution </ANSWER>\n\nReason: The skin sensitization test ruled out Acetaminophen as it is a non-sensitizer. Therefore, the only remaining compound is Saline solution. We have identified the correct compound."], "consumed_tokens": 5797, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}, {"action": "Pharmacokinetics profiling", "observation": "Short half-life"}, {"action": "Skin sensitization test", "observation": "Non-sensitizer"}], "successful": true, "parse_error": false}, {"actions": ["Human clinical trial Phase I", "Pharmacokinetics profiling", "Acetaminophen", {"predicted_truth": "Acetaminophen"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Given the outcomes associated with each clinical trial, the Human clinical trial Phase I is a critical step to rule out Metoprolol due to its severe adverse effects observed in Phase I trials. This will help us eliminate one of the compounds quickly and focus on the remaining ones.", "<ANSWER> Pharmacokinetics profiling </ANSWER>\n\nReason: Since Metoprolol has been ruled out due to severe adverse effects in the Human clinical trial Phase I, we can now focus on the remaining compounds: Furosemide, Saline solution, and Acetaminophen. The Pharmacokinetics profiling trial can help us eliminate Furosemide because it has a short half-life, leaving us with either Saline solution or Acetaminophen.", "<ANSWER> Acetaminophen </ANSWER>\n\nReason: Since Furosemide has a short half-life, it has been ruled out by the Pharmacokinetics profiling trial. This leaves us with Saline solution and Acetaminophen. Acetaminophen is an analgesic and antipyretic agent, while Saline solution is primarily used for hydration. Given the context and the nature of the compounds, Acetaminophen is the most likely remaining pharmaceutical compound."], "consumed_tokens": 4156, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}, {"action": "Pharmacokinetics profiling", "observation": "Short half-life"}], "successful": false, "parse_error": false}], "seed": 19, "average_actions": 4.2, "average_tokens": 4574.4, "average_correct": 0.4, "average_parse_error": 0.0, "average_successful_action_num": 5.0, "average_successful_tokens": 5887.5}
{"trajectories": [{"actions": ["hERG channel inhibition assay", "P-glycoprotein interaction assay", "QT prolongation assessment", "Atenolol", {"predicted_truth": "Atenolol"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: The hERG channel inhibition assay is a critical test for evaluating the potential cardiac effects of a drug. Since Cisapride is known to be associated with cardiac issues due to its interaction with hERG potassium channels, this assay will help us rule out Cisapride if it shows significant hERG inhibition. This step is crucial for identifying the correct compound based on the observed outcomes.", "Observation from previous action: The hERG channel inhibition assay resulted in an inhibition level of 3.1690398324559297%, which is above the 10% threshold for significant hERG inhibition.\n\nSince Cisapride is excluded based on the hERG channel inhibition assay, we can now focus on the remaining compounds: Erythromycin, Ketoconazole, and Atenolol.\n\n<ANSWER> P-glycoprotein interaction assay </ANSWER>", "Observation from previous action: The P-glycoprotein interaction assay resulted in an inhibitor. Since Ketoconazole is known to be an inhibitor of P-glycoprotein, it can be ruled out.\n\nWe are now left with Erythromycin and Atenolol. To further narrow down the options, we can perform the QT prolongation assessment.\n\n<ANSWER> QT prolongation assessment </ANSWER>", "Observation from previous action: The QT prolongation assessment showed no effect on the QT interval. Since Erythromycin is known to prolong the QT interval, the absence of this effect rules it out.\n\nWe are now left with Atenolol. Since no further tests are provided and Atenolol is the only remaining compound, we can confidently identify it as the correct compound.\n\n<ANSWER> Atenolol </ANSWER>"], "consumed_tokens": 6015, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 3.1690398324559297}, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}, {"action": "QT prolongation assessment", "observation": "No effect on QT"}], "successful": false, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "Human clinical trial Phase I", "Ketoconazole", {"predicted_truth": "Ketoconazole"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>\n\nBy starting with the hERG channel inhibition assay, we can immediately rule out Cisapride if it shows significant hERG channel inhibition, which would indicate a potential risk for arrhythmias. This will help narrow down the possible compounds and guide further testing.", "Observation from previous action: The hERG channel inhibition assay resulted in 3.1690398324559297, which is within the range of 0-10%.\n\nSince the hERG channel inhibition assay result is within the range of 0-10%, Cisapride can be ruled out. This leaves us with the following compounds: Erythromycin, Ketoconazole, and Atenolol.\n\n<ANSWER> Human clinical trial Phase I </ANSWER>", "Observation from previous action: The human clinical trial Phase I resulted in severe adverse effects.\n\nSince severe adverse effects were observed, Atenolol can be ruled out as it is the only compound we haven't excluded yet that might be considered for further evaluation in this context.\n\n<ANSWER> Ketoconazole </ANSWER>"], "consumed_tokens": 4212, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 3.1690398324559297}, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": false, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "hERG channel inhibition assay", "hERG channel inhibition assay", "P-glycoprotein interaction assay", "QT prolongation assessment", "Atenolol", {"predicted_truth": "Atenolol"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: Starting with the hERG channel inhibition assay is a strategic choice because Cisapride is known to have a significant effect on the hERG potassium channels, which can lead to cardiac issues. By performing this assay, we can quickly eliminate Cisapride if it shows hERG inhibition, thus narrowing down our options.", "Observation from previous action: {'action': 'hERG channel inhibition assay', 'observation': 3.1690398324559297}\n\nThe observation of 3.1690398324559297 for the hERG channel inhibition assay is above the threshold for hERG inhibition (0-10%), indicating significant hERG inhibition. According to the analysis guidebook, if a compound shows significant hERG inhibition, it should be ruled out.\n\n<ANSWER> Cisapride </ANSWER>\n\nNow that Cisapride has been ruled out, we can proceed with the remaining compounds: Erythromycin, Ketoconazole, and Atenolol. The next logical step is to perform another assay that can help further narrow down the options. \n\n<ANSWER> hERG channel inhibition assay </ANSWER> (to confirm that Erythromycin and Ketoconazole do not show significant hERG inhibition)", "Observation from previous action: {'action': 'hERG channel inhibition assay', 'observation': 3.1690398324559297}\n\nGiven the observation of 3.1690398324559297, which indicates significant hERG inhibition, we have ruled out Cisapride. The remaining compounds are Erythromycin, Ketoconazole, and Atenolol.\n\nTo further narrow down the options, we can perform another assay. The hERG channel inhibition assay is a good choice again because it can help us rule out Erythromycin and Ketoconazole if they also show significant hERG inhibition.\n\n<ANSWER> hERG channel inhibition assay </ANSWER>", "Observation from previous action: {'action': 'hERG channel inhibition assay', 'observation': 3.1690398324559297}\n\nGiven that the previous hERG channel inhibition assay resulted in 3.1690398324559297, which is above the threshold for significant hERG inhibition (0-10%), we have already ruled out Cisapride. The next logical step is to perform the P-glycoprotein interaction assay to further narrow down the remaining compounds: Erythromycin, Ketoconazole, and Atenolol.\n\n<ANSWER> P-glycoprotein interaction assay </ANSWER>", "Observation from previous action: {'action': 'P-glycoprotein interaction assay', 'observation': 'Inhibitor'}\n\nGiven that Ketoconazole is an inhibitor in the P-glycoprotein interaction assay, we can rule it out. This leaves us with Erythromycin and Atenolol.\n\nThe next logical step is to perform the QT prolongation assessment to further narrow down the remaining options.\n\n<ANSWER> QT prolongation assessment </ANSWER>", "Observation from previous action: {'action': 'QT prolongation assessment', 'observation': 'No effect on QT'}\n\nGiven that Erythromycin does not have an effect on the QT interval, we can rule it out. This leaves us with Atenolol as the remaining compound.\n\n<ANSWER> Atenolol </ANSWER>"], "consumed_tokens": 10844, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 3.1690398324559297}, {"action": "hERG channel inhibition assay", "observation": 3.1690398324559297}, {"action": "hERG channel inhibition assay", "observation": 3.1690398324559297}, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}, {"action": "QT prolongation assessment", "observation": "No effect on QT"}], "successful": false, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "QT prolongation assessment", "P-glycoprotein interaction assay", "Atenolol", {"predicted_truth": "Atenolol"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: Since Cisapride is known to have a significant risk of causing cardiac issues, including QT interval prolongation and hERG channel inhibition, performing the hERG channel inhibition assay first can help quickly eliminate it as a potential compound if it shows inhibition. This will provide early insight into the potential cardiac risks of the compound being tested.", "Observation from previous action: The hERG channel inhibition assay result was 3.1690398324559297. Since this value is above the threshold indicating significant hERG channel inhibition (typically 10% or less would suggest potential cardiac risk), Cisapride can be eliminated from the list of possible compounds.\n\n<ANSWER> Cisapride </ ANSWER>\n\nNow that Cisapride has been ruled out, we can focus on the remaining compounds: Erythromycin, Ketoconazole, and Atenolol. The next logical step is to perform the QT prolongation assessment to further narrow down the possibilities. \n\n<ANSWER> QT prolongation assessment </ANSWER>", "Observation from previous action: The QT prolongation assessment result showed \"No effect on QT.\" This outcome rules out Erythromycin, as it is known to have the potential to prolong the QT interval.\n\n<ANSWER> Ketoconazole </ANSWER>\n\nSince Erythromycin has been ruled out, we now need to determine between Ketoconazole and Atenolol. The next logical step is to perform the P-glycoprotein interaction assay to further narrow down the possibilities.\n\n<ANSWER> P-glycoprotein interaction assay </ANSWER>", "Observation from previous action: The P-glycoprotein interaction assay result showed \"Inhibitor,\" which rules out Ketoconazole since it is known to inhibit P-glycoprotein.\n\n<ANSWER> Atenolol </ANSWER>"], "consumed_tokens": 6119, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 3.1690398324559297}, {"action": "QT prolongation assessment", "observation": "No effect on QT"}, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}], "successful": false, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "P-glycoprotein interaction assay", "Ketoconazole", {"predicted_truth": "Ketoconazole"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER> \n\nReason: Starting with the hERG channel inhibition assay is a strategic choice because compounds that significantly inhibit hERG channels can have serious cardiac effects. By performing this assay, we can quickly eliminate Cisapride if it shows significant hERG inhibition, which would indicate a heightened potential for cardiac issues and thus a quicker narrowing down of the possible compounds.", "Observation from the hERG channel inhibition assay is 3.1690398324559297. Since the value is within the range of 0-10%, this indicates that Cisapride is not significantly inhibiting the hERG channel. Therefore, we can rule out Cisapride based on this result.\n\n<ANSWER> Cisapride </ANSWER>\n\nNext, we should consider performing the P-glycoprotein interaction assay to further narrow down the possibilities. \n\n<ANSWER> P-glycoprotein interaction assay </ANSWER>", "Observation from the P-glycoprotein interaction assay indicates that the compound is an inhibitor. This result allows us to rule out Ketoconazole.\n\n<ANSWER> Ketoconazole </ANSWER>"], "consumed_tokens": 4273, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 3.1690398324559297}, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}], "successful": false, "parse_error": false}], "seed": 20, "average_actions": 5.0, "average_tokens": 6292.6, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["Immunogenicity testing", "Insulin", {"predicted_truth": "Insulin"}], "generated_text": ["<ANSWER> Immunogenicity testing </ANSWER> \n\nReason: Given the properties of the pharmaceutical compounds, immunogenicity testing is a critical assay. Insulin is known to be immunogenic, so if the compound is immunogenic, we can immediately rule out Insulin. This test can help us quickly eliminate one of the possible compounds from the list.", "<ANSWER> Insulin </ANSWER>\n\nReason: Since the observation from the immunogenicity test is 'Immunogenic', we can rule out Insulin as a possible compound. Insulin is known to be immunogenic, so if the compound is immunogenic, it must be Insulin. Therefore, we can confidently identify Insulin as the compound."], "consumed_tokens": 2621, "observations": [null, {"action": "Immunogenicity testing", "observation": "Immunogenic"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Immunogenicity testing", "Animal behavioral study", "Sertraline", {"predicted_truth": "Sertraline"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay can provide initial information to rule out some compounds based on their enzyme inhibition capacity. Specifically, it can help us rule out Albuterol and Sildenafil in certain outcome ranges, which can quickly narrow down our list of potential compounds.", "<ANSWER> Immunogenicity testing </ANSWER>\n\nReason: The observation from the in vitro enzyme inhibition assay is 1.4121348940183798, which falls within the 1,000-10,000 range. According to the guidebook, this range leads to ruling out Sildenafil. Therefore, we can now focus on the remaining compounds: Insulin, Sertraline, and Albuterol. The next step is to use immunogenicity testing to further narrow down the possibilities.", "<ANSWER> Animal behavioral study </ANSWER>\n\nReason: The observation from the immunogenicity testing is \"Immunogenic,\" which indicates that Insulin should be ruled out due to its known immunogenic properties. This leaves us with Sertraline and Albuterol. The next best step is to use the animal behavioral study to further exclude one of these compounds.", "<ANSWER> Sertraline </ANSWER>\n\nReason: The observation from the animal behavioral study is \"No behavioral changes,\" which suggests ruling out Sertraline since it typically affects behavior due to its antidepressant properties. This leaves us with Albuterol as the remaining compound."], "consumed_tokens": 5833, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 1.4121348940183798}, {"action": "Immunogenicity testing", "observation": "Immunogenic"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Sildenafil", {"predicted_truth": "Sildenafil"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay can help rule out specific compounds based on their inhibition capacity. This assay is particularly useful for eliminating Albuterol, which is expected to be ruled out if the outcome falls within the 0-100 range. Additionally, this assay provides clear criteria for exclusion, making it an effective starting point for narrowing down the potential compounds.", "<ANSWER> Sildenafil </ANSWER>\n\nReason: The observation from the In vitro enzyme inhibition assay is 1.4121348940183798, which falls within the 1,000-10,000 range. According to the guidebook, this range leads to ruling out Sildenafil as a relevant candidate. Therefore, Sildenafil can be eliminated from the list of potential compounds."], "consumed_tokens": 2689, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 1.4121348940183798}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Sildenafil", {"predicted_truth": "Sildenafil"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Sildenafil </ANSWER>\n\nThe observation from the In vitro enzyme inhibition assay is 1.4121348940183798, which falls within the 1,000-10,000 range. According to the guidebook, compounds in this range should be ruled out, and Sildenafil is the only remaining compound that fits this criterion. Therefore, we can confidently rule out Sildenafil."], "consumed_tokens": 2540, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 1.4121348940183798}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Immunogenicity testing", "In vitro enzyme inhibition assay", "Animal behavioral study", "Sertraline", {"predicted_truth": "Sertraline"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay can help us rule out certain compounds based on their inhibition capacity. Specifically, it can help us eliminate Albuterol, which is not expected to have significant enzyme inhibition activity. This will help narrow down the potential candidates more quickly.", "Observation from previous action: {'action': 'In vitro enzyme inhibition assay', 'observation': 1.4121348940183798}\n\nSince the observation is within the range of 1,000-10,000, we can rule out Sildenafil. This leaves us with the following potential compounds: ['Insulin', 'Sertraline', 'Albuterol'].\n\n<ANSWER> Immunogenicity testing </ANSWER>", "Observation from previous action: {'action': 'Immunogenicity testing', 'observation': 'Immunogenic'}\n\nSince the observation is that the compound is immunogenic, we can rule out Insulin. This leaves us with the following potential compounds: ['Sertraline', 'Albuterol'].\n\n<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "Observation from previous action: {'action': 'In vitro enzyme inhibition assay', 'observation': 1.4121348940183798}\n\nSince the observation from the in vitro enzyme inhibition assay is within the range of 1,000-10,000, we can rule out Sildenafil. This leaves us with the following potential compounds: ['Sertraline', 'Albuterol'].\n\n<ANSWER> Animal behavioral study </ANSWER>", "Observation from previous action: {'action': 'Animal behavioral study', 'observation': 'No behavioral changes'}\n\nSince the animal behavioral study did not observe any behavioral changes, we can rule out Sertraline, as it is known to affect behavior due to its antidepressant properties. This leaves us with the following potential compound: ['Albuterol'].\n\n<ANSWER> Sertraline </ANSWER>"], "consumed_tokens": 7650, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 1.4121348940183798}, {"action": "Immunogenicity testing", "observation": "Immunogenic"}, {"action": "In vitro enzyme inhibition assay", "observation": 1.4121348940183798}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}], "successful": false, "parse_error": false}], "seed": 21, "average_actions": 4.0, "average_tokens": 4266.6, "average_correct": 0.4, "average_parse_error": 0.0, "average_successful_action_num": 3.0, "average_successful_tokens": 2614.5}
{"trajectories": [{"actions": ["hERG channel inhibition assay", "hERG channel inhibition assay", "P-glycoprotein interaction assay", "Cisapride", {"predicted_truth": "Cisapride"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> Cisapride </ANSWER>\n\nBased on the observation from the P-glycoprotein interaction assay, where the compound was identified as a substrate, we can rule out **Digoxin**. However, since the hERG channel inhibition assay result for Cisapride is within the range that typically leads to its exclusion (0 M to 10 M), we can confidently rule out Cisapride. Therefore, the remaining compounds are Fluoxetine and Amiodarone. Since no further trials are needed to distinguish between these two, we can predict the truth."], "consumed_tokens": 5376, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 9.594850618366994}, {"action": "hERG channel inhibition assay", "observation": 9.594850618366994}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}], "successful": false, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "hERG channel inhibition assay", "P-glycoprotein interaction assay", "P-glycoprotein interaction assay", "hERG channel inhibition assay", "P-glycoprotein interaction assay", "hERG channel inhibition assay", "hERG channel inhibition assay", "Amiodarone", {"predicted_truth": "Amiodarone"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nGiven the observation of 9.594850618366994 from the hERG channel inhibition assay, which falls within the range that excludes Cisapride, we can now focus on the remaining three compounds: Fluoxetine, Amiodarone, and Digoxin. The next logical step is to perform a P-glycoprotein interaction assay. \n\n- If Digoxin is ruled out as a substrate in this assay, then it will be excluded from consideration.\n- If Fluoxetine or Amiodarone show no interaction, we will need to further investigate with other assays.\n\nTherefore, performing the P-glycoprotein interaction assay will help us eliminate one of the remaining compounds.", "<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nGiven the observation that Digoxin is a substrate in the P-glycoprotein interaction assay, Digoxin can be ruled out. This leaves us with the compounds Fluoxetine, Amiodarone, and Cisapride. The next logical step is to perform another assay to further narrow down the possibilities. \n\nPerforming the hERG channel inhibition assay again could be useful, as it has distinct outcomes for Cisapride. If Cisapride shows hERG channel inhibition within the specified range, it can be excluded.\n\nTherefore, the next action is to perform the hERG channel inhibition assay.", "<ANSWER> hERG channel inhibition assay </ANSWER>\n\nGiven that Digoxin has been ruled out as a substrate in the P-glycoprotein interaction assay, we are left with Fluoxetine, Amiodarone, and Cisapride. Since Cisapride is known to have hERG channel inhibition, performing the hERG channel inhibition assay will help us exclude Cisapride if it shows inhibition within the specified range.", "<ANSWER> hERG channel inhibition assay </ANSWER>\n\nGiven the observation of 9.594850618366994 from the hERG channel inhibition assay, which falls within the range that excludes Cisapride, we can now rule out Cisapride. This leaves us with Fluoxetine and Amiodarone. To further narrow down the possibilities, we can perform another hERG channel inhibition assay. However, since the choices are limited, we can also consider the P-glycoprotein interaction assay next to see if any further exclusions can be made. \n\nPerforming the P-glycoprotein interaction assay will help us determine if Fluoxetine or Amiodarone interacts with P-glycoprotein. \n\n<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> hERG channel inhibition assay </ANSWER>\n\nGiven that both Digoxin and Cisapride have been ruled out, we are left with Fluoxetine and Amiodarone. Since the P-glycoprotein interaction assay indicated that the compound is a substrate, we know it is not Cisapride. Now, performing the hERG channel inhibition assay will help us determine if the remaining compound (Amiodarone) shows hERG channel inhibition. Amiodarone is known to have significant hERG channel inhibition, so this assay will help us confirm if it is the correct compound.", "<ANSWER> hERG channel inhibition assay </ANSWER>\n\nGiven the observation of 9.594850618366994 from the hERG channel inhibition assay, which falls within the range that excludes Cisapride, we can confirm that Cisapride is not the correct compound. Now, we are left with Fluoxetine and Amiodarone. Since Amiodarone is known to have significant hERG channel inhibition, performing the hERG channel inhibition assay again will help us confirm if the compound is Amiodarone. If the observation confirms the hERG channel inhibition, we can predict that the compound is Amiodarone.", "<ANSWER> Amiodarone </ANSWER>\n\nThe observation of 9.594850618366994 from the hERG channel inhibition assay confirms that the compound is Amiodarone, as it falls within the range that indicates hERG channel inhibition. Since Amiodarone is known to have significant hERG channel inhibition, and the observation matches this characteristic, we can confidently predict that the compound is Amiodarone."], "consumed_tokens": 16671, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 9.594850618366994}, {"action": "hERG channel inhibition assay", "observation": 9.594850618366994}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}, {"action": "hERG channel inhibition assay", "observation": 9.594850618366994}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}, {"action": "hERG channel inhibition assay", "observation": 9.594850618366994}, {"action": "hERG channel inhibition assay", "observation": 9.594850618366994}], "successful": true, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "hERG channel inhibition assay", "P-glycoprotein interaction assay", "Digoxin", {"predicted_truth": "Digoxin"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> Digoxin </ANSWER>"], "consumed_tokens": 5263, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 9.594850618366994}, {"action": "hERG channel inhibition assay", "observation": 9.594850618366994}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}], "successful": false, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "P-glycoprotein interaction assay", "Fluoxetine", {"predicted_truth": "Fluoxetine"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> Fluoxetine </ANSWER>"], "consumed_tokens": 3847, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 9.594850618366994}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}], "successful": false, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "hERG channel inhibition assay", "P-glycoprotein interaction assay", "Cisapride", {"predicted_truth": "Cisapride"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> Cisapride </ANSWER>\n\nBased on the observation from the P-glycoprotein interaction assay, where the compound was found to be a substrate, we can rule out Digoxin. However, since the hERG channel inhibition assay also indicated that the compound is Cisapride (with an inhibition value of 9.594850618366994 M, which is within the range to be concerned), and considering Cisapride's known cardiac side effects, we can confidently rule out Fluoxetine, Amiodarone, and Digoxin. Therefore, the remaining plausible compound is Cisapride."], "consumed_tokens": 5394, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 9.594850618366994}, {"action": "hERG channel inhibition assay", "observation": 9.594850618366994}, {"action": "P-glycoprotein interaction assay", "observation": "Substrate"}], "successful": false, "parse_error": false}], "seed": 22, "average_actions": 5.8, "average_tokens": 7310.2, "average_correct": 0.2, "average_parse_error": 0.0, "average_successful_action_num": 10.0, "average_successful_tokens": 16671.0}
{"trajectories": [{"actions": ["hERG channel inhibition assay", "Mitochondrial toxicity test", "Cell viability assay", "Metformin", {"predicted_truth": "Metformin"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: The hERG channel inhibition assay is a critical test for evaluating the potential of compounds to inhibit potassium channels, which is important for cardiac safety. Since Cetirizine and Loratadine are both antihistamines, they are less likely to be related to cardiac safety concerns compared to Sodium Valproate, which is an antiepileptic medication. Metformin, being a diabetes medication, is also less likely to have significant cardiac effects. Therefore, starting with the hERG channel inhibition assay can help us rule out compounds that do not pose significant cardiac risks. If either Cetirizine or Loratadine shows a percentage range of 50 to 100% inhibition, they can be ruled out, and we can focus on Sodium Valproate and Metformin.", "<ANSWER> Mitochondrial toxicity test </ANSWER>\n\nReason: The hERG channel inhibition assay showed a percentage of 61.05195865786096, which does not fall within the range of 50 to 100% inhibition. Therefore, we can rule out Cetirizine and Loratadine. This leaves us with Sodium Valproate and Metformin. The next logical step is to perform the Mitochondrial toxicity test, as Sodium Valproate is known to have potential mitochondrial toxicity. If the Mitochondrial toxicity test shows significant toxicity, we can rule out Sodium Valproate. If not, we can proceed to other tests or predict Metformin.", "<ANSWER> Cell viability assay </ANSWER>\n\nReason: The Mitochondrial toxicity test showed that Sodium Valproate is toxic to mitochondria. This confirms that Sodium Valproate can be ruled out. We are left with Metformin. The next logical test to perform is the Cell viability assay. If Metformin shows low cell viability, it would be consistent with its mechanism of action. However, since Metformin is generally well-tolerated and does not typically cause significant cell viability issues, this test will likely confirm that Metformin is the remaining compound.", "<ANSWER> Metformin </ANSWER>\n\nReason: The Cell viability assay showed 72.75164794238583, which is above the 50% range and indicates good cell viability. This is consistent with Metformin's known mechanism of action and safety profile. Since all other compounds have been ruled out, Metformin is the remaining and correct pharmaceutical compound."], "consumed_tokens": 6183, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 61.05195865786096}, {"action": "Mitochondrial toxicity test", "observation": "Mitochondrial toxic"}, {"action": "Cell viability assay", "observation": 72.75164794238583}], "successful": true, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "Mitochondrial toxicity test", "Metformin", {"predicted_truth": "Metformin"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: The hERG channel inhibition assay is a critical test for evaluating the potential of compounds to inhibit potassium channels, which is important for cardiac safety. Since Cetirizine and Loratadine are antihistamines, they are less likely to be associated with cardiac safety issues compared to Sodium Valproate, which is an antiepileptic medication. Therefore, performing the hERG channel inhibition assay can help rule out Cetirizine and Loratadine, and provide more information about Sodium Valproate.", "Observation from previous action: The hERG channel inhibition assay result is 61.05195865786096, which falls within the range of 50 to 100% inhibition.\n\nBased on this result, we can rule out Cetirizine and Loratadine.\n\n<ANSWER> Cetirizine </ANSWER>\n<ANSWER> Loratadine </ANSWER>\n\nNow, we are left with Sodium Valproate and Metformin. The next step is to use another assay to further narrow down the possibilities. \n\n<ANSWER> Mitochondrial toxicity test </ANSWER>", "Observation from previous action: The Mitochondrial toxicity test result is positive (mitochondrial toxic), which indicates that Sodium Valproate should be ruled out.\n\n<ANSWER> Sodium Valproate </ANSWER>\n\nNow we are left with Metformin. We can predict the remaining compound:\n\n<ANSWER> Metformin </ANSWER>"], "consumed_tokens": 4156, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 61.05195865786096}, {"action": "Mitochondrial toxicity test", "observation": "Mitochondrial toxic"}], "successful": true, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "Mitochondrial toxicity test", "Cell viability assay", "Cetirizine", {"predicted_truth": "Cetirizine"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: The hERG channel inhibition assay is a critical test for evaluating the potential of compounds to inhibit potassium channels, which is important for cardiac safety. Since Cetirizine and Loratadine both fall under the category of antihistamines and Sodium Valproate is an antiepileptic medication, this assay could help rule out one or more of these compounds based on their inhibition percentage range. Metformin, being an oral diabetes medication, is less likely to be tested for hERG channel inhibition, making it a good starting point to eliminate other compounds.", "<ANSWER> Mitochondrial toxicity test </ANSWER>\n\nReason: The hERG channel inhibition assay showed an inhibition of 61.05195865786096%, which falls outside the range of 50 to 100% inhibition that would rule out Cetirizine and Loratadine. However, Sodium Valproate is known to have a higher risk of hERG inhibition, so this result does not rule it out. Given the current uncertainty, we can proceed with another test. The Mitochondrial toxicity test is a good next step to rule out Sodium Valproate if it shows mitochondrial toxicity.", "<ANSWER> Cell viability assay </ANSWER>\n\nReason: The Mitochondrial toxicity test result indicates mitochondrial toxicity, which rules out Sodium Valproate. Now we are left with Cetirizine, Loratadine, and Metformin. The Cell viability assay can help rule out Metformin as it shows a range of cell viability results that can be used to eliminate this compound.", "<ANSWER> Cetirizine </ANSWER>\n\nReason: The Cell viability assay result is 72.75164794238583%, which falls within the 50 to 100% range that would rule out Metformin. Since we have already ruled out Sodium Valproate from the Mitochondrial toxicity test, and the Cell viability assay has excluded Metformin, we are left with Cetirizine and Loratadine. However, since there is no further test to distinguish between Cetirizine and Loratadine, and given the process of elimination, Cetirizine is the most plausible remaining compound."], "consumed_tokens": 5922, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 61.05195865786096}, {"action": "Mitochondrial toxicity test", "observation": "Mitochondrial toxic"}, {"action": "Cell viability assay", "observation": 72.75164794238583}], "successful": false, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "Mitochondrial toxicity test", "hERG channel inhibition assay", "Sodium Valproate", {"predicted_truth": "Sodium Valproate"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> Mitochondrial toxicity test </ANSWER>", "<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> Sodium Valproate </ANSWER>\n\nGiven the observation that the hERG channel inhibition assay resulted in 61.05195865786096% inhibition, which falls within the range of 50-100%, we can rule out Cetirizine and Loratadine. Since Sodium Valproate is known to inhibit the hERG channel, this result is consistent with it being the compound tested. Therefore, we can confidently predict that the compound is Sodium Valproate."], "consumed_tokens": 4905, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 61.05195865786096}, {"action": "Mitochondrial toxicity test", "observation": "Mitochondrial toxic"}, {"action": "hERG channel inhibition assay", "observation": 61.05195865786096}], "successful": false, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "Mitochondrial toxicity test", "Cell viability assay", "Cetirizine", {"predicted_truth": "Cetirizine"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: The hERG channel inhibition assay is a critical test for evaluating cardiac safety. Since Cetirizine and Loratadine have been ruled out based on their classification as antihistamines, and Sodium Valproate is an antiepileptic medication, it is likely that Sodium Valproate could potentially inhibit the hERG channel. This test will help us rule out Sodium Valproate if the inhibition is observed, or narrow down the possibilities if it is not.", "<ANSWER> Mitochondrial toxicity test </ANSWER>\n\nReason: The hERG channel inhibition assay showed 61.05195865786096% inhibition, which is within the range to rule out Cetirizine and Loratadine. Since Sodium Valproate is an antiepileptic medication, it is less likely to show significant hERG channel inhibition. Therefore, we can rule out Cetirizine, Loratadine, and Sodium Valproate based on this assay. The remaining compound, Metformin, does not typically affect the hERG channel or mitochondrial toxicity. Thus, performing the Mitochondrial toxicity test will help us rule out Sodium Valproate and further narrow down the possibilities.", "<ANSWER> Cell viability assay </ANSWER>\n\nReason: The Mitochondrial toxicity test showed that the compound is toxic to mitochondria. Sodium Valproate has been ruled out. Cetirizine, Loratadine, and Metformin do not typically show mitochondrial toxicity. Therefore, the remaining compounds (Cetirizine, Loratadine, and Metformin) can be further narrowed down using the Cell viability assay. If the cell viability is within the 0 to 50% range, we can rule out Metformin. If not, we can further differentiate between Cetirizine and Loratadine.", "<ANSWER> Cetirizine </ANSWER>\n\nReason: The Cell viability assay showed 72.75164794238583% viability, which is above the 50% range. This eliminates Metformin from the list of possible compounds. Therefore, the remaining compounds are Cetirizine and Loratadine. Since the Mitochondrial toxicity test ruled out Sodium Valproate and the Cell viability assay did not eliminate Metformin, the only remaining compound is Cetirizine."], "consumed_tokens": 5993, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 61.05195865786096}, {"action": "Mitochondrial toxicity test", "observation": "Mitochondrial toxic"}, {"action": "Cell viability assay", "observation": 72.75164794238583}], "successful": false, "parse_error": false}], "seed": 23, "average_actions": 4.8, "average_tokens": 5431.8, "average_correct": 0.4, "average_parse_error": 0.0, "average_successful_action_num": 4.5, "average_successful_tokens": 5169.5}
{"trajectories": [{"actions": ["In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "Insulin", {"predicted_truth": "Insulin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nBased on the observation from the 'In vitro enzyme inhibition assay' (7520.043956485525), which falls within the range of (1000, 10000), we can rule out Morphine and Simvastatin. This leaves us with Artificial tears and Insulin as potential candidates. However, since Artificial tears are eye-related and the assay is an enzyme inhibition assay, it is less likely to be directly related to eye function. Therefore, Insulin is the more likely candidate.", "<ANSWER> Insulin </ANSWER>"], "consumed_tokens": 4036, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 7520.043956485525}, {"action": "In vitro enzyme inhibition assay", "observation": 7520.043956485525}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Simvastatin", {"predicted_truth": "Simvastatin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay can help rule out Simvastatin when the inhibition activity falls within the range of (1000, 10000). This will help narrow down the list of possible compounds.", "<ANSWER> Simvastatin </ANSWER>\n\nReason: The observation from the In vitro enzyme inhibition assay is 7520.043956485525, which falls within the range of (1000, 10000). According to the guidebook, this range rules out Simvastatin. Therefore, Simvastatin is not the correct compound."], "consumed_tokens": 2651, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 7520.043956485525}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Immunogenicity testing", "Eye irritation test", "Morphine", {"predicted_truth": "Morphine"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay can help rule out Simvastatin based on its inhibition activity range. This will provide a clear outcome to narrow down the list of possible compounds.", "<ANSWER> Immunogenicity testing </ANSWER>\n\nReason: The in vitro enzyme inhibition assay result of 7520.043956485525 falls within the range (1000, 10000), which rules out Simvastatin. Now, we need to consider the remaining compounds: Morphine, Artificial tears, and Insulin. Next, we can perform immunogenicity testing to rule out Insulin, as it is known to trigger an immune response.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: The immunogenicity testing result shows that the compound is immunogenic, which rules out Insulin. Now we are left with Morphine, Artificial tears, and Simvastatin. The eye irritation test can help rule out Artificial tears, as they are designed to lubricate the eyes and would not be expected to cause irritation.", "<ANSWER> Morphine </ANSWER>\n\nReason: The eye irritation test result shows that the compound is non-irritant, which rules out Artificial tears. Now we are left with Morphine and Simvastatin. Since Simvastatin is an enzyme inhibitor and the in vitro enzyme inhibition assay already ruled it out, the remaining compound must be Morphine."], "consumed_tokens": 5798, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 7520.043956485525}, {"action": "Immunogenicity testing", "observation": "Immunogenic"}, {"action": "Eye irritation test", "observation": "Non-irritant"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Simvastatin", {"predicted_truth": "Simvastatin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay can help us rule out certain compounds based on their ability to inhibit specific enzymes. Simvastatin is known to inhibit the enzyme HMG-CoA reductase, so this assay could provide a clear outcome that helps us eliminate other compounds. Additionally, Morphine, Artificial tears, and Insulin are less likely to show significant inhibition in this assay, making it a good starting point to narrow down our options.", "<ANSWER> Simvastatin </ANSWER>\n\nReason: The observation from the In vitro enzyme inhibition assay is 7520.043956485525, which falls within the range (1000, 10000). According to the guidebook, this range rules out Morphine. Since Simvastatin is known to inhibit enzymes, it fits this range, while Artificial tears and Insulin do not. Therefore, Simvastatin is the most plausible compound remaining."], "consumed_tokens": 2758, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 7520.043956485525}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Immunogenicity testing", "Immunogenicity testing", "Eye irritation test", "Simvastatin", {"predicted_truth": "Simvastatin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay can help rule out certain compounds based on their ability to inhibit specific enzymes. Simvastatin is known to inhibit the enzyme HMG-CoA reductase, so this test can provide a clear outcome. Additionally, this test can help differentiate between Morphine, Artificial tears, and Insulin, as they do not inhibit HMG-CoA reductase.", "<ANSWER> Immunogenicity testing </ANSWER>\n\nReason: The In vitro enzyme inhibition assay resulted in an inhibition activity of 7520.043956485525, which falls within the range (1000, 10000). This range rules out Simvastatin. Now we need to further narrow down the possibilities between Morphine, Artificial tears, and Insulin. The next best test to perform is Immunogenicity testing, as it can rule out Insulin since it does not trigger an immune response.", "<ANSWER> Immunogenicity testing </ANSWER>\n\nReason: The observation from the Immunogenicity testing indicates that the compound is Immunogenic. Since Insulin is non-immunogenic, it can be ruled out. Now we are left with Morphine, Artificial tears, and Simvastatin. To further narrow down the possibilities, we can perform the Eye irritation test, as Artificial tears are specifically designed to lubricate and provide moisture to the eyes, making them non-irritant. This will help us rule out Artificial tears.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: The observation from the Immunogenicity testing indicates that the compound is Immunogenic, ruling out Insulin. We are left with Morphine, Artificial tears, and Simvastatin. Since Artificial tears are non-irritant, performing the Eye irritation test will help us rule them out, leaving us with either Morphine or Simvastatin.", "<ANSWER> Simvastatin </ANSWER>\n\nReason: The Eye irritation test resulted in a Non-irritant outcome, which rules out Artificial tears. We are now left with Morphine and Simvastatin. Since Simvastatin is known to be non-irritant to the eyes, and the test result is Non-irritant, Simvastatin is the correct compound."], "consumed_tokens": 7910, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 7520.043956485525}, {"action": "Immunogenicity testing", "observation": "Immunogenic"}, {"action": "Immunogenicity testing", "observation": "Immunogenic"}, {"action": "Eye irritation test", "observation": "Non-irritant"}], "successful": false, "parse_error": false}], "seed": 24, "average_actions": 4.2, "average_tokens": 4630.6, "average_correct": 0.2, "average_parse_error": 0.0, "average_successful_action_num": 5.0, "average_successful_tokens": 5798.0}
{"trajectories": [{"actions": ["Genotoxicity assay", "Imatinib", {"predicted_truth": "Imatinib"}], "generated_text": ["<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Imatinib </ANSWER>\n\nGiven that the Genotoxicity assay observed genotoxicity, we can rule out Estradiol and Metformin because neither of these compounds are expected to be genotoxic. Now, we need to differentiate between Imatinib and Artificial tears. Since Imatinib is a targeted cancer therapy, it is more likely to show genotoxic effects compared to Artificial tears, which are used to treat eye conditions. Therefore, Imatinib is the most plausible compound remaining."], "consumed_tokens": 2486, "observations": [null, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Genotoxicity assay", "Imatinib", {"predicted_truth": "Imatinib"}], "generated_text": ["<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Imatinib </ANSWER>\n\nSince the Genotoxicity assay detected genotoxicity, we can rule out Estradiol and Metformin, as they are generally not genotoxic. This leaves us with Imatinib and Artificial tears. However, Artificial tears are known to be non-genotoxic, so we can confidently rule out Artificial tears. Therefore, the remaining plausible compound is Imatinib."], "consumed_tokens": 2467, "observations": [null, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Genotoxicity assay", "Imatinib", {"predicted_truth": "Imatinib"}], "generated_text": ["<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Imatinib </ANSWER>\n\nBased on the genotoxicity assay, we observed that the compound is genotoxic. Since Imatinib is known to be non-genotoxic, we can rule it out. This leaves us with the remaining compounds: Estradiol, Artificial tears, and Metformin. Next, let's perform the Eye irritation test to further narrow down the options."], "consumed_tokens": 2464, "observations": [null, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["Genotoxicity assay", "CYP450 metabolism assay", "Clinical biomarker identification", "Artificial tears", {"predicted_truth": "Artificial tears"}], "generated_text": ["<ANSWER> Genotoxicity assay </ANSWER>\n\nReason: Starting with the genotoxicity assay is a good choice because it can quickly eliminate compounds that are genotoxic, which is a critical safety concern. Since Estradiol is a hormone and can have potential genotoxic effects, performing this test first can help us rule out Estradiol if it shows genotoxicity. This will also help us narrow down the possible compounds more efficiently.", "<ANSWER> Genotoxicity assay </ANSWER>\n\nReason: Since the genotoxicity assay has shown that the compound is genotoxic, we can confidently rule out Estradiol. Now, we need to perform another assay to further narrow down the possibilities between Imatinib, Artificial tears, and Metformin. The CYP450 metabolism assay is a good choice because it can help us eliminate one of these compounds based on their metabolic inhibition properties. \n\n<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> Clinical biomarker identification </ANSWER>\n\nReason: Since the CYP450 metabolism assay showed no inhibition, we can rule out Metformin. Now, we are left with Imatinib and Artificial tears. The next logical step is to perform the Clinical biomarker identification assay. Imatinib is a targeted cancer therapy, and a lack of identified biomarkers would be unusual for it. Therefore, if no biomarker is identified, Imatinib can be ruled out, leaving Artificial tears as the most plausible compound. \n\n<ANSWER> Clinical biomarker identification </ANSWER>", "<ANSWER> Artificial tears </ANSWER>\n\nReason: Since the clinical biomarker identification assay did not identify any biomarkers, we can rule out Imatinib. With no other information to rule out Artificial tears or Metformin at this point, we can conclude that Artificial tears is the most plausible remaining compound."], "consumed_tokens": 5856, "observations": [null, {"action": "Genotoxicity assay", "observation": "Genotoxic"}, {"action": "CYP450 metabolism assay", "observation": "No inhibition"}, {"action": "Clinical biomarker identification", "observation": "No biomarker identified"}], "successful": false, "parse_error": false}, {"actions": ["Genotoxicity assay", "Estradiol", {"predicted_truth": "Estradiol"}], "generated_text": ["<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Estradiol </ANSWER>\n\nBased on the observation from the genotoxicity assay that the compound is genotoxic, we can rule out Estradiol, as it is used in hormone replacement therapies and should not be genotoxic."], "consumed_tokens": 2433, "observations": [null, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}], "seed": 25, "average_actions": 3.4, "average_tokens": 3141.2, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["In vitro enzyme inhibition assay", "Human clinical trial Phase I", "Eye irritation test", "Placebo", {"predicted_truth": "Placebo"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nLet's start by performing the In vitro enzyme inhibition assay. This trial can help us rule out Montelukast, as it has already been identified as not fitting within the enzyme inhibition range of (0, 100). By conducting this assay, we can further narrow down the possibilities and eliminate more compounds based on their enzyme inhibition properties.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nGiven the observation from the In vitro enzyme inhibition assay, we know that the compound does not match the range of 0 to 100, which rules out Montelukast. Now, let's proceed with the Human clinical trial Phase I to observe the adverse effects, as this trial can provide insights into the safety profile of the remaining compounds.", "<ANSWER> Eye irritation test </ANSWER>\n\nGiven that the compound showed no adverse effects in the Human clinical trial Phase I, we can rule out Warfarin. Now, let's perform the Eye irritation test to further eliminate Formaldehyde, as it is known to be irritant in such tests. This will help us narrow down the possibilities to either Montelukast or Placebo.", "<ANSWER> Placebo </ANSWER>\n\nThe observation from the Eye irritation test indicates that the compound is irritant. Since Formaldehyde is the only compound known to be irritant in such tests, and it has already been ruled out, the remaining compound must be Placebo, which does not cause irritation.\n\nGiven the process of elimination and the observations from the trials, the remaining plausible compound is Placebo."], "consumed_tokens": 5675, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 98.67575298826218}, {"action": "Human clinical trial Phase I", "observation": "No adverse effects"}, {"action": "Eye irritation test", "observation": "Irritant"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Human clinical trial Phase I", "Animal toxicity test", "Warfarin", {"predicted_truth": "Warfarin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nBy starting with the in vitro enzyme inhibition assay, we can quickly rule out Montelukast, as it does not fit within the enzyme inhibition range of 0 to 100. This will help narrow down the possibilities and move closer to identifying the correct compound.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nGiven the observation from the in vitro enzyme inhibition assay (98.67575298826218, which falls within the range (100, 1000)), Montelukast, Warfarin, and Formaldehyde can still be potential candidates. We will now move to the Human clinical trial Phase I to further narrow down the possibilities. If there are severe adverse effects, Warfarin can be ruled out. If there are no adverse effects, Placebo can be ruled out. If there are mild adverse effects, we will need to continue the process.", "<ANSWER> Animal toxicity test </ANSWER>\n\nGiven that the human clinical trial Phase I showed no adverse effects, we can rule out Placebo. Now, we have three remaining compounds: Warfarin, Montelukast, and Formaldehyde. The next logical step is to perform the Animal toxicity test to further narrow down the possibilities. If the compound is highly toxic, it will be Warfarin. If it shows moderate toxicity, Warfarin will be ruled out, and we will have to consider the remaining compounds. If it shows low toxicity, we can further analyze the other tests.\n\nPerforming the animal toxicity test will provide more specific information to rule out one of the remaining compounds.", "<ANSWER> Warfarin </ANSWER>\n\nGiven the observations from the in vitro enzyme inhibition assay and the animal toxicity test, we can conclude that the compound is Warfarin. The in vitro enzyme inhibition assay ruled out Montelukast and Formaldehyde, and the animal toxicity test confirmed high toxicity, which aligns with Warfarin's known properties. Therefore, the remaining compound is Warfarin."], "consumed_tokens": 5901, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 98.67575298826218}, {"action": "Human clinical trial Phase I", "observation": "No adverse effects"}, {"action": "Animal toxicity test", "observation": "High toxicity"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Animal toxicity test", "Formaldehyde", {"predicted_truth": "Formaldehyde"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay provides a specific range that can help us rule out certain compounds. Montelukast is ruled out in the 0 to 100 range, which means we can use this assay to further narrow down the possibilities. Since we have already ruled out Montelukast and are left with Warfarin, Formaldehyde, and Placebo, this assay can help us eliminate one of these compounds.", "<ANSWER> Animal toxicity test </ANSWER>\n\nReason: Since the in vitro enzyme inhibition assay has ruled out Montelukast and provided a value of 98.67575298826218, which falls in a range that does not rule out any other compounds directly, we should move to another type of assay to further narrow down the possibilities. The animal toxicity test can help us rule out Warfarin based on its moderate toxicity. This will leave us with either Formaldehyde or Placebo.", "<ANSWER> Formaldehyde </ANSWER>\n\nReason: The animal toxicity test has ruled out Warfarin due to its high toxicity. This leaves us with Formaldehyde, Placebo, and Montelukast. Since Montelukast is an antiallergic and anti-asthmatic drug, it is highly unlikely to show high toxicity in animal tests. Placebo is also ruled out as it is an inert substance with no active pharmacological effects. Therefore, the remaining compound is Formaldehyde."], "consumed_tokens": 4211, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 98.67575298826218}, {"action": "Animal toxicity test", "observation": "High toxicity"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Human clinical trial Phase I", "Eye irritation test", "Placebo", {"predicted_truth": "Placebo"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay can help us eliminate Montelukast, as it is ruled out in the 0 to 100 range of enzyme inhibition. This will help us narrow down the possible compounds and move closer to identifying the correct one.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Since Montelukast is ruled out from the in vitro enzyme inhibition assay, we can proceed with the next most informative test. A human clinical trial Phase I would help us determine if the compound causes severe adverse effects, which would further narrow down our options.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: Since the human clinical trial Phase I did not show any adverse effects, we can rule out Warfarin and Montelukast. The remaining compounds are Formaldehyde and Placebo. The eye irritation test can help us eliminate Formaldehyde as it is known to be an irritant. Therefore, the remaining compound is Placebo. However, since the action is to choose the next test, the Eye irritation test is the best choice to further confirm our findings.", "<ANSWER> Placebo </ANSWER>\n\nReason: The eye irritation test ruled out Formaldehyde as it is an irritant. Since the remaining compounds are Warfarin, Montelukast, and Placebo, and Placebo is known to be inert with no adverse effects, it is the most plausible compound. To confirm, we can perform the teratogenicity assessment, but since Placebo is the only non-toxic and non-irritant option, it is the most likely correct answer."], "consumed_tokens": 5631, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 98.67575298826218}, {"action": "Human clinical trial Phase I", "observation": "No adverse effects"}, {"action": "Eye irritation test", "observation": "Irritant"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "Human clinical trial Phase I", "In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "Placebo", {"predicted_truth": "Placebo"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nGiven the observation from the in vitro enzyme inhibition assay (98.67575298826218), which falls within the range of (100, 1000), we can rule out Montelukast, as it does not fit within this range. This step helps narrow down the possibilities for the remaining pharmaceutical compounds.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nThe observation from the in vitro enzyme inhibition assay (98.67575298826218) falls within the range of (100, 1000), so Montelukast, Formaldehyde, and Warfarin are still in the running. However, based on the rule-out outcomes, we know that Warfarin would have severe adverse effects, and Placebo would show no adverse effects. Since 98.67575298826218 is a high value, it is unlikely to be related to a placebo response or severe adverse effects. Therefore, the most likely remaining compound is Warfarin.\n\nTo further confirm, we can perform a human clinical trial Phase I to observe any adverse effects. If there are no severe adverse effects, it would further support Warfarin as the correct compound.", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nGiven that the human clinical trial Phase I showed \"No adverse effects,\" this outcome rules out Warfarin, as it is known to cause severe adverse effects. Since we have already ruled out Montelukast, Formaldehyde, and Warfarin, the only remaining compound is Placebo. However, to further confirm, we can perform another in vitro enzyme inhibition assay to ensure there are no enzyme inhibition effects, which would support the placebo being the correct compound.\n\nLet's proceed with the in vitro enzyme inhibition assay to confirm the results.", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nGiven the previous observations, the in vitro enzyme inhibition assay with an observation of 98.67575298826218 falls within the range of (100, 1000), which rules out Montelukast, Formaldehyde, and Warfarin. The remaining compound is Placebo. To confirm, we can perform another in vitro enzyme inhibition assay to ensure there are no enzyme inhibition effects.", "<ANSWER> Placebo </ANSWER>\n\nGiven the observation from the in vitro enzyme inhibition assay (98.67575298826218) which falls within the range of (100, 1000), we have already ruled out Montelukast, Formaldehyde, and Warfarin. The only remaining compound is Placebo. Since the in vitro enzyme inhibition assay did not show any enzyme inhibition effects, Placebo is the most plausible compound."], "consumed_tokens": 9578, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 98.67575298826218}, {"action": "In vitro enzyme inhibition assay", "observation": 98.67575298826218}, {"action": "Human clinical trial Phase I", "observation": "No adverse effects"}, {"action": "In vitro enzyme inhibition assay", "observation": 98.67575298826218}, {"action": "In vitro enzyme inhibition assay", "observation": 98.67575298826218}], "successful": false, "parse_error": false}], "seed": 26, "average_actions": 5.2, "average_tokens": 6199.2, "average_correct": 0.2, "average_parse_error": 0.0, "average_successful_action_num": 5.0, "average_successful_tokens": 5901.0}
{"trajectories": [{"actions": ["Bioavailability study", "Drug-drug interaction studies", "Penicillin", {"predicted_truth": "Penicillin"}], "generated_text": ["<ANSWER> Bioavailability study </ANSWER>\n\nReason: Since Warfarin is an anticoagulant and its effectiveness depends on its absorption, a bioavailability study would provide crucial information about its absorption rate and extent. This can help us rule out Warfarin if its bioavailability falls in the range of 0% to 20%, as it would indicate poor absorption and make it an unlikely candidate for the observed outcomes. Additionally, this study does not require assumptions about behavioral changes, receptor binding, or teratogenic effects, making it a straightforward choice to eliminate one of the compounds.", "<ANSWER> Drug-drug interaction studies </ANSWER>\n\nReason: Given that the bioavailability of Warfarin is 16.68%, which falls within the range of 0% to 20%, we can rule out Warfarin. Next, we need to consider the remaining compounds: Albuterol, Penicillin, and Sertraline. A drug-drug interaction study can help us eliminate one of these compounds by checking for significant interactions that would affect their therapeutic efficacy when co-administered.", "<ANSWER> Penicillin </ANSWER>\n\nReason: Since there is a significant interaction observed in the drug-drug interaction study, Warfarin can be ruled out. This leaves us with Albuterol, Penicillin, and Sertraline. \n\n- Albuterol is a bronchodilator and is not typically used in combination with other respiratory medications in a way that would cause significant interactions.\n- Sertraline is an antidepressant and does not have significant interactions with common respiratory or cardiovascular medications.\n- Penicillin, however, is known to interact significantly with anticoagulants like Warfarin, which is consistent with the observed interaction.\n\nGiven that Penicillin is the only remaining compound that could plausibly show a significant interaction with Warfarin, we can confidently rule out Penicillin and proceed to check the other remaining compounds with further tests. However, based on the interaction observed, Penicillin is the most likely compound to be ruled out.\n\n<ANSWER> Penicillin </ANSWER>"], "consumed_tokens": 4673, "observations": [null, {"action": "Bioavailability study", "observation": 16.683036508391172}, {"action": "Drug-drug interaction studies", "observation": "Significant interaction"}], "successful": false, "parse_error": false}, {"actions": ["Bioavailability study", "Penicillin", {"predicted_truth": "Penicillin"}], "generated_text": ["<ANSWER> Bioavailability study </ANSWER>\n\nReason: The bioavailability study can help us determine how well the drug is absorbed, which is a crucial characteristic for all four compounds. By performing this test, we can eliminate one of the compounds that does not match the expected bioavailability range. This will provide us with more information about the absorption properties of each drug and help narrow down the possibilities.", "Observation from previous action: {'action': 'Bioavailability study', 'observation': 16.683036508391172}\n\nThe observation of 16.683036508391172 falls within the range of 0% to 20%, which is the rule-out range for bioavailability. Therefore, we can eliminate Penicillin from our list of possible compounds.\n\n<ANSWER> Penicillin </ANSWER>"], "consumed_tokens": 2811, "observations": [null, {"action": "Bioavailability study", "observation": 16.683036508391172}], "successful": false, "parse_error": false}, {"actions": ["Bioavailability study", "Drug-drug interaction studies", "Penicillin", {"predicted_truth": "Penicillin"}], "generated_text": ["<ANSWER> Bioavailability study </ANSWER>\n\nReason: The bioavailability study can help us determine if a drug is absorbed into the bloodstream effectively. For this round, Penicillin is a good candidate to rule out if it has poor bioavailability, as it is an antibiotic that is expected to have good absorption. If the bioavailability falls between 0% and 20%, we can confidently rule out Penicillin. This action provides a clear and decisive step in narrowing down the possible compounds.", "<ANSWER> Drug-drug interaction studies </ANSWER>\n\nReason: Given the bioavailability of Penicillin is within the expected range (16.683036508391172), we can't rule out Penicillin based on bioavailability. The next logical step is to perform a drug-drug interaction study. This will help us identify if Penicillin interacts significantly with other drugs, which could affect its therapeutic profile. If a significant interaction is observed, we can rule out Penicillin. If not, we will proceed to the next step.", "<ANSWER> Penicillin </ANSWER>\n\nReason: The observation of a significant interaction in the drug-drug interaction study rules out Penicillin. Therefore, Penicillin is no longer a viable option, leaving us with the other three compounds: Albuterol, Sertraline, and Warfarin."], "consumed_tokens": 4493, "observations": [null, {"action": "Bioavailability study", "observation": 16.683036508391172}, {"action": "Drug-drug interaction studies", "observation": "Significant interaction"}], "successful": false, "parse_error": false}, {"actions": ["Bioavailability study", "Warfarin", {"predicted_truth": "Warfarin"}], "generated_text": ["<ANSWER> Bioavailability study </ANSWER>\n\nReason: Since Warfarin is an anticoagulant and its effectiveness depends on its bioavailability, performing a bioavailability study will help us determine if Warfarin meets the expected absorption and delivery standards. If the bioavailability falls between 0% and 20%, Warfarin can be ruled out, which will help narrow down the possible compounds.", "Observation from previous action: {'action': 'Bioavailability study', 'observation': 16.683036508391172}\n\nThe bioavailability of the compound is 16.683036508391172%, which falls within the range of 0% to 20%. According to the rule-out outcomes, this indicates that Warfarin can be ruled out.\n\n<ANSWER> Warfarin </ANSWER>"], "consumed_tokens": 2816, "observations": [null, {"action": "Bioavailability study", "observation": 16.683036508391172}], "successful": false, "parse_error": false}, {"actions": ["Bioavailability study", "Penicillin", {"predicted_truth": "Penicillin"}], "generated_text": ["<ANSWER> Bioavailability study </ANSWER>\n\nReason: Starting with a bioavailability study can help us quickly eliminate one of the compounds. Penicillin is known to be highly bioavailable, so if the bioavailability falls between 0% and 20%, we can rule it out immediately. This action has a high potential to eliminate one of the compounds in a single step.", "Observation from previous action: {'action': 'Bioavailability study', 'observation': 16.683036508391172}\n\nSince the bioavailability is 16.683036508391172%, which falls within the range of 0% to 20%, we can rule out Penicillin. \n\n<ANSWER> Penicillin </ANSWER>"], "consumed_tokens": 2795, "observations": [null, {"action": "Bioavailability study", "observation": 16.683036508391172}], "successful": false, "parse_error": false}], "seed": 27, "average_actions": 3.4, "average_tokens": 3517.6, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["Animal toxicity test", "Skin sensitization test", "Eye irritation test", "Phenytoin", {"predicted_truth": "Phenytoin"}], "generated_text": ["<ANSWER> Animal toxicity test </ANSWER>\n\nReason: The animal toxicity test has already ruled out Clopidogrel based on moderate toxicity observed. Now, we can use this test to further evaluate the other compounds. Since Formaldehyde is a known irritant and sensitizing agent, it is less likely to pass the animal toxicity test without showing some level of toxicity. On the other hand, Neomycin sulfate and Phenytoin have not been ruled out by this test yet. However, given that Formaldehyde is a known irritant and sensitizing agent, it is more probable that it will show some level of toxicity in this test. Therefore, performing the animal toxicity test will help us rule out Formaldehyde as a likely candidate.", "<ANSWER> Skin sensitization test </ANSWER>\n\nReason: Since the animal toxicity test ruled out Clopidogrel, we are left with Neomycin sulfate, Phenytoin, and Formaldehyde. The skin sensitization test has already ruled out Neomycin sulfate, so we can use this test to further narrow down the options between Phenytoin and Formaldehyde. Given that Formaldehyde is a known irritant and sensitizing agent, it is more likely to show positive results in the skin sensitization test. Therefore, performing the skin sensitization test will help us rule out Formaldehyde as a likely candidate.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: The skin sensitization test has ruled out Formaldehyde. We are left with Neomycin sulfate and Phenytoin. The eye irritation test can help us rule out one of these compounds. Since Neomycin sulfate is an antibiotic commonly used for skin infections, it is more likely to be an irritant to the eyes. Therefore, performing the eye irritation test will help us rule out Neomycin sulfate.", "<ANSWER> Phenytoin </ANSWER>\n\nReason: The eye irritation test ruled out Neomycin sulfate, leaving us with Phenytoin and Formaldehyde. Since Formaldehyde has already been ruled out by the skin sensitization test and the eye irritation test, Phenytoin must be the remaining compound."], "consumed_tokens": 6200, "observations": [null, {"action": "Animal toxicity test", "observation": "Moderate toxicity"}, {"action": "Skin sensitization test", "observation": "Sensitizer"}, {"action": "Eye irritation test", "observation": "Irritant"}], "successful": true, "parse_error": false}, {"actions": ["Animal toxicity test", "Skin sensitization test", "Eye irritation test", "Phenytoin", {"predicted_truth": "Phenytoin"}], "generated_text": ["<ANSWER> Animal toxicity test </ANSWER>\n\nReason: The animal toxicity test has already ruled out Clopidogrel due to moderate toxicity. The remaining compounds are Neomycin sulfate, Phenytoin, and Formaldehyde. The animal toxicity test is a general safety assessment that can help us eliminate one of these compounds based on the observed outcomes. Since Formaldehyde is known to have irritant properties and Phenytoin does not typically show significant toxicity in animal models, testing the remaining compounds (Neomycin sulfate and Phenytoin) would provide more specific information. However, starting with the animal toxicity test can help us make an initial elimination.", "<ANSWER> Skin sensitization test </ANSWER>\n\nReason: Since the animal toxicity test has already ruled out Clopidogrel, we are left with Neomycin sulfate, Phenytoin, and Formaldehyde. Given that Neomycin sulfate is known to be a skin sensitizer, performing a skin sensitization test will help us rule out Neomycin sulfate based on the observed outcomes.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: The skin sensitization test has ruled out Neomycin sulfate. We are left with Phenytoin and Formaldehyde. Formaldehyde is known to be an irritant, so the eye irritation test will help us rule out Formaldehyde. This will leave us with Phenytoin as the remaining compound.", "<ANSWER> Phenytoin </ANSWER>\n\nReason: The eye irritation test has ruled out Formaldehyde. We are left with Phenytoin and the only remaining compound to consider is Phenytoin. Since all other compounds have been ruled out based on the observed outcomes from the previous tests, Phenytoin is the correct compound."], "consumed_tokens": 5962, "observations": [null, {"action": "Animal toxicity test", "observation": "Moderate toxicity"}, {"action": "Skin sensitization test", "observation": "Sensitizer"}, {"action": "Eye irritation test", "observation": "Irritant"}], "successful": true, "parse_error": false}, {"actions": ["Animal toxicity test", "Skin sensitization test", "Eye irritation test", "Pharmacogenomics analysis", "Clopidogrel", {"predicted_truth": "Clopidogrel"}], "generated_text": ["<ANSWER> Animal toxicity test </ANSWER>\n\nReason: The animal toxicity test has already ruled out Clopidogrel based on moderate toxicity observed. Therefore, we can use this test to further narrow down the possibilities between Neomycin sulfate, Phenytoin, and Formaldehyde. Since Neomycin sulfate is known to have disinfectant properties and can be a skin irritant, it is a plausible candidate that could show toxicity in this test. However, to definitively rule out one of the remaining compounds, we can choose Phenytoin or Formaldehyde for the test. Given that Formaldehyde is known for its irritant properties, it is a strong candidate to show toxicity in this test. Thus, we can select Phenytoin or Formaldehyde for the Animal toxicity test to see if it shows moderate toxicity and can be ruled out.", "<ANSWER> Skin sensitization test </ANSWER>\n\nReason: Since the Animal toxicity test ruled out Clopidogrel, we are left with Neomycin sulfate, Phenytoin, and Formaldehyde. Neomycin sulfate is known to cause skin irritation, making it a likely candidate to show sensitization in the Skin sensitization test. Phenytoin and Formaldehyde are less likely to show moderate toxicity but could potentially show sensitization. To definitively rule out one of the remaining compounds, we can test Phenytoin or Formaldehyde. Given that Formaldehyde is known for its sensitization properties, it is a strong candidate for this test. However, to maintain a systematic approach, we will test Phenytoin first.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: The Skin sensitization test has ruled out Phenytoin. We are now left with Neomycin sulfate and Formaldehyde. Neomycin sulfate is known to cause skin irritation and eye irritation, making it a strong candidate to show irritation in the Eye irritation test. Formaldehyde is also known to cause eye irritation. To definitively rule out one of the remaining compounds, we can test Formaldehyde. Given that Formaldehyde is known for its irritant properties, it is a strong candidate for this test. Thus, we will test Formaldehyde in the Eye irritation test.", "<ANSWER> Pharmacogenomics analysis </ANSWER>\n\nReason: The Eye irritation test has ruled out Formaldehyde. We are now left with Neomycin sulfate and Clopidogrel. Neomycin sulfate does not have significant genetic variability impacts, while Clopidogrel does. Since the Eye irritation test did not rule out Neomycin sulfate, the remaining compound must be Clopidogrel. To confirm this, we can perform the Pharmacogenomics analysis. Given the known genetic variability impact of Clopidogrel, this test should definitively rule it out.", "<ANSWER> Clopidogrel </ANSWER>\n\nReason: The Pharmacogenomics analysis did not show any genetic impact, which means the remaining compound must be Clopidogrel. Since all other compounds have been ruled out through previous tests, Clopidogrel is the only plausible compound left."], "consumed_tokens": 8436, "observations": [null, {"action": "Animal toxicity test", "observation": "Moderate toxicity"}, {"action": "Skin sensitization test", "observation": "Sensitizer"}, {"action": "Eye irritation test", "observation": "Irritant"}, {"action": "Pharmacogenomics analysis", "observation": "No genetic impact"}], "successful": false, "parse_error": false}, {"actions": ["Animal toxicity test", "Skin sensitization test", "Eye irritation test", "Phenytoin", {"predicted_truth": "Phenytoin"}], "generated_text": ["<ANSWER> Animal toxicity test </ANSWER>\n\nReason: The animal toxicity test has already ruled out Clopidogrel due to moderate toxicity. Therefore, testing the remaining compounds (Neomycin sulfate, Phenytoin, and Formaldehyde) with this test can help further narrow down the possibilities. Since Neomycin sulfate and Formaldehyde are both known to have irritant properties, it is likely that they will show moderate toxicity as well. Phenytoin, on the other hand, is less likely to show significant toxicity based on its mechanism of action and known properties.", "<ANSWER> Skin sensitization test </ANSWER>\n\nReason: Since the animal toxicity test ruled out Clopidogrel, we now need to test the remaining compounds (Neomycin sulfate, Phenytoin, and Formaldehyde) for their sensitization properties. The skin sensitization test is the next logical step to eliminate one of these compounds based on the given guidebook.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: The skin sensitization test has ruled out Neomycin sulfate as it detected a sensitizer. We are left with Phenytoin and Formaldehyde. The eye irritation test can help us rule out one of these compounds. Since Formaldehyde is known to be an irritant, it is likely to show positive results in the eye irritation test. Therefore, testing Formaldehyde in the eye irritation test will help us confirm its irritant properties and eliminate it as a candidate.", "<ANSWER> Phenytoin </ANSWER>\n\nReason: The eye irritation test has ruled out Formaldehyde as it detected an irritant. We are left with Phenytoin and Clopidogrel. Since the animal toxicity test and pharmacogenomics analysis have not yet been performed on Phenytoin, and the dose-response study is not typically used to rule out compounds based on the provided guidebook, we can predict that Phenytoin is the remaining plausible compound."], "consumed_tokens": 5977, "observations": [null, {"action": "Animal toxicity test", "observation": "Moderate toxicity"}, {"action": "Skin sensitization test", "observation": "Sensitizer"}, {"action": "Eye irritation test", "observation": "Irritant"}], "successful": true, "parse_error": false}, {"actions": ["Animal toxicity test", "Skin sensitization test", "Eye irritation test", "Phenytoin", {"predicted_truth": "Phenytoin"}], "generated_text": ["<ANSWER> Animal toxicity test </ANSWER>\n\nReason: The animal toxicity test has already ruled out Clopidogrel based on moderate toxicity observed. This test can help us further narrow down the options by checking for toxicity in the remaining compounds (Neomycin sulfate, Phenytoin, and Formaldehyde). Since Neomycin sulfate and Formaldehyde are known to have potential toxicity issues (sensitization and irritant effects), the animal toxicity test can help us determine if either of these compounds also exhibit moderate toxicity, thereby further reducing our list of potential compounds.", "<ANSWER> Skin sensitization test </ANSWER>\n\nReason: Since the animal toxicity test ruled out Clopidogrel, we are left with Neomycin sulfate, Phenytoin, and Formaldehyde. The next logical step is to check for sensitization properties, as Neomycin sulfate is known to be a sensitizer. If Neomycin sulfate shows sensitization, it will be ruled out, leaving us with Phenytoin and Formaldehyde.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: The skin sensitization test has ruled out Neomycin sulfate. We are left with Phenytoin and Formaldehyde. The next logical step is to check for irritant properties using the eye irritation test. Formaldehyde is known to be an irritant, so if this test shows irritant effects, Formaldehyde will be ruled out, leaving us with Phenytoin as the likely candidate.", "<ANSWER> Phenytoin </ANSWER>\n\nReason: The eye irritation test ruled out Formaldehyde, leaving us with Phenytoin. Since no further tests are needed to identify the remaining compound, we can confidently predict that the correct pharmaceutical compound is Phenytoin."], "consumed_tokens": 5951, "observations": [null, {"action": "Animal toxicity test", "observation": "Moderate toxicity"}, {"action": "Skin sensitization test", "observation": "Sensitizer"}, {"action": "Eye irritation test", "observation": "Irritant"}], "successful": true, "parse_error": false}], "seed": 28, "average_actions": 5.2, "average_tokens": 6505.2, "average_correct": 0.8, "average_parse_error": 0.0, "average_successful_action_num": 5.0, "average_successful_tokens": 6022.5}
{"trajectories": [{"actions": ["CYP450 metabolism assay", "P-glycoprotein interaction assay", "Animal behavioral study", "Lisinopril", {"predicted_truth": "Lisinopril"}], "generated_text": ["<ANSWER> CYP450 metabolism assay </ANSWER>\n\nBy performing the CYP450 metabolism assay, we can determine if any of the compounds are strong inhibitors of the CYP450 enzyme system. This will help us rule out Omeprazole and Ketoconazole, as we know from the guidebook that Omeprazole is a strong inhibitor of the CYP450 system and Ketoconazole is not. This step will narrow down our list of potential compounds.", "<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nGiven that the CYP450 metabolism assay showed a strong inhibitor, we can rule out Omeprazole. Now, we need to determine if Ketoconazole is a P-glycoprotein inhibitor. From the guidebook, Ketoconazole is known to interact with the P-glycoprotein system. Therefore, performing the P-glycoprotein interaction assay will help us rule out Ketoconazole.", "<ANSWER> Animal behavioral study </ANSWER>\n\nGiven the results from the previous assays, we have ruled out Omeprazole and Ketoconazole. This leaves us with Lisinopril and Sertraline. The Animal behavioral study will help us rule out Sertraline, as the guidebook states that Sertraline does not induce behavioral changes in animal studies. This will allow us to confidently identify the remaining compound.", "<ANSWER> Lisinopril </ANSWER>\n\nSince the animal behavioral study showed no behavioral changes, we can rule out Sertraline. This leaves us with Lisinopril. Therefore, we can confidently predict that the remaining compound is Lisinopril."], "consumed_tokens": 5526, "observations": [null, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}], "successful": true, "parse_error": false}, {"actions": ["CYP450 metabolism assay", "P-glycoprotein interaction assay", "Animal behavioral study", "Blood-brain barrier permeability test", "Ketoconazole", {"predicted_truth": "Ketoconazole"}], "generated_text": ["<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>", "<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Ketoconazole </ANSWER>\n\nBased on the observations:\n- Strong inhibitor in the CYP450 metabolism assay rules out Omeprazole.\n- Inhibitor in the P-glycoprotein interaction assay rules out Ketoconazole.\n- No behavioral changes in the animal behavioral study rules out Sertraline.\n- Does not penetrate the BBB in the blood-brain barrier permeability test rules out Lisinopril.\n\nThe only compound remaining is Ketoconazole."], "consumed_tokens": 6109, "observations": [null, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}], "successful": false, "parse_error": false}, {"actions": ["CYP450 metabolism assay", "P-glycoprotein interaction assay", "Animal behavioral study", "Cardiac function test", "Blood-brain barrier permeability test", "Omeprazole", {"predicted_truth": "Omeprazole"}], "generated_text": ["<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>", "<ANSWER> Cardiac function test </ANSWER>", "<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Omeprazole </ANSWER>"], "consumed_tokens": 7359, "observations": [null, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "Cardiac function test", "observation": "Cardiotoxic"}, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}], "successful": false, "parse_error": false}, {"actions": ["CYP450 metabolism assay", "P-glycoprotein interaction assay", "Animal behavioral study", "Blood-brain barrier permeability test", "Omeprazole", {"predicted_truth": "Omeprazole"}], "generated_text": ["<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>", "<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Omeprazole </ANSWER>"], "consumed_tokens": 6020, "observations": [null, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}], "successful": false, "parse_error": false}, {"actions": ["CYP450 metabolism assay", "P-glycoprotein interaction assay", "Animal behavioral study", "Blood-brain barrier permeability test", "Lisinopril", {"predicted_truth": "Lisinopril"}], "generated_text": ["<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>", "<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Lisinopril </ANSWER>\n\nBased on the observed outcomes:\n1. The CYP450 metabolism assay showed that the compound is a strong inhibitor, so we ruled out Omeprazole.\n2. The P-glycoprotein interaction assay showed that the compound is an inhibitor, so we ruled out Ketoconazole.\n3. The animal behavioral study showed no behavioral changes, so we ruled out Sertraline.\n4. The blood-brain barrier permeability test showed that the compound does not penetrate the BBB, so we ruled out Lisinopril.\n\nSince Lisinopril is the only compound left that does not match all the observed outcomes, it must be the correct compound."], "consumed_tokens": 6155, "observations": [null, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}], "successful": true, "parse_error": false}], "seed": 29, "average_actions": 6.0, "average_tokens": 6233.8, "average_correct": 0.4, "average_parse_error": 0.0, "average_successful_action_num": 5.5, "average_successful_tokens": 5840.5}
{"trajectories": [{"actions": ["Eye irritation test", "Sodium Valproate", {"predicted_truth": "Sodium Valproate"}], "generated_text": ["<ANSWER> Eye irritation test </ANSWER> \n\nReason: The eye irritation test can help us rule out Formaldehyde quickly since it is known to cause eye irritation. This test will provide a clear outcome that can eliminate one of the compounds early in the process.", "<ANSWER> Sodium Valproate </ANSWER>\n\nReason: Since the Eye irritation test result is 'Irritant', Formaldehyde can be ruled out. This leaves us with Sodium Valproate, Cisapride, and Montelukast. The next logical step is to use the Mitochondrial toxicity test to further eliminate a compound, as Sodium Valproate is known to have potential mitochondrial toxicity. If the result is 'Mitochondrial toxic', then Sodium Valproate is the correct compound. If not, we can proceed with other tests to differentiate between Cisapride and Montelukast. However, since the Mitochondrial toxicity test is designed to identify this characteristic, it is a good next step."], "consumed_tokens": 2590, "observations": [null, {"action": "Eye irritation test", "observation": "Irritant"}], "successful": false, "parse_error": false}, {"actions": ["Eye irritation test", "Formaldehyde", {"predicted_truth": "Formaldehyde"}], "generated_text": ["<ANSWER> Eye irritation test </ANSWER>", "<ANSWER> Formaldehyde </ANSWER>"], "consumed_tokens": 2364, "observations": [null, {"action": "Eye irritation test", "observation": "Irritant"}], "successful": false, "parse_error": false}, {"actions": ["Eye irritation test", "Mitochondrial toxicity test", "In vitro enzyme inhibition assay", "QT prolongation assessment", "Sodium Valproate", {"predicted_truth": "Sodium Valproate"}], "generated_text": ["<ANSWER> Eye irritation test </ANSWER>\n\nReason: The Eye irritation test is a straightforward method to rule out Formaldehyde, which is known for its irritant properties on the eyes. By performing this test, we can eliminate Formaldehyde as a candidate, which will narrow down our list of potential compounds.", "<ANSWER> Mitochondrial toxicity test </ANSWER>\n\nReason: Since the Eye irritation test has ruled out Formaldehyde, we now need to focus on the remaining compounds: Sodium Valproate, Cisapride, and Montelukast. The Mitochondrial toxicity test is a critical test for Sodium Valproate, as it is known to have potential mitochondrial toxicity. A positive result for mitochondrial toxicity would rule out Sodium Valproate. Therefore, this test will help us narrow down the list further.", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The Mitochondrial toxicity test has ruled out Sodium Valproate. Now we are left with Cisapride and Montelukast. The In vitro enzyme inhibition assay is critical for ruling out Montelukast, as it is known to have specific enzyme inhibition properties. By performing this test, we can determine if the compound inhibits enzymes in a way that distinguishes Cisapride from Montelukast.", "<ANSWER> QT prolongation assessment </ANSWER>\n\nReason: The In vitro enzyme inhibition assay has provided a value of 0.7606677662469474, which does not rule out Montelukast (since it does not fall below 100 units). Therefore, we need to use another test to distinguish between Cisapride and Montelukast. The QT prolongation assessment is a critical test for Cisapride, as it can affect the QT interval, which Montelukast typically does not. By performing this test, we can conclusively identify the remaining compound.", "<ANSWER> Sodium Valproate </ANSWER>\n\nReason: The QT prolongation assessment has identified that the compound prolongs the QT interval, which is a known adverse effect of Cisapride. Since Formaldehyde, Eye irritation test, Mitochondrial toxicity test, In vitro enzyme inhibition assay, and Ames mutagenicity test have all been ruled out or are not applicable, Cisapride is the only remaining candidate. Therefore, the compound must be Sodium Valproate, as it is the only remaining option that fits all the observed outcomes."], "consumed_tokens": 7540, "observations": [null, {"action": "Eye irritation test", "observation": "Irritant"}, {"action": "Mitochondrial toxicity test", "observation": "Mitochondrial toxic"}, {"action": "In vitro enzyme inhibition assay", "observation": 0.7606677662469474}, {"action": "QT prolongation assessment", "observation": "Prolongs QT"}], "successful": false, "parse_error": false}, {"actions": ["Eye irritation test", "Mitochondrial toxicity test", "QT prolongation assessment", "In vitro enzyme inhibition assay", "Montelukast", {"predicted_truth": "Montelukast"}], "generated_text": ["<ANSWER> Eye irritation test </ANSWER>\n\nReason: Since Formaldehyde is known for its irritative properties, particularly to the eyes and mucous membranes, performing an Eye irritation test will likely rule it out quickly. This test will provide clear results that can help us eliminate Formaldehyde as a candidate, making it an efficient choice for the first round of testing.", "<ANSWER> Sodium Valproate </ANSWER>\n\nReason: Since the Eye irritation test showed that Formaldehyde is an irritant, we can eliminate Formaldehyde from the list. Now we are left with Sodium Valproate, Cisapride, and Montelukast. Given that Sodium Valproate is known to affect mitochondrial function, performing a Mitochondrial toxicity test will likely rule out Sodium Valproate. However, to minimize the number of steps, we can predict that Sodium Valproate will show mitochondrial toxicity, thus eliminating it from the list. \n\n<ANSWER> Mitochondrial toxicity test </ANSWER>", "<ANSWER> Cisapride </ANSWER>\n\nReason: Given the test results, we have ruled out Formaldehyde and Sodium Valproate. This leaves us with Cisapride and Montelukast. Cisapride is known to have cardiac effects, such as QT prolongation. To confirm this, we can perform a QT prolongation assessment. If the result shows no QT prolongation, Montelukast will be the remaining and correct compound. However, since Cisapride is known to prolong the QT interval, the result here will confirm that Cisapride is the correct compound.\n\n<ANSWER> QT prolongation assessment </ANSWER>", "<ANSWER> Sodium Valproate </ANSWER>\n\nReason: The QT prolongation assessment showed that the compound prolongs the QT interval, which is a known effect of Cisapride. Since Cisapride is the only remaining compound that can prolong the QT interval, and it has already been ruled out, the remaining compound must be Montelukast. To confirm this, we can perform an In vitro enzyme inhibition assay. If Montelukast does not inhibit the enzyme activity, it will be confirmed as the correct compound.\n\n<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Montelukast </ANSWER>\n\nReason: The In vitro enzyme inhibition assay resulted in an enzyme activity inhibition of 0.76, which does not fall into the range of 0 to 100 units that would eliminate Montelukast. Since all other compounds have been ruled out, Montelukast must be the correct compound."], "consumed_tokens": 7732, "observations": [null, {"action": "Eye irritation test", "observation": "Irritant"}, {"action": "Mitochondrial toxicity test", "observation": "Mitochondrial toxic"}, {"action": "QT prolongation assessment", "observation": "Prolongs QT"}, {"action": "In vitro enzyme inhibition assay", "observation": 0.7606677662469474}], "successful": false, "parse_error": false}, {"actions": ["Eye irritation test", "In vitro enzyme inhibition assay", "QT prolongation assessment", "hERG channel inhibition assay", "Sodium Valproate", {"predicted_truth": "Sodium Valproate"}], "generated_text": ["<ANSWER> Eye irritation test </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nBased on the eye irritation test result of 'Irritant', we can rule out Formaldehyde. Now, we will perform the in vitro enzyme inhibition assay to further narrow down the possibilities.", "<ANSWER> QT prolongation assessment </ANSWER>\n\nThe in vitro enzyme inhibition assay resulted in an enzyme activity inhibition of 0.7606677662469474, which does not eliminate Montelukast (since it falls within the range of 100 to 1000 and 1000 to 10000 units). Next, we will perform the QT prolongation assessment to rule out Cisapride.", "<ANSWER> hERG channel inhibition assay </ANSWER>\n\nThe QT prolongation assessment showed that the compound prolongs the QT interval, which does not directly rule out any of the compounds. However, since Cisapride was already ruled out by this test, we can now confirm that Cisapride is not the correct compound. To further narrow down the possibilities, we will perform the hERG channel inhibition assay. If the inhibition is in the range of 0 to 10, it would rule out Sodium Valproate. \n\nLet's proceed with the hERG channel inhibition assay.", "<ANSWER> Sodium Valproate </ANSWER>\n\nThe hERG channel inhibition assay showed an inhibition range of 30.89434832113146, which does not rule out Sodium Valproate (since it falls outside the range of 0 to 10). Therefore, based on the process of elimination, the remaining compound is Sodium Valproate."], "consumed_tokens": 7054, "observations": [null, {"action": "Eye irritation test", "observation": "Irritant"}, {"action": "In vitro enzyme inhibition assay", "observation": 0.7606677662469474}, {"action": "QT prolongation assessment", "observation": "Prolongs QT"}, {"action": "hERG channel inhibition assay", "observation": 30.89434832113146}], "successful": false, "parse_error": false}], "seed": 30, "average_actions": 4.8, "average_tokens": 5456.0, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["Clinical biomarker identification", "Teratogenicity assessment", "Valproic Acid", {"predicted_truth": "Valproic Acid"}], "generated_text": ["<ANSWER> Clinical biomarker identification </ANSWER>", "<ANSWER> Teratogenicity assessment </ANSWER>", "<ANSWER> Valproic Acid </ANSWER>"], "consumed_tokens": 3814, "observations": [null, {"action": "Clinical biomarker identification", "observation": "No biomarker identified"}, {"action": "Teratogenicity assessment", "observation": "Teratogenic"}], "successful": false, "parse_error": false}, {"actions": ["Clinical biomarker identification", "Teratogenicity assessment", "Imatinib", {"predicted_truth": "Imatinib"}], "generated_text": ["<ANSWER> Clinical biomarker identification </ANSWER>", "<ANSWER> Teratogenicity assessment </ANSWER>", "<ANSWER> Imatinib </ANSWER>\n\nBased on the observation that the compound is teratogenic, we can rule out Valproic Acid from our list of possible compounds. Imatinib is known to be safe and not teratogenic, while the other two compounds (Doxycycline and Neomycin sulfate) are more likely to be teratogenic. Therefore, Imatinib is the correct compound."], "consumed_tokens": 3890, "observations": [null, {"action": "Clinical biomarker identification", "observation": "No biomarker identified"}, {"action": "Teratogenicity assessment", "observation": "Teratogenic"}], "successful": false, "parse_error": false}, {"actions": ["Clinical biomarker identification", "Teratogenicity assessment", "Valproic Acid", {"predicted_truth": "Valproic Acid"}], "generated_text": ["<ANSWER> Clinical biomarker identification </ANSWER>", "<ANSWER> Teratogenicity assessment </ANSWER>", "<ANSWER> Valproic Acid </ANSWER>"], "consumed_tokens": 3814, "observations": [null, {"action": "Clinical biomarker identification", "observation": "No biomarker identified"}, {"action": "Teratogenicity assessment", "observation": "Teratogenic"}], "successful": false, "parse_error": false}, {"actions": ["Clinical biomarker identification", "Teratogenicity assessment", "Neomycin sulfate", {"predicted_truth": "Neomycin sulfate"}], "generated_text": ["<ANSWER> Clinical biomarker identification </ANSWER>\n\nReason: Since the goal is to identify the compound with the fewest steps, we can start by choosing a trial that has a clear outcome rule-out for at least one compound. The Clinical Biomarker Identification trial has a clear rule-out for Imatinib. If no biomarker is identified, then Imatinib can be ruled out. This simplifies the list and helps us identify the compound more quickly.", "<ANSWER> Teratogenicity assessment </ANSWER>\n\nReason: Since Imatinib has been ruled out by the \"Clinical Biomarker Identification\" trial, we can now focus on the remaining compounds: Doxycycline, Neomycin sulfate, and Valproic Acid. The Teratogenicity assessment trial can help us eliminate Valproic Acid, as it exhibits teratogenic effects. This will further narrow down our options.", "<ANSWER> Neomycin sulfate </ANSWER>\n\nReason: Given that Valproic Acid has been ruled out by the Teratogenicity assessment, we are left with Doxycycline and Neomycin sulfate. The next step is to use the Skin Sensitization test. Neomycin sulfate is known to be a sensitizing agent, so if the outcome is a sensitizing agent, Neomycin sulfate will be the remaining compound."], "consumed_tokens": 4297, "observations": [null, {"action": "Clinical biomarker identification", "observation": "No biomarker identified"}, {"action": "Teratogenicity assessment", "observation": "Teratogenic"}], "successful": false, "parse_error": false}, {"actions": ["Clinical biomarker identification", "Teratogenicity assessment", "Valproic Acid", {"predicted_truth": "Valproic Acid"}], "generated_text": ["<ANSWER> Clinical biomarker identification </ANSWER>\n\nReason: The goal is to systematically rule out pharmaceutical compounds that do not match the observed outcomes. The Clinical Biomarker Identification trial can help us eliminate Imatinib, as its absence in this trial would indicate that it is not associated with specific biomarkers for the current assessment. This step moves us closer to identifying the correct compound among the remaining options.", "<ANSWER> Teratogenicity assessment </ANSWER>\n\nReason: Since the Clinical Biomarker Identification trial did not identify any biomarkers for Imatinib, we can rule out Imatinib from our list of possible compounds. Next, we should perform the Teratogenicity assessment to check for any teratogenic effects, which can help us eliminate Valproic Acid. This step will further narrow down our options.", "<ANSWER> Valproic Acid </ANSWER>\n\nReason: The Teratogenicity assessment ruled out Valproic Acid because it exhibits teratogenic effects. This leaves us with Doxycycline and Neomycin sulfate. Since the question asks for a prediction and we have ruled out Valproic Acid, the correct remaining compound is Doxycycline. However, the provided options for the final answer are either an action or a truth, and since the action of Ames mutagenicity test can further differentiate between Doxycycline and Neomycin sulfate, and we need to predict the truth, the correct answer is Doxycycline."], "consumed_tokens": 4295, "observations": [null, {"action": "Clinical biomarker identification", "observation": "No biomarker identified"}, {"action": "Teratogenicity assessment", "observation": "Teratogenic"}], "successful": false, "parse_error": false}], "seed": 31, "average_actions": 4.0, "average_tokens": 4022.0, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["P-glycoprotein interaction assay", "Renal function test", "Paracetamol", {"predicted_truth": "Paracetamol"}], "generated_text": ["<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: The P-glycoprotein interaction assay is a critical test that can help rule out Ketoconazole, as it is known to have significant inhibitory properties on P-glycoprotein. This assay will provide a clear outcome that can help us eliminate Ketoconazole from our list of possible compounds.", "<ANSWER> Artificial tears </ANSWER>\n\nReason: Since the P-glycoprotein interaction assay indicates an inhibitor outcome, we can rule out Ketoconazole. This leaves us with 'Artificial tears', 'Paracetamol', and 'Amphotericin B'. The next step is to use an assay that can help us eliminate more compounds. The Renal function test can help us rule out Amphotericin B due to its known nephrotoxicity. Therefore, we will perform the Renal function test.\n\n<ANSWER> Renal function test </ANSWER>", "<ANSWER> Paracetamol </ANSWER>\n\nReason: The Renal function test indicates a nephrotoxic outcome, which rules out Amphotericin B. This leaves us with 'Artificial tears' and 'Paracetamol'. Since Artificial tears are generally considered safe with minimal systemic interactions, they are less likely to show adverse outcomes in tests compared to Paracetamol. The next logical step is to use the Oxidative stress assay, which has already ruled out Paracetamol in previous rounds. However, since we have only two options left and we need to identify the compound, we can predict that the remaining compound is Paracetamol.\n\n<ANSWER> Paracetamol </ANSWER>"], "consumed_tokens": 4347, "observations": [null, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}, {"action": "Renal function test", "observation": "Nephrotoxic"}], "successful": false, "parse_error": false}, {"actions": ["P-glycoprotein interaction assay", "Oxidative stress assay", "Renal function test", "Artificial tears", {"predicted_truth": "Artificial tears"}], "generated_text": ["<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: The P-glycoprotein interaction assay can help us rule out Ketoconazole since it is known to have significant inhibitory properties on P-glycoprotein. This assay will provide a clear outcome that can help us eliminate Ketoconazole from the list of possible compounds.", "<ANSWER> Oxidative stress assay </ANSWER>\n\nReason: Since the P-glycoprotein interaction assay ruled out Ketoconazole, we can now eliminate it from our list. The next step is to use the Oxidative stress assay to further narrow down the possibilities. Paracetamol does not induce oxidative stress, so if the assay shows no induction of ROS, we can rule out Paracetamol as well. This will help us identify whether the compound is Artificial tears or Amphotericin B.", "<ANSWER> Renal function test </ANSWER>\n\nReason: Since the Oxidative stress assay ruled out Paracetamol, we are left with Artificial tears and Amphotericin B. The Renal function test can help us rule out Amphotericin B due to its known nephrotoxic effects. If the test shows no nephrotoxic outcome, the remaining compound will be Artificial tears.", "<ANSWER> Artificial tears </ANSWER>\n\nReason: The Renal function test ruled out Amphotericin B, leaving us with Artificial tears as the only remaining compound. Since no other clinical trials are listed and we have successfully narrowed down the options, we can confidently identify the compound as Artificial tears."], "consumed_tokens": 5880, "observations": [null, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}, {"action": "Oxidative stress assay", "observation": "Does not induce ROS"}, {"action": "Renal function test", "observation": "Nephrotoxic"}], "successful": true, "parse_error": false}, {"actions": ["P-glycoprotein interaction assay", "Renal function test", "Glutathione depletion assay", "Artificial tears", {"predicted_truth": "Artificial tears"}], "generated_text": ["<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: The P-glycoprotein interaction assay can help us rule out Ketoconazole since it is known to have significant inhibitory properties on P-glycoprotein. This assay will provide us with the first definitive outcome to eliminate one of the potential compounds.", "<ANSWER> Amphotericin B </ANSWER>\n\nReason: Since the P-glycoprotein interaction assay indicates that Ketoconazole is an inhibitor, we can rule out Ketoconazole. This leaves us with Artificial tears, Paracetamol, and Amphotericin B. \n\nNext, we can perform the Renal function test. Amphotericin B is known for its potential nephrotoxic effects, so performing this test will likely show a nephrotoxic outcome, ruling out Amphotericin B.\n\n<ANSWER> Renal function test </ANSWER>", "<ANSWER> Artificial tears </ANSWER>\n\nReason: The Renal function test showing a nephrotoxic outcome rules out Amphotericin B. This leaves us with Artificial tears, Paracetamol. \n\nNext, we can perform the Glutathione depletion assay. Paracetamol is known to deplete glutathione levels, so this test will likely show a depletes glutathione outcome, ruling out Paracetamol and leaving us with Artificial tears as the remaining plausible compound. \n\n<ANSWER> Glutathione depletion assay </ANSWER>", "<ANSWER> Artificial tears </ANSWER>"], "consumed_tokens": 5928, "observations": [null, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}, {"action": "Renal function test", "observation": "Nephrotoxic"}, {"action": "Glutathione depletion assay", "observation": "Depletes glutathione"}], "successful": true, "parse_error": false}, {"actions": ["P-glycoprotein interaction assay", "Renal function test", "Glutathione depletion assay", "Artificial tears", {"predicted_truth": "Artificial tears"}], "generated_text": ["<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: The P-glycoprotein interaction assay is a critical test that can quickly rule out Ketoconazole, as it is known to have significant inhibitory properties on P-glycoprotein. This will help narrow down the list of potential compounds more efficiently.", "<ANSWER> Ketoconazole </ANSWER>\n\nReason: The P-glycoprotein interaction assay outcome is \"Inhibitor,\" which rules out Ketoconazole. This leaves us with the compounds Artificial tears, Paracetamol, and Amphotericin B. To further narrow down the possibilities, we can choose the next appropriate assay. The Renal function test is a good choice because Amphotericin B is known for its nephrotoxic effects, and this test can help rule it out. \n\n<ANSWER> Renal function test </ANSWER>", "<ANSWER> Artificial tears </ANSWER>\n\nReason: The Renal function test outcome is \"Nephrotoxic,\" which rules out Amphotericin B. This leaves us with Artificial tears, Paracetamol, and Ketoconazole. Since Ketoconazole has already been ruled out by the P-glycoprotein interaction assay, we are left with Artificial tears and Paracetamol. \n\nTo distinguish between Artificial tears and Paracetamol, we can use the Glutathione depletion assay. Paracetamol is known to deplete glutathione, while Artificial tears generally do not have this effect. \n\n<ANSWER> Glutathione depletion assay </ANSWER>", "<ANSWER> Artificial tears </ANSWER>\n\nReason: The Glutathione depletion assay outcome is \"Depletes glutathione,\" which rules out Paracetamol. This leaves us with Artificial tears as the only remaining compound. Therefore, we can confidently identify the compound as Artificial tears."], "consumed_tokens": 6015, "observations": [null, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}, {"action": "Renal function test", "observation": "Nephrotoxic"}, {"action": "Glutathione depletion assay", "observation": "Depletes glutathione"}], "successful": true, "parse_error": false}, {"actions": ["P-glycoprotein interaction assay", "Renal function test", "Glutathione depletion assay", "Artificial tears", {"predicted_truth": "Artificial tears"}], "generated_text": ["<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: The P-glycoprotein interaction assay is the most straightforward and decisive test to eliminate Ketoconazole, as it is known to have significant inhibitory properties on P-glycoprotein. This assay will help us rule out Ketoconazole early in the process, narrowing down the possible compounds more efficiently.", "<ANSWER> Artificial tears </ANSWER>\n\nReason: Since the P-glycoprotein interaction assay ruled out Ketoconazole as an inhibitor, we are left with 'Artificial tears', 'Paracetamol', and 'Amphotericin B'. The next step is to use an assay that can help us eliminate more compounds. The Renal function test is a good choice because Amphotericin B is known to be nephrotoxic. If the test shows a nephrotoxic outcome, we can rule out Amphotericin B.\n\n<ANSWER> Renal function test </ANSWER>", "<ANSWER> Paracetamol </ANSWER>\n\nReason: The renal function test ruled out Amphotericin B due to its nephrotoxic nature. This leaves us with 'Artificial tears', 'Paracetamol', and 'Ketoconazole'. Next, we can use the Glutathione depletion assay to further narrow down the possibilities. Paracetamol is known to deplete glutathione, while the other two compounds do not have this effect. Therefore, if the assay shows that the compound depletes glutathione, we can rule out Paracetamol and be left with 'Artificial tears' and 'Ketoconazole'. However, since we have already ruled out Ketoconazole from the P-glycoprotein interaction assay, the remaining compound must be 'Artificial tears'.\n\n<ANSWER> Glutathione depletion assay </ANSWER>", "<ANSWER> Artificial tears </ANSWER>"], "consumed_tokens": 6108, "observations": [null, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}, {"action": "Renal function test", "observation": "Nephrotoxic"}, {"action": "Glutathione depletion assay", "observation": "Depletes glutathione"}], "successful": true, "parse_error": false}], "seed": 32, "average_actions": 4.8, "average_tokens": 5655.6, "average_correct": 0.8, "average_parse_error": 0.0, "average_successful_action_num": 5.0, "average_successful_tokens": 5982.75}
{"trajectories": [{"actions": ["Carcinogenicity study", "P-glycoprotein interaction assay", "Knockout mouse model efficacy study", "Penicillin", {"predicted_truth": "Penicillin"}], "generated_text": ["<ANSWER> Carcinogenicity study </ANSWER>\n\nReason: Since Prednisone is the only compound that has the potential to be a carcinogen, performing a carcinogenicity study can help us quickly rule out Prednisone. This will simplify the process and allow us to focus on the remaining compounds.", "<ANSWER> Insulin </ANSWER>\n\nReason: Since the carcinogenicity study ruled out Prednisone, we now have three remaining compounds: Nifedipine, Insulin, and Penicillin. Insulin is the only compound that has been identified as immunogenic. However, the immunogenicity testing has not been performed yet. Given that the carcinogenicity study resulted in a positive outcome (cancerous), we can rule out Prednisone. Now, we need to choose an action that will help us narrow down between Nifedipine and Penicillin. The P-glycoprotein interaction assay is a good choice because Nifedipine shows no interaction with P-glycoprotein, making it a strong candidate to rule out Nifedipine in this test. \n\n<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> Insulin </ANSWER>\n\nReason: Since the P-glycoprotein interaction assay showed no interaction for Nifedipine, we can now rule out Nifedipine. This leaves us with Insulin and Penicillin. Next, we need to choose an action that will help us differentiate between Insulin and Penicillin. The knockout mouse model efficacy study is a good choice because it has been noted that Insulin is ineffective in this model, while Penicillin is effective. \n\n<ANSWER> Knockout mouse model efficacy study </ANSWER>", "<ANSWER> Penicillin </ANSWER>\n\nReason: The knockout mouse model efficacy study showed that the compound was ineffective. Since Insulin was ruled out in the knockout mouse model efficacy study, the remaining compound is Penicillin."], "consumed_tokens": 6182, "observations": [null, {"action": "Carcinogenicity study", "observation": "Carcinogenic"}, {"action": "P-glycoprotein interaction assay", "observation": "No interaction"}, {"action": "Knockout mouse model efficacy study", "observation": "Ineffective"}], "successful": true, "parse_error": false}, {"actions": ["P-glycoprotein interaction assay", "Carcinogenicity study", null], "generated_text": ["<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: Based on the provided guidebook, the P-glycoprotein interaction assay can help eliminate Nifedipine, which does not interact with P-glycoprotein. This assay will help us narrow down the list of potential compounds. Since Nifedipine is the only compound that does not interact with P-glycoprotein, it is a good starting point for ruling out other compounds. After performing this assay, we can either confirm Nifedipine as one of the remaining candidates or eliminate it if the trial provides outcomes that do not match its properties.", "<ANSWER> Carcinogenicity study </ANSWER>\n\nReason: Since the P-glycoprotein interaction assay ruled out Nifedipine and we are left with Insulin, Prednisone, and Penicillin, the next logical step is to use a carcinogenicity study. Prednisone is known to be carcinogenic, so if the study indicates carcinogenicity, Prednisone can be eliminated. This will help us narrow down the potential compounds further.", "<ANSWER> Immunoactivity testing </ANSWER>\n\nReason: Given that the carcinogenicity study ruled out Prednisone, we are left with Insulin and Penicillin. Insulin is known to be immunogenic, while Penicillin is not. Therefore, performing an immunogenicity test will help us eliminate Insulin."], "consumed_tokens": 4426, "observations": [null, {"action": "P-glycoprotein interaction assay", "observation": "No interaction"}, {"action": "Carcinogenicity study", "observation": "Carcinogenic"}], "successful": false, "parse_error": true}, {"actions": ["Carcinogenicity study", "Insulin", {"predicted_truth": "Insulin"}], "generated_text": ["<ANSWER> Carcinogenicity study </ANSWER>\n\nReason: Given the initial list of possible pharmaceutical compounds ('Nifedipine', 'Insulin', 'Prednisone', 'Penicillin') and the clinical trials available, the Carcinogenicity study is a logical first step. Prednisone is known to be a potential carcinogen, which would allow us to quickly rule it out if the study shows it to be carcinogenic. This process of elimination can help narrow down the possibilities more efficiently.", "<ANSWER> Insulin </ANSWER>\n\nReason: Since the Carcinogenicity study has shown that the compound is carcinogenic and Prednisone is known to be a potential carcinogen, we have already ruled out Prednisone. Now, we are left with Nifedipine, Insulin, and Penicillin. Among these, Insulin is less likely to be carcinogenic. Therefore, the most plausible remaining compound given the observed outcome is Insulin."], "consumed_tokens": 2781, "observations": [null, {"action": "Carcinogenicity study", "observation": "Carcinogenic"}], "successful": false, "parse_error": false}, {"actions": ["P-glycoprotein interaction assay", "Immunogenicity testing", "Prednisone", {"predicted_truth": "Prednisone"}], "generated_text": ["<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: Given the list of available pharmaceutical compounds, we can already rule out some compounds based on the guidebook. Specifically, Nifedipine is ruled out as it shows no interaction with P-glycoprotein. Insulin and Penicillin can also be ruled out because they are not P-glycoprotein substrates or inhibitors. Therefore, performing a P-glycoprotein interaction assay will help us confirm the remaining compound, which is Prednisone.", "<ANSWER> Immunogenicity testing </ANSWER>\n\nReason: Since the P-glycoprotein interaction assay has ruled out Nifedipine, and we are left with three compounds (Insulin, Prednisone, Penicillin), the next logical step is to use a test that can differentiate between these. The Immunogenicity testing can help us eliminate either Insulin or Penicillin, as Insulin is known to be immunogenic.", "<ANSWER> Prednisone </ANSWER>\n\nReason: Since the immunogenicity test confirmed that the compound is immunogenic, we can rule out Penicillin. The remaining compounds are Nifedipine and Prednisone. Given that Penicillin was already ruled out by the P-glycoprotein interaction assay, and Insulin is known to be immunogenic, the only compound left that matches the criteria of being immunogenic is Prednisone."], "consumed_tokens": 4371, "observations": [null, {"action": "P-glycoprotein interaction assay", "observation": "No interaction"}, {"action": "Immunogenicity testing", "observation": "Immunogenic"}], "successful": false, "parse_error": false}, {"actions": ["Carcinogenicity study", "Prednisone", {"predicted_truth": "Prednisone"}], "generated_text": ["<ANSWER> Carcinogenicity study </ANSWER>\n\nRationale: Given the outcomes of the various bioassays, we can rule out several compounds. Insulin and Penicillin can be ruled out based on their interactions with P-glycoprotein and bioavailability, respectively. Prednisone can be ruled out if it shows carcinogenic properties, leaving us with Nifedipine. Performing a carcinogenicity study will help us eliminate either Prednisone or Nifedipine, narrowing down the possibilities.", "<ANSWER> Prednisone </ANSWER>\n\nRationale: Since the carcinogenicity study showed that the compound is carcinogenic, we can eliminate Prednisone as it is not known to be carcinogenic. This leaves us with Nifedipine as the only plausible remaining compound."], "consumed_tokens": 2748, "observations": [null, {"action": "Carcinogenicity study", "observation": "Carcinogenic"}], "successful": false, "parse_error": false}], "seed": 33, "average_actions": 3.6, "average_tokens": 4101.6, "average_correct": 0.2, "average_parse_error": 0.2, "average_successful_action_num": 5.0, "average_successful_tokens": 6182.0}
{"trajectories": [{"actions": ["In vitro enzyme inhibition assay", "Azithromycin", {"predicted_truth": "Azithromycin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay can provide initial insights into the properties of the compounds. Specifically, it can help us eliminate Codeine and Simvastatin based on their known inhibition patterns. This will narrow down our list of potential compounds and make the identification process more efficient.", "Observation from previous action: The in vitro enzyme inhibition assay resulted in an inhibition value of 3468.0660972272867. This value is in the range of 1000-10000 units, which rules out Simvastatin.\n\n<ANSWER> Azithromycin </ANSWER>\n\nReason: The high inhibition value (1000-10000 units) is characteristic of Simvastatin. Since Simvastatin is ruled out, we are left with Azithromycin, Codeine, and Lamivudine. The next step is to choose an appropriate assay to further narrow down the possibilities."], "consumed_tokens": 2719, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 3468.0660972272867}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Simvastatin", {"predicted_truth": "Simvastatin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay is a good starting point because it can help us eliminate compounds based on their interaction with specific enzymes. Simvastatin is known to inhibit the enzyme HMG-CoA reductase, which is essential in cholesterol biosynthesis. By performing this assay, we can quickly rule out compounds that do not exhibit this property. Additionally, the outcomes of this assay can help us narrow down the possibilities and make further predictions.", "Observation from previous action: The in vitro enzyme inhibition assay resulted in an inhibition value of 3468.0660972272867. This value is in the range of 1000-10000 units, which is higher than the range for Simvastatin (0-100 units of inhibition). This suggests that the compound being tested is not Simvastatin.\n\n<ANSWER> Simvastatin </ANSWER>"], "consumed_tokens": 2744, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 3468.0660972272867}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Codeine", {"predicted_truth": "Codeine"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: Starting with the in vitro enzyme inhibition assay can help us quickly eliminate compounds that do not inhibit the relevant enzyme (HMG-CoA reductase) within a specific range. This assay is particularly useful for differentiating between Simvastatin and other compounds based on their known mechanism of action.", "The observed enzyme inhibition value of 3468.0660972272867 falls within the range of 1000-10000 units, which rules out Simvastatin as it is known to be a potent inhibitor of HMG-CoA reductase.\n\n<ANSWER> Codeine </ANSWER>"], "consumed_tokens": 2657, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 3468.0660972272867}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Ames mutagenicity test", "Cytokine release assay", "Azithromycin", {"predicted_truth": "Azithromycin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nI choose the In vitro enzyme inhibition assay because it can help us rule out certain compounds based on their interaction with specific enzymes. For instance, if the inhibition is in the range of 1000-10000 units, it would rule out Simvastatin. This assay provides a clear way to start eliminating compounds and narrowing down the possibilities.", "The observed value from the In vitro enzyme inhibition assay is 3468.0660972272867, which falls within the range of 1000-10000 units. Based on this outcome, we can rule out Simvastatin.\n\n<ANSWER> Simvastatin </ANSWER>\n\nNow, we need to choose another assay to perform. Let's choose the Ames mutagenicity test next, as it will help us eliminate compounds that show mutagenic properties.\n\n<ANSWER> Ames mutagenicity test </ANSWER>", "The Ames mutagenicity test result is positive, which excludes Lamivudine from consideration. We are now left with the compounds Azithromycin and Codeine.\n\nNext, let's choose the Cytokine release assay to further narrow down the possibilities. If the cytokine release is high, it will exclude Codeine.\n\n<ANSWER> Cytokine release assay </ANSWER>", "Since the Cytokine release assay showed low cytokine release, Codeine is no longer a viable option. This leaves us with Azithromycin.\n\n<ANSWER> Azithromycin </ANSWER>"], "consumed_tokens": 5946, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 3468.0660972272867}, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "Cytokine release assay", "observation": "Low cytokine release"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Ames mutagenicity test", "Solubility test", "In vitro enzyme inhibition assay", "Ames mutagenicity test", "Azithromycin", {"predicted_truth": "Azithromycin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay can help us rule out Simvastatin, as it is a potent inhibitor of HMG-CoA reductase. This assay will provide direct evidence of enzyme inhibition, which can quickly eliminate one of the compounds from consideration.", "The observation from the in vitro enzyme inhibition assay is 3468.0660972272867 units of enzyme inhibition. This value is significantly lower than the 1000-10000 units that would rule out Simvastatin. Therefore, Simvastatin can be eliminated as a potential compound.\n\n<ANSWER> Simvastatin </ANSWER>\n\nNow, we can proceed with another test to further narrow down the remaining compounds. Let's choose the Ames mutagenicity test next.\n\n<ANSWER> Ames mutagenicity test </ANSWER>", "The observation from the Ames mutagenicity test is positive, which excludes Lamivudine. This leaves us with the compounds Azithromycin and Codeine.\n\n<ANSWER> Solubility test </ANSWER>\n\nReason: The solubility test can help us eliminate Codeine, which is known to have poor solubility issues. If the solubility test shows poor solubility for the remaining compound, it will be Azithromycin.", "The observation from the solubility test is highly soluble, which excludes Codeine. This leaves us with the compounds Azithromycin and Lamivudine. Since the solubility test has already ruled out Codeine, we can proceed with another test to further narrow down the remaining compounds. Let's choose the in vitro enzyme inhibition assay next.\n\n<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "The observation from the in vitro enzyme inhibition assay is 3468.0660972272867 units of enzyme inhibition. This value is within the range that would exclude Simvastatin, but since Simvastatin has already been eliminated and we are left with Azithromycin and Lamivudine, this value does not provide new information about the remaining compounds.\n\nGiven that the solubility test excluded Codeine and the in vitro enzyme inhibition assay did not provide new exclusion criteria, we can proceed with the Ames mutagenicity test to further narrow down the options.\n\n<ANSWER> Ames mutagenicity test </ANSWER>", "The observation from the Ames mutagenicity test is positive, which excludes Lamivudine. This leaves us with the compound Azithromycin.\n\n<ANSWER> Azithromycin </ANSWER>"], "consumed_tokens": 9751, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 3468.0660972272867}, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "Solubility test", "observation": "Highly soluble"}, {"action": "In vitro enzyme inhibition assay", "observation": 3468.0660972272867}, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": false, "parse_error": false}], "seed": 34, "average_actions": 4.2, "average_tokens": 4763.4, "average_correct": 0.2, "average_parse_error": 0.0, "average_successful_action_num": 3.0, "average_successful_tokens": 2657.0}
{"trajectories": [{"actions": ["Dose-response study", "Losartan", {"predicted_truth": "Losartan"}], "generated_text": ["<ANSWER> Dose-response study </ANSWER>", "<ANSWER> Losartan </ANSWER>\n\nGiven the observation 'Linear response' from the Dose-response study, we can rule out Phenytoin. Now, we are left with Lisinopril, Losartan, and Cyclosporine. The linear response in a dose-response study typically indicates a consistent and proportional effect, which is more characteristic of Lisinopril (an ACE inhibitor) rather than the other compounds. However, to be thorough, we should eliminate the options that do not fit the observed outcome. Since Phenytoin is ruled out, we are left with Lisinopril, Losartan, and Cyclosporine. Given that a linear response is more typical of Lisinopril, we can confidently rule out Losartan and Cyclosporine based on the context provided."], "consumed_tokens": 2268, "observations": [null, {"action": "Dose-response study", "observation": "Linear response"}], "successful": true, "parse_error": false}, {"actions": ["Dose-response study", "Losartan", {"predicted_truth": "Losartan"}], "generated_text": ["<ANSWER> Dose-response study </ANSWER>", "<ANSWER> Losartan </ANSWER>\n\nGiven the observation of 'Linear response' in the Dose-response study, we can rule out Phenyltoin. The remaining compounds are Lisinopril, Losartan, and Cyclosporine. Since a linear response is observed, it indicates that the compound is likely to be Phenytoin, which can be ruled out. This leaves us with Lisinopril, Losartan, and Cyclosporine. However, since the question asks for the most likely compound and we have ruled out Phenytoin, the remaining options are Losartan and possibly Cyclosporine, but given the context of the Dose-response study, Losartan is more likely to fit the profile of an ARB with a linear dose-response relationship."], "consumed_tokens": 2264, "observations": [null, {"action": "Dose-response study", "observation": "Linear response"}], "successful": true, "parse_error": false}, {"actions": ["Dose-response study", "Losartan", {"predicted_truth": "Losartan"}], "generated_text": ["<ANSWER> Dose-response study </ANSWER>", "<ANSWER> Losartan </ANSWER>\n\nGiven the observation of a 'Linear response' in the Dose-response study, we can rule out Lisinopril. This leaves us with Losartan, Phenytoin, and Cyclosporine as possible compounds. Losartan is the only ARB among the remaining options, and the linear response is not typically associated with Phenytoin or Cyclosporine. Therefore, Losartan is the most plausible remaining compound."], "consumed_tokens": 2198, "observations": [null, {"action": "Dose-response study", "observation": "Linear response"}], "successful": true, "parse_error": false}, {"actions": ["Cardiac function test", "Dose-response study", "Losartan", {"predicted_truth": "Losartan"}], "generated_text": ["<ANSWER> Cardiac function test </ANSWER>\n\nReason: By selecting the Cardiac function test, we can observe if the drug is cardiotoxic. According to the guidebook, if the outcome is non-cardiotoxic, Lisinopril can be ruled out. This step will help narrow down the possible compounds more effectively.", "<ANSWER> Dose-response study </ANSWER>\n\nReason: Since the Cardiac function test ruled out Lisinopril, we can now perform a Dose-response study to further narrow down the possibilities. If the outcome is linear, Phenytoin can be ruled out. This will help us identify the correct compound more efficiently.", "<ANSWER> Losartan </ANSWER>\n\nReason: The observation of a linear response in the Dose-response study rules out Phenytoin. This leaves us with Losartan and Cyclosporine. Since we have no further information to rule out Cyclosporine at this point, we can conclude that the correct compound is Losartan."], "consumed_tokens": 3577, "observations": [null, {"action": "Cardiac function test", "observation": "Non-cardiotoxic"}, {"action": "Dose-response study", "observation": "Linear response"}], "successful": true, "parse_error": false}, {"actions": ["Dose-response study", "Losartan", {"predicted_truth": "Losartan"}], "generated_text": ["<ANSWER> Dose-response study </ANSWER>", "<ANSWER> Losartan </ANSWER>\n\nGiven the observation of a 'Linear response' in the Dose-response study, we can rule out Phenytoin. Since a linear response is not consistent with the properties of Lisinopril or Losartan, and Phenytoin is already excluded, the remaining options are Lisinopril and Losartan. However, a linear dose-response relationship is more characteristic of Lisinopril, an ACE inhibitor, rather than Losartan, an ARB. Therefore, Losartin can be ruled out, leaving us with Lisinopril as the most plausible compound."], "consumed_tokens": 2225, "observations": [null, {"action": "Dose-response study", "observation": "Linear response"}], "successful": true, "parse_error": false}], "seed": 35, "average_actions": 3.2, "average_tokens": 2506.4, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 3.2, "average_successful_tokens": 2506.4}
{"trajectories": [{"actions": ["Receptor binding affinity assay", "Loratadine", {"predicted_truth": "Loratadine"}], "generated_text": ["<ANSWER> Receptor binding affinity assay </ANSWER>\n\nBy performing the Receptor binding affinity assay, we can start eliminating compounds based on their binding affinities. Given the guidebook information, low binding affinity compounds can be ruled out immediately. Since Loratadine has a low binding affinity, it is likely to be eliminated early in this process. Let's proceed with this assay to narrow down the possibilities.", "The Receptor binding affinity assay result is 18.225687578353345, which falls within the range of 0 to 50, indicating a low binding affinity. Based on the guidebook, compounds with low binding affinity should be ruled out. Therefore, Loratadine can be eliminated from the list.\n\n<ANSWER> Loratadine </ANSWER>"], "consumed_tokens": 2847, "observations": [null, {"action": "Receptor binding affinity assay", "observation": 18.225687578353345}], "successful": false, "parse_error": false}, {"actions": ["Receptor binding affinity assay", "Off-target activity screening", "Animal behavioral study", "In vitro enzyme inhibition assay", "Blood-brain barrier permeability test", "Losartan", {"predicted_truth": "Losartan"}], "generated_text": ["<ANSWER> Receptor binding affinity assay </ANSWER>", "<ANSWER> Off-target activity screening </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Losartan </ANSWER>"], "consumed_tokens": 8502, "observations": [null, {"action": "Receptor binding affinity assay", "observation": 18.225687578353345}, {"action": "Off-target activity screening", "observation": "High off-target activity"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "In vitro enzyme inhibition assay", "observation": 26.808724211733836}, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}], "successful": true, "parse_error": false}, {"actions": ["Receptor binding affinity assay", "Loratadine", {"predicted_truth": "Loratadine"}], "generated_text": ["<ANSWER> Receptor binding affinity assay </ANSWER>", "The observed binding affinity value is 18.225687578353345, which falls within the range of 0 to 50. According to the guidebook, compounds with low binding affinity (0 to 50) are eliminated as possibilities. Therefore, we can rule out 'Loratadine'.\n\n<ANSWER> Loratadine </ANSWER>"], "consumed_tokens": 2702, "observations": [null, {"action": "Receptor binding affinity assay", "observation": 18.225687578353345}], "successful": false, "parse_error": false}, {"actions": ["Receptor binding affinity assay", "Off-target activity screening", "Animal behavioral study", "In vitro enzyme inhibition assay", "Pharmacodynamics evaluation", "Blood-brain barrier permeability test", "Tadalafil", {"predicted_truth": "Tadalafil"}], "generated_text": ["<ANSWER> Receptor binding affinity assay </ANSWER>", "<ANSWER> Off-target activity screening </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>\n\nBased on the previous observations, Tadalafil and Losartan have been ruled out due to their off-target activity and receptor binding affinity, respectively. Loratadine and Sertraline remain as potential compounds. The Animal Behavioral Study should help us distinguish between these two by identifying any behavioral changes that might occur, which would allow us to rule out one of them.", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nGiven that both Loratadine and Sertraline did not cause any behavioral changes, the next step is to perform the In vitro Enzyme Inhibition Assay to further differentiate between these two compounds. Certificate of enzyme inhibition can provide clear evidence to rule one of them out.", "<ANSWER> Pharmacodynamics evaluation </ANSWER>", "<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Tadalafil </ANSWER>\n\nBased on the observations, Tadalafil has been ruled out due to its high off-target activity, behavioral effects, significant enzyme inhibition, expected pharmacodynamic effect, and inability to penetrate the blood-brain barrier. Loratadine is the remaining compound that has not been ruled out by these trials."], "consumed_tokens": 10744, "observations": [null, {"action": "Receptor binding affinity assay", "observation": 18.225687578353345}, {"action": "Off-target activity screening", "observation": "High off-target activity"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "In vitro enzyme inhibition assay", "observation": 26.808724211733836}, {"action": "Pharmacodynamics evaluation", "observation": "Expected effect"}, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}], "successful": false, "parse_error": false}, {"actions": ["Receptor binding affinity assay", "Off-target activity screening", "Animal behavioral study", "In vitro enzyme inhibition assay", "Pharmacodynamics evaluation", "Blood-brain barrier permeability test", "Loratadine", {"predicted_truth": "Loratadine"}], "generated_text": ["<ANSWER> Receptor binding affinity assay </ANSWER>", "<ANSWER> Off-target activity screening </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>\n\nThe observed high off-target activity in the off-target activity screening rules out Tadalafil. Next, we should check for any behavioral changes in the animals to further narrow down the possibilities.", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Pharmacodynamics evaluation </ANSWER>", "<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Loratadine </ANSWER>"], "consumed_tokens": 10265, "observations": [null, {"action": "Receptor binding affinity assay", "observation": 18.225687578353345}, {"action": "Off-target activity screening", "observation": "High off-target activity"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "In vitro enzyme inhibition assay", "observation": 26.808724211733836}, {"action": "Pharmacodynamics evaluation", "observation": "Expected effect"}, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}], "successful": false, "parse_error": false}], "seed": 36, "average_actions": 5.8, "average_tokens": 7012.0, "average_correct": 0.2, "average_parse_error": 0.0, "average_successful_action_num": 7.0, "average_successful_tokens": 8502.0}
{"trajectories": [{"actions": ["Human clinical trial Phase I", "Eye irritation test", "Micronucleus test", "Cisplatin", {"predicted_truth": "Cisplatin"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Since Metoprolol was ruled out based on severe adverse effects observed in the Human clinical trial Phase I, we can start by confirming if the other compounds are consistent with the outcomes of this trial. This trial will help us eliminate more compounds based on the observed adverse effects.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: Since Metoprolol has already been ruled out, we can focus on the remaining compounds: Sodium lauryl sulfate, Cisplatin, and Aspirin. The Eye irritation test can help us eliminate Sodium lauryl sulfate, which is known to cause eye irritation. This will help narrow down the possible compounds further.", "<ANSWER> Micronucleus test </ANSWER>\n\nReason: Since Sodium lauryl sulfate has been ruled out due to eye irritation, we are left with Cisplatin and Aspirin. The Micronucleus test can help us eliminate Aspirin, as it has been observed to cause chromosomal damage or mutations. This will leave us with Cisplatin as the remaining possible compound.", "<ANSWER> Cisplatin </ANSWER>\n\nReason: The Micronucleus test resulted in a negative outcome for Aspirin, confirming that Aspirin can be ruled out. This leaves us with Cisplatin as the only remaining pharmaceutical compound."], "consumed_tokens": 6018, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}, {"action": "Eye irritation test", "observation": "Irritant"}, {"action": "Micronucleus test", "observation": "Negative"}], "successful": false, "parse_error": false}, {"actions": ["Human clinical trial Phase I", "Oxidative stress assay", "Eye irritation test", "Micronucleus test", "Aspirin", {"predicted_truth": "Aspirin"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>", "<ANSWER> Oxidative stress assay </ANSWER>", "<ANSWER> Eye irritation test </ANSWER>", "<ANSWER> Micronucleus test </ANSWER>", "<ANSWER> Aspirin </ANSWER>"], "consumed_tokens": 6869, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}, {"action": "Oxidative stress assay", "observation": "Induces ROS"}, {"action": "Eye irritation test", "observation": "Irritant"}, {"action": "Micronucleus test", "observation": "Negative"}], "successful": true, "parse_error": false}, {"actions": ["Human clinical trial Phase I", "Oxidative stress assay", "Eye irritation test", "Cisplatin", {"predicted_truth": "Cisplatin"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Since Metoprolol was ruled out due to severe adverse effects in the Human clinical trial Phase I, this trial provides a significant piece of information to further narrow down the possible compounds. By selecting this action, we can rule out one more compound based on the observed outcomes.", "<ANSWER> Oxidative stress assay </ANSWER>\n\nReason: Given that Metoprolol and Aspirin have been ruled out, we now focus on Sodium lauryl sulfate and Cisplatin. The Oxidative stress assay can help us determine if Cisplatin is the correct compound since it is known to induce ROS production.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: Since Cisplatin is known to induce oxidative stress, it is still under consideration. The Eye irritation test will help us determine if Sodium lauryl sulfate is the correct compound, as it is known to cause eye irritation. This test will allow us to rule out one of the remaining compounds.", "<ANSWER> Cisplatin </ANSWER>\n\nReason: Based on the observations from the previous tests, we have ruled out Metoprolol, Aspirin, and Sodium lauryl sulfate. The only remaining compound is Cisplatin, which fits all the criteria from the tests performed."], "consumed_tokens": 5987, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}, {"action": "Oxidative stress assay", "observation": "Induces ROS"}, {"action": "Eye irritation test", "observation": "Irritant"}], "successful": false, "parse_error": false}, {"actions": ["Human clinical trial Phase I", "Metoprolol", {"predicted_truth": "Metoprolol"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Given the outcomes from the other trials, we can rule out Sodium lauryl sulfate, Metoprolol, Cisplatin, and Aspirin based on the specific findings from the eye irritation test, oxidative stress assay, micronucleus test, animal toxicity test, and mitochondrial toxicity test. The human clinical trial Phase I is the only trial left that can help us confirm the remaining compound. Since Metoprolol was ruled out due to severe adverse effects in Phase I, and the other compounds were ruled out based on other tests, this trial should help us identify the correct compound.", "<ANSWER> Metoprolol </ANSWER>\n\nReason: Given that Metoprolol was ruled out due to severe adverse effects in the human clinical trial Phase I, we can confidently predict that the compound in question is not Metoprolol. Since the other compounds have been ruled out by their respective bioassays, the remaining compound must be one of the options not yet eliminated. Based on the information provided and the process of elimination, the correct compound is Aspirin."], "consumed_tokens": 2938, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}], "successful": false, "parse_error": false}, {"actions": ["Human clinical trial Phase I", "Oxidative stress assay", "Eye irritation test", "Cisplatin", {"predicted_truth": "Cisplatin"}], "generated_text": ["<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Based on the guidebook, the Human clinical trial Phase I indicates severe adverse effects for Metoprolol and mild adverse effects for Aspirin. By performing this trial, we can quickly eliminate two out of the four compounds. Since Metoprolol is ruled out due to severe adverse effects, and Aspirin is ruled out due to mild adverse effects, this trial will help us narrow down the possible compounds to Sodium lauryl sulfate and Cisplatin.", "<ANSWER> Oxidative stress assay </ANSWER>\n\nReason: Since we have already ruled out Metoprolol and Aspirin based on the severe and mild adverse effects observed in the Human clinical trial Phase I, the next logical step is to use the Oxidative stress assay. Cisplatin is known to induce ROS (reactive oxygen species), while Sodium lauryl sulfate is not associated with ROS induction. Therefore, this assay will help us eliminate Cisplatin.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: We have now ruled out Cisplatin because it induces ROS. The remaining compound is Sodium lauryl sulfate. The Eye irritation test will confirm if Sodium lauryl sulfate is an irritant, thus allowing us to identify the compound.", "<ANSWER> Cisplatin </ANSWER>\n\nReason: Based on the observations from the previous trials, we have ruled out Metoprolol, Aspirin, and Cisplatin. The only remaining compound is Sodium lauryl sulfate, which was ruled out by the Eye irritation test. Therefore, the correct compound is Cisplatin."], "consumed_tokens": 6220, "observations": [null, {"action": "Human clinical trial Phase I", "observation": "Severe adverse effects"}, {"action": "Oxidative stress assay", "observation": "Induces ROS"}, {"action": "Eye irritation test", "observation": "Irritant"}], "successful": false, "parse_error": false}], "seed": 37, "average_actions": 4.8, "average_tokens": 5606.4, "average_correct": 0.2, "average_parse_error": 0.0, "average_successful_action_num": 6.0, "average_successful_tokens": 6869.0}
{"trajectories": [{"actions": ["In vitro enzyme inhibition assay", "Off-target activity screening", "Ames mutagenicity test", "High-throughput screening assay", "Atenolol", {"predicted_truth": "Atenolol"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nI choose the \"In vitro enzyme inhibition assay\" because it provides clear criteria for eliminating specific compounds based on the concentration required for enzyme inhibition. This will help us quickly narrow down the list of possible compounds.", "<ANSWER> Off-target activity screening </ANSWER>\n\nBased on the observation from the \"In vitro enzyme inhibition assay\" (26.69633158304182 nM), which falls between 100-1000 nM, we can rule out Sildenafil. Now, we need to further narrow down the possibilities by selecting the \"Off-target activity screening\" to see if it shows any high off-target activity. If it does, we can rule out Sildenafil again, and if not, we will proceed to the next step.\n\n<ANSWER> Off-target activity screening </ANSWER>", "<ANSWER> Lamivudine </ANSWER>\n\nGiven the \"Off-target activity screening\" result shows \"High off-target activity,\" we can rule out Sildenafil. Now we need to determine which of the remaining compounds (Lamivudine, Atenolol, Codeine) matches the observed outcomes. \n\nLet's perform the \"Ames mutagenicity test\" to see if Lamivudine is ruled out based on a positive result.\n\n<ANSWER> Ames mutagenicity test </ANSWER>", "<ANSWER> Lamivudine </ANSWER>\n\nGiven the \"Ames mutagenicity test\" result shows a \"Positive\" result, we can rule out Lamivudine. \n\nNow, we are left with two compounds: Atenolol and Codeine. We need to perform the \"High-throughput screening assay\" to further narrow down the possibilities.\n\n<ANSWER> High-throughput screening assay </ANSWER>", "<ANSWER> Atenolol </ANSWER>\n\nGiven the \"High-throughput screening assay\" result shows \"Active,\" we can rule out Codeine. \n\nThus, the remaining compound is Atenolol. \n\n<ANSWER> Atenolol </ANSWER>"], "consumed_tokens": 8041, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 26.69633158304182}, {"action": "Off-target activity screening", "observation": "High off-target activity"}, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "High-throughput screening assay", "observation": "Active"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Off-target activity screening", "Atenolol", {"predicted_truth": "Atenolol"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nI chose the In vitro enzyme inhibition assay because it provides clear rules for eliminating specific compounds based on the concentration required for inhibition. This assay can quickly narrow down the possibilities and help identify the correct compound.", "<ANSWER> Off-target activity screening </ANSWER>\n\nBased on the observation from the In vitro enzyme inhibition assay (26.69633158304182 nM), which falls between 100-1000 nM, we can rule out Sildenafil. Now, we have the following compounds left: Lamivudine, Atenolol, and Codeine. \n\nNext, I will choose the Off-target activity screening to further narrow down the possibilities. This assay will help us eliminate one of the remaining compounds based on its off-target activity.", "<ANSWER> Atenolol </ANSWER>\n\nGiven the high off-target activity observed in the Off-target activity screening, we can rule out Sildenafil. This leaves us with Lamivudine, Atenolol, and Codeine. \n\nSince Atenolol is known to have low off-target activity, it is the most likely candidate. To confirm, we can perform the Ames mutagenicity test. If the result is negative, it will rule out Lamivudine, leaving us with Atenolol and Codeine. Given that Atenolol is known to have a negative result in this test, we can predict:\n\n<ANSWER> Atenolol </ANSWER>"], "consumed_tokens": 4454, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 26.69633158304182}, {"action": "Off-target activity screening", "observation": "High off-target activity"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Off-target activity screening", "Ames mutagenicity test", "Lamivudine", {"predicted_truth": "Lamivudine"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: Starting with the in vitro enzyme inhibition assay can help us quickly eliminate compounds based on their ability to inhibit specific enzymes. This assay has clear guidelines for ruling out Codeine and Sildenafil, which can provide us with significant information to narrow down the possibilities.", "<ANSWER> Off-target activity screening </ANSWER>\n\nReason: The in vitro enzyme inhibition assay result of 26.69633158304182 nM falls within the range of 100-1000 nM, which does not rule out any compounds. Therefore, we can proceed with another assay. The off-target activity screening can help us rule out Sildenafil if it shows high off-target activity, which is a clear and decisive step in narrowing down the possibilities.", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: Since the off-target activity screening showed high off-target activity for Sildenafil, we can rule it out. Now, we are left with Lamivudine, Atenolol, and Codeine. The next logical step is to perform the Ames mutagenicity test. A positive result would rule out Lamivudine, leaving us with Atenolol and Codeine. If the result is negative, we can rule out Lamivudine and proceed further.", "<ANSWER> Lamivudine </ANSWER>\n\nReason: The Ames mutagenicity test showed a positive result, which rules out Lamivudine. Therefore, the remaining compounds are Atenolol and Codeine. Since we have ruled out Lamivudine, the correct compound must be either Atenolol or Codeine. Given the information and the need to identify the compound, we can conclude that the remaining compound is Atenolol."], "consumed_tokens": 6175, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 26.69633158304182}, {"action": "Off-target activity screening", "observation": "High off-target activity"}, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Ames mutagenicity test", "Lamivudine", {"predicted_truth": "Lamivudine"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nLet's start by performing the In vitro enzyme inhibition assay. This assay will help us rule out Sildenafil and Codeine based on the concentration required for enzyme inhibition. If the enzyme inhibition is observed between 0-100 nM, we can rule out Codeine. If the inhibition is observed between 1000-10000 nM, we can rule out Sildenafil. This will narrow down our list of potential compounds.", "Observation from previous action: {'action': 'In vitro enzyme inhibition assay', 'observation': 26.69633158304182}\n\nThe observation of 26.69633158304182 nM falls within the range of 100-1000 nM, which means we do not rule out any compounds based on this assay result. \n\n<ANSWER> Ames mutagenicity test </ANSWER>", "Observation from previous action: {'action': 'Ames mutagenicity test', 'observation': 'Positive'}\n\nThe positive result from the Ames mutagenicity test indicates that we should rule out Lamivudine.\n\n<ANSWER> Lamivudine </ANSWER>"], "consumed_tokens": 4487, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 26.69633158304182}, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Off-target activity screening", "Ames mutagenicity test", "High-throughput screening assay", "Atenolol", {"predicted_truth": "Atenolol"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay is a good starting point because it can quickly rule out two compounds based on the concentration required for inhibition. This will help narrow down the list of potential compounds more efficiently.", "<ANSWER> Off-target activity screening </ANSWER>\n\nReason: The in vitro enzyme inhibition assay result of 26.69633158304182 nM falls between 100-1000 nM, which does not rule out any compounds. Therefore, we need to choose another assay to rule out some of the remaining compounds. The off-target activity screening is a good choice as it can rule out Sildenafil if it has high off-target activity.", "<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: Since the off-target activity screening ruled out Sildenafil, we now have three potential compounds remaining: Lamivudine, Atenolol, and Codeine. The next step is to perform the Ames mutagenicity test. A positive result will rule out Lamivudine, leaving us with Atenolol and Codeine. \n\n<ANSWER> Ames mutagenicity test </ANSWER>", "<ANSWER> Lamivudine </ANSWER>\n\nReason: The Ames mutagenicity test resulted in a positive outcome, which rules out Lamivudine. This leaves us with Atenolol and Codeine. Since we need to continue ruling out compounds, the next step is to perform another assay. The high-throughput screening assay can help us determine if the remaining compounds are active.\n\n<ANSWER> High-throughput screening assay </ANSWER>", "<ANSWER> Atenolol </ANSWER>\n\nReason: The high-throughput screening assay showed that the compound is active, which rules out Codeine. This leaves us with Atenolol as the only remaining possibility."], "consumed_tokens": 7899, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 26.69633158304182}, {"action": "Off-target activity screening", "observation": "High off-target activity"}, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "High-throughput screening assay", "observation": "Active"}], "successful": true, "parse_error": false}], "seed": 38, "average_actions": 5.0, "average_tokens": 6211.2, "average_correct": 0.6, "average_parse_error": 0.0, "average_successful_action_num": 5.333333333333333, "average_successful_tokens": 6798.0}
{"trajectories": [{"actions": ["In vitro enzyme inhibition assay", "Etoricoxib", {"predicted_truth": "Etoricoxib"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Etoricoxib </ANSWER>\n\nThe observation from the in vitro enzyme inhibition assay is 71.03923423461468, which falls within the range of 100-1000. According to the guidebook, this range does not rule out any compounds. Therefore, we can eliminate Montelukast and Simvastatin based on the other information we have. Since the value is closer to 100 rather than 1000, it suggests a moderate effect, but we still need to perform more trials to narrow it down. Given the current information, Etoricoxib is the most plausible compound, as it is a nonsteroidal anti-inflammatory drug and the observed value is within a range that does not immediately rule it out."], "consumed_tokens": 2670, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 71.03923423461468}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "hERG channel inhibition assay", "Lipophilicity measurement (LogP)", "Etoricoxib", {"predicted_truth": "Etoricoxib"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nBy selecting the In vitro enzyme inhibition assay, we can gather information that will help us rule out Montelukast or Simvastatin based on the given thresholds. This will bring us closer to identifying the correct compound.", "Since the observation from the In vitro enzyme inhibition assay is 71.03923423461468, which falls within the range of 100-1000, we can rule out Montelukast.\n\n<ANSWER> Montelukast </ANSWER>\n\nNow, we have the following compounds left: ['Etoricoxib', 'Simvastatin', 'Cisapride']. The next step is to choose another trial to further narrow down the possibilities. Let's select the hERG channel inhibition assay.\n\n<ANSWER> hERG channel inhibition assay </ANSWER>", "Since the observation from the hERG channel inhibition assay is 9.588964865706114, which falls within the range of 10-50, we can rule out Simvastatin.\n\n<ANSWER> Simvastatin </ANSWER>\n\nNow, we have the following compounds left: ['Etoricoxib', 'Cisapride']. The next step is to choose another trial to further narrow down the possibilities. Let's select the Lipophilicity measurement (LogP) assay.\n\n<ANSWER> Lipophilicity measurement (LogP) </ANSWER>", "Since the observation from the Lipophilicity measurement (LogP) assay is -4.8644577229766295, which falls within the range of -5 to 0, we can rule out Simvastatin (which we already knew from previous steps) and further narrow down our options to Cisapride and Etoricoxib. However, Cisapride falls within this range, so it can be ruled out.\n\n<ANSWER> Etoricoxib </ANSWER>"], "consumed_tokens": 6156, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 71.03923423461468}, {"action": "hERG channel inhibition assay", "observation": 9.588964865706114}, {"action": "Lipophilicity measurement (LogP)", "observation": -4.8644577229766295}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "hERG channel inhibition assay", "Lipophilicity measurement (LogP)", "Simvastatin", {"predicted_truth": "Simvastatin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay can help rule out Montelukast, which we can do if the outcome is in the range of 0-100. This will allow us to eliminate one of the compounds quickly and narrow down the possibilities.", "The observation from the In vitro enzyme inhibition assay is 71.03923423461468, which falls within the range of 100-1000. According to the guidebook, this range does not rule out any of the compounds. Therefore, we need to perform another assay to further narrow down the possibilities.\n\n<ANSWER> hERG channel inhibition assay </ANSWER>", "The observation from the hERG channel inhibition assay is 9.588964865706114, which falls within the range of 10-50. According to the guidebook, this range does not rule out any of the compounds. Therefore, we need to perform another assay to further narrow down the possibilities.\n\n<ANSWER> Lipophilicity measurement (LogP) </ANSWER>", "The observation from the Lipophilicity measurement (LogP) is -4.8644577229766295, which falls within the range of -5 to 0. According to the guidebook, this range rules out Simvastatin.\n\n<ANSWER> Simvastatin </ANSWER>"], "consumed_tokens": 5933, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 71.03923423461468}, {"action": "hERG channel inhibition assay", "observation": 9.588964865706114}, {"action": "Lipophilicity measurement (LogP)", "observation": -4.8644577229766295}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "hERG channel inhibition assay", "Lipophilicity measurement (LogP)", "Simvastatin", {"predicted_truth": "Simvastatin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay can help us rule out Montelukast, which is known to block leukotrienes. This assay will provide a specific numerical outcome that can help us make a decision based on the given thresholds.", "The observation from the in vitro enzyme inhibition assay is 71.03923423461468, which falls within the range of 100-1000. According to the guidebook, this range does not rule out any of the compounds.\n\n<ANSWER> hERG channel inhibition assay </ANSWER>", "The observation from the hERG channel inhibition assay is 9.588964865706114, which falls within the range of 10-50. According to the guidebook, this range does not rule out any of the compounds.\n\n<ANSWER> Lipophilicity measurement (LogP) </ANSWER>", "The observation from the lipophilicity measurement (LogP) is -4.8644577229766295, which falls within the range of -5 to 0. According to the guidebook, this range rules out Simvastatin.\n\n<ANSWER> Simvastatin </ANSWER>"], "consumed_tokens": 5842, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 71.03923423461468}, {"action": "hERG channel inhibition assay", "observation": 9.588964865706114}, {"action": "Lipophilicity measurement (LogP)", "observation": -4.8644577229766295}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "hERG channel inhibition assay", "Lipophilicity measurement (LogP)", "In vitro enzyme inhibition assay", "hERG channel inhibition assay", "QT prolongation assessment", "Bioavailability study", "Montelukast", {"predicted_truth": "Montelukast"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Montelukast </ANSWER>\n\nThe observation from the in vitro enzyme inhibition assay is 71.03923423461468, which falls in the range of 100-1000. According to the guidebook, this range does not rule out any compounds. Therefore, Montelukast is the most likely candidate among the remaining compounds. However, since we need to systematically rule out other compounds, we should choose another trial to gather more information.\n\n<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> hERG channel inhibition assay </ANSWER>\n\nThe observation from the hERG channel inhibition assay is 9.588964865706114, which falls in the range of 10-50. According to the guidebook, this range does not rule out any compounds. Therefore, we need to choose another trial to gather more information.\n\n<ANSWER> Lipophilicity measurement (LogP) </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nThe observation from the Lipophilicity measurement (LogP) is -4.8644577229766295, which falls in the range of -5 to 0. According to the guidebook, this range rules out Simvastatin. Therefore, Simvastatin can be ruled out as a potential compound. \n\nNext, we should choose another trial to further narrow down the possibilities. \n\n<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "The observation from the in vitro enzyme inhibition assay is 71.03923423461468, which falls in the range of 100-1000. According to the guidebook, this range does not rule out any compounds. Therefore, we need to choose another trial to gather more information.\n\n<ANSWER> hERG channel inhibition assay </ANSWER>", "The observation from the hERG channel inhibition assay is 9.588964865706114, which falls in the range of 10-50. According to the guidebook, this range does not rule out any compounds. Therefore, we need to choose another trial to gather more information.\n\n<ANSWER> QT prolongation assessment </ANSWER>", "<ANSWER> Bioavailability study </ANSWER>\n\nThe observation from the QT prolongation assessment is \"No effect on QT\", which does not rule out any compounds. Therefore, we need to choose another trial to gather more information. The bioavailability study will help us determine the extent and rate at which the active ingredient is absorbed and becomes available at the site of action.\n\n<ANSWER> Bioavailability study </ANSWER>", "The observation from the bioavailability study is 93.49589241784409, which falls in the range of 80-100. According to the guidebook, this range rules out Simvastatin. Therefore, Simvastatin can be ruled out as a potential compound.\n\nGiven the remaining compounds are Montelukast, Etoricoxib, and Cisapride, and we have ruled out Simvastatin, we can now make an educated guess based on the remaining options.\n\n<ANSWER> Montelukast </ANSWER>"], "consumed_tokens": 14103, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 71.03923423461468}, {"action": "hERG channel inhibition assay", "observation": 9.588964865706114}, {"action": "Lipophilicity measurement (LogP)", "observation": -4.8644577229766295}, {"action": "In vitro enzyme inhibition assay", "observation": 71.03923423461468}, {"action": "hERG channel inhibition assay", "observation": 9.588964865706114}, {"action": "QT prolongation assessment", "observation": "No effect on QT"}, {"action": "Bioavailability study", "observation": 93.49589241784409}], "successful": false, "parse_error": false}], "seed": 39, "average_actions": 5.4, "average_tokens": 6940.8, "average_correct": 0.4, "average_parse_error": 0.0, "average_successful_action_num": 4.0, "average_successful_tokens": 4413.0}
{"trajectories": [{"actions": ["Drug-drug interaction studies", "hERG channel inhibition assay", "Terfenadine", {"predicted_truth": "Terfenadine"}], "generated_text": ["<ANSWER> Drug-drug interaction studies </ANSWER>\n\nReason: Since Amiodarone is known for its complex interaction profile with other medications, performing a drug-drug interaction study would help rule it out if there are no significant interactions observed. This action is also informative as it can eliminate Amiodarone from further consideration if the outcome is negative.", "<ANSWER> hERG channel inhibition assay </ANSWER>\n\nReason: Since the drug-drug interaction study ruled out Amiodarone due to a significant interaction, the next step is to use the hERG channel inhibition assay. Terfenadine is known to inhibit the hERG channel, so if this assay shows significant inhibition, it will help rule out other compounds.", "Observation from the hERG channel inhibition assay is 8.188743593441846, which is a significant inhibition level. Since Terfenadine is known to significantly inhibit the hERG channel, this result helps rule it out as the compound.\n\n<ANSWER> Terfenadine </ANSWER>"], "consumed_tokens": 3949, "observations": [null, {"action": "Drug-drug interaction studies", "observation": "Significant interaction"}, {"action": "hERG channel inhibition assay", "observation": 8.188743593441846}], "successful": false, "parse_error": false}, {"actions": ["Drug-drug interaction studies", "Terfenadine", {"predicted_truth": "Terfenadine"}], "generated_text": ["<ANSWER> Drug-drug interaction studies </ANSWER>\n\nReason: Since Amiodarone is known for its complex interaction profile with other medications, performing a drug-drug interaction study will help rule out this compound if there is a significant interaction observed. This action will also help maintain the list of potential compounds by eliminating Amiodarone if the outcome is positive for a significant interaction.", "<ANSWER> Terfenadine </ANSWER>\n\nReason: Since the drug-drug interaction study indicated a significant interaction, we can rule out Amiodarone. Now, we need to further investigate the remaining compounds. Terfenadine is known to cause cardiac issues due to its interaction with cardiac ion channels. Therefore, performing the hERG channel inhibition assay will help us rule out Terfenadine if it inhibits the hERG channel significantly."], "consumed_tokens": 2539, "observations": [null, {"action": "Drug-drug interaction studies", "observation": "Significant interaction"}], "successful": false, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "Drug-drug interaction studies", "Clinical biomarker identification", "hERG channel inhibition assay", "Drug-drug interaction studies", "hERG channel inhibition assay", "QT prolongation assessment", "Oxidative stress assay", "Drug-drug interaction studies", "Trastuzumab", {"predicted_truth": "Trastuzumab"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> Drug-drug interaction studies </ANSWER>", "<ANSWER> Clinical biomarker identification </ANSWER>", "<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> Drug-drug interaction studies </ANSWER>", "<ANSWER> hERG channel inhibition assay </ANSWER>", "The observation from the hERG channel inhibition assay indicates an inhibition level of 8.188743593441846%, which is significant. Given that the inhibition level is not at 0-10%, we can rule out Terfenadine. Now, we need to focus on the remaining compounds: Trastuzumab, Cisplatin, and Amiodarone.\n\nLet's perform the QT prolongation assessment to further narrow down the possibilities.\n\n<ANSWER> QT prolongation assessment </ANSWER>", "The observation from the QT prolongation assessment indicates no effect on the QT interval. This rules out Terfenadine, as it is known to cause QT interval prolongation.\n\nNow, we are left with the compounds: Trastuzumab, Cisplatin, and Amiodarone.\n\nNext, let's perform the oxidative stress assay to further narrow down the possibilities.\n\n<ANSWER> Oxidative stress assay </ANSWER>", "The observation from the oxidative stress assay indicates that the compound does not induce ROS. This rules out Cisplatin, as it is known to significantly induce oxidative stress.\n\nNow, we are left with the compounds: Trastuzumab and Amiodarone.\n\nNext, let's perform the drug-drug interaction studies to further narrow down the possibilities.\n\n<ANSWER> Drug-drug interaction studies </ANSWER>", "The observation from the drug-drug interaction studies indicates a significant interaction. Given that Amiodarone is known to have significant drug interaction issues, we can rule out Amiodarone.\n\nThis leaves us with the only remaining compound: Trastuzumab.\n\n<ANSWER> Trastuzumab </ANSWER>"], "consumed_tokens": 14664, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 8.188743593441846}, {"action": "Drug-drug interaction studies", "observation": "Significant interaction"}, {"action": "Clinical biomarker identification", "observation": "No biomarker identified"}, {"action": "hERG channel inhibition assay", "observation": 8.188743593441846}, {"action": "Drug-drug interaction studies", "observation": "Significant interaction"}, {"action": "hERG channel inhibition assay", "observation": 8.188743593441846}, {"action": "QT prolongation assessment", "observation": "No effect on QT"}, {"action": "Oxidative stress assay", "observation": "Does not induce ROS"}, {"action": "Drug-drug interaction studies", "observation": "Significant interaction"}], "successful": false, "parse_error": false}, {"actions": ["Drug-drug interaction studies", "Drug-drug interaction studies", "hERG channel inhibition assay", "Terfenadine", {"predicted_truth": "Terfenadine"}], "generated_text": ["<ANSWER> Drug-drug interaction studies </ANSWER>", "<ANSWER> Drug-drug interaction studies </ANSWER>\n\nBased on the observation that there was a significant interaction, we can rule out Amiodarone. Now, we need to further investigate between the remaining compounds: Trastuzumab, Terfenadine, and Cisplatin. The next logical step is to perform another drug interaction study, as it is a distinctive assay that can provide more insights into the interactions among these compounds. However, since we need to eliminate one more compound, let's choose an assay that can differentiate between Trastuzumab and the other two, such as the hERG channel inhibition assay, as Terfenadine is known to significantly inhibit the hERG channel.", "<ANSWER> hERG channel inhibition assay </ANSWER>\n\nSince we have ruled out Amiodarone due to the significant interaction observed in the previous trial, we can now differentiate between Trastuzumab and Terfenadine. The hERG channel inhibition assay is particularly useful here because Terfenadine is known to significantly inhibit the hERG channel, while Trastuzumab is not expected to have such an effect.", "<ANSWER> Terfenadine </ANSWER>\n\nThe hERG channel inhibition assay observed an inhibition level of 8.188743593441846%, which rules out Trastuzumab (as it does not inhibit the hERG channel). Given that Terfenadine is known to significantly inhibit the hERG channel and the observed level is non-zero, Terfenadine is the most plausible compound."], "consumed_tokens": 5504, "observations": [null, {"action": "Drug-drug interaction studies", "observation": "Significant interaction"}, {"action": "Drug-drug interaction studies", "observation": "Significant interaction"}, {"action": "hERG channel inhibition assay", "observation": 8.188743593441846}], "successful": false, "parse_error": false}, {"actions": ["hERG channel inhibition assay", "Drug-drug interaction studies", "Clinical biomarker identification", "hERG channel inhibition assay", "hERG channel inhibition assay", "Terfenadine", {"predicted_truth": "Terfenadine"}], "generated_text": ["<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> Drug-drug interaction studies </ANSWER>", "<ANSWER> Clinical biomarker identification </ANSWER>", "<ANSWER> hERG channel inhibition assay </ANSWER>\n\nSince no biomarker was identified, we have ruled out Trastuzumab. Now, we need to determine if the compound is Terfenadine, Cisplatin, or Amiodarone. The hERG channel inhibition assay can help us eliminate one of these. Terfenadine is known to significantly inhibit the hERG channel, while Cisplatin and Amiodarone do not have notable effects on the hERG channel. Given the previous result of 8.188743593441846 for the hERG channel inhibition assay, this suggests a moderate inhibitory effect, which is consistent with Terfenadine. However, let's confirm this by checking the hERG channel inhibition assay again to ensure Terfenadine is the correct compound.", "<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> Terfenadine </ANSWER>\n\nThe observation from the hERG channel inhibition assay shows a moderate inhibitory effect, which is consistent with Terfenadine. Given the previous eliminations and the current assay results, Terfenadine is the most plausible compound."], "consumed_tokens": 8233, "observations": [null, {"action": "hERG channel inhibition assay", "observation": 8.188743593441846}, {"action": "Drug-drug interaction studies", "observation": "Significant interaction"}, {"action": "Clinical biomarker identification", "observation": "No biomarker identified"}, {"action": "hERG channel inhibition assay", "observation": 8.188743593441846}, {"action": "hERG channel inhibition assay", "observation": 8.188743593441846}], "successful": false, "parse_error": false}], "seed": 40, "average_actions": 6.0, "average_tokens": 6977.8, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["In vitro enzyme inhibition assay", "Genotoxicity assay", "Estradiol", {"predicted_truth": "Estradiol"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Genotoxicity assay </ANSWER>", "<ANSWER> Estradiol </ANSWER>\n\nBased on the genotoxicity assay result, Estradiol is ruled out since the outcome is genotoxic. This leaves us with the compounds Losartan, Prednisone, and Insulin."], "consumed_tokens": 3622, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 8030.886107993402}, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "Genotoxicity assay", "Carcinogenicity study", "Prednisone", {"predicted_truth": "Prednisone"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nThe observed value of 8030.886107993402 falls within the range of 1000 to 10000, which indicates that Losartan can be ruled out. Therefore, we can eliminate Losartan from our list of possible compounds.", "<ANSWER> Genotoxicity assay </ANSWER>\n\nSince we have ruled out Losartan, we can now perform a genotoxicity assay to further narrow down the possibilities. If the compound is genotoxic, Estradiol can be ruled out. If it is non-genotoxic, we will have to consider the remaining compounds (Prednisone and Insulin) with further assays.", "<ANSWER> Carcinogenicity study </ANSWER>\n\nThe genotoxicity assay indicated that the compound is genotoxic. Since Estradiol is known to be genotoxic, we can rule it out. This leaves us with Prednisone and Insulin. The next step is to perform a carcinogenicity study to further narrow down the possibilities. If the compound is carcinogenic, Prednisone can be ruled out, leaving Insulin as the remaining possibility. If it is non-carcinogenic, we will need to perform a bioavailability study to confirm if it is Insulin.", "<ANSWER> Prednisone </ANSWER>\n\nThe carcinogenicity study indicated that the compound is carcinogenic. Since Prednisone is known to have carcinogenic properties, we can rule it out. This leaves us with Insulin as the remaining possibility. Therefore, we can predict that the compound is Insulin."], "consumed_tokens": 6997, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 8030.886107993402}, {"action": "In vitro enzyme inhibition assay", "observation": 8030.886107993402}, {"action": "Genotoxicity assay", "observation": "Genotoxic"}, {"action": "Carcinogenicity study", "observation": "Carcinogenic"}], "successful": false, "parse_error": false}, {"actions": ["Genotoxicity assay", "Estradiol", {"predicted_truth": "Estradiol"}], "generated_text": ["<ANSWER> Genotoxicity assay </ANSWER>\n\nReason: Starting with the genotoxicity assay can help us quickly eliminate compounds that are genotoxic, as this property is a significant concern for drug safety. If Estradiol is ruled out, we can narrow down the possibilities more efficiently.", "<ANSWER> Estradiol </ANSWER>\n\nReason: The genotoxicity assay indicated that the compound is genotoxic. Since Estradiol is known to have genotoxic properties, it can be ruled out based on the observed outcome. This leaves us with Losartan, Prednisone, and Insulin as potential candidates."], "consumed_tokens": 2472, "observations": [null, {"action": "Genotoxicity assay", "observation": "Genotoxic"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "Genotoxicity assay", "Carcinogenicity study", "Insulin", {"predicted_truth": "Insulin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nThe observation from the in vitro enzyme inhibition assay is 8030.886107993402, which falls within the range of 1000 and 10000. According to the guidebook, for values in this range, Losartan is ruled out. Therefore, we can eliminate Losartan from our list of possible compounds. The remaining compounds are Estradiol, Prednisone, and Insulin.", "<ANSWER> Genotoxicity assay </ANSWER>\n\nSince Losartan has been ruled out, we can now proceed with a genotoxicity assay to further narrow down the possibilities. If the compound is genotoxic, Estradiol would be ruled out. If it is non-genotoxic, we will still have Prednisone and Insulin to consider, but we will have eliminated one of the two.", "<ANSWER> Carcinogenicity study </ANSWER>\n\nThe genotoxicity assay has shown that the compound is genotoxic, which rules out Estradiol. Now we need to determine whether Prednisone or Insulin is the correct compound. The next step is to perform a carcinogenicity study. If the study indicates carcinogenic properties, Prednisone will be ruled out, leaving Insulin as the remaining compound. If it is non-carcinogenic, we will still have to consider Insulin, but we will have eliminated Prednisone.", "<ANSWER> Insulin </ANSWER>\n\nThe carcinogenicity study has shown that the compound is carcinogenic, which rules out Prednisone. Since both Estradiol and Insulin are left, and Prednisone has been eliminated, the remaining compound must be Insulin."], "consumed_tokens": 7116, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 8030.886107993402}, {"action": "In vitro enzyme inhibition assay", "observation": 8030.886107993402}, {"action": "Genotoxicity assay", "observation": "Genotoxic"}, {"action": "Carcinogenicity study", "observation": "Carcinogenic"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "Genotoxicity assay", "Carcinogenicity study", "Animal behavioral study", "Insulin", {"predicted_truth": "Insulin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Genotoxicity assay </ANSWER>\n\nGiven the enzyme inhibition value of 8030.886107993402, which falls in the range of 1000 and 10000, Losartan can be ruled out based on the guidebook. The next logical step is to perform a genotoxicity assay to further narrow down the possibilities.", "<ANSWER> Carcinogenicity study </ANSWER>\n\nThe genotoxicity assay result indicates that the compound is genotoxic, which rules out Estradiol. The next step is to perform a carcinogenicity study to further narrow down the possibilities between Losartan, Prednisone, and Insulin.", "<ANSWER> Animal behavioral study </ANSWER>\n\nThe carcinogenicity study result indicates that the compound is carcinogenic, which rules out Prednisone. The remaining compounds are Losartan and Insulin. The next step is to perform an animal behavioral study to further narrow down the possibilities.", "<ANSWER> Insulin </ANSWER>\n\nThe animal behavioral study observed no behavioral changes, which rules out Losartan. Given that Losartan is ruled out, the only remaining compound is Insulin. Therefore, we can confidently predict that the compound is Insulin."], "consumed_tokens": 8259, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 8030.886107993402}, {"action": "In vitro enzyme inhibition assay", "observation": 8030.886107993402}, {"action": "Genotoxicity assay", "observation": "Genotoxic"}, {"action": "Carcinogenicity study", "observation": "Carcinogenic"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}], "successful": true, "parse_error": false}], "seed": 41, "average_actions": 5.2, "average_tokens": 5693.2, "average_correct": 0.4, "average_parse_error": 0.0, "average_successful_action_num": 6.5, "average_successful_tokens": 7687.5}
{"trajectories": [{"actions": ["Skin sensitization test", "Neomycin sulfate", {"predicted_truth": "Neomycin sulfate"}], "generated_text": ["<ANSWER> Skin sensitization test </ANSWER>\n\nReason: The Skin Sensitization Test is a critical assay to eliminate Neomycin Sulfate, as it is known to be a skin sensitizer. By performing this test, we can confirm whether Neomycin Sulfate is a potential candidate or rule it out based on the observed outcome. This step will help narrow down the list of possible compounds.", "<ANSWER> Neomycin sulfate </ANSWER>\n\nReason: Since the Skin Sensitization Test revealed that the compound is a sensitizer, we can confidently rule out Neomycin Sulfate from the list of possible compounds. This leaves us with the remaining compounds: Cisapride, Penicillin, and Amiodarone."], "consumed_tokens": 2590, "observations": [null, {"action": "Skin sensitization test", "observation": "Sensitizer"}], "successful": false, "parse_error": false}, {"actions": ["Skin sensitization test", "Neomycin sulfate", {"predicted_truth": "Neomycin sulfate"}], "generated_text": ["<ANSWER> Skin sensitization test </ANSWER>", "<ANSWER> Neomycin sulfate </ANSWER>"], "consumed_tokens": 2385, "observations": [null, {"action": "Skin sensitization test", "observation": "Sensitizer"}], "successful": false, "parse_error": false}, {"actions": ["Skin sensitization test", "Neomycin sulfate", {"predicted_truth": "Neomycin sulfate"}], "generated_text": ["<ANSWER> Skin sensitization test </ANSWER>", "<ANSWER> Neomycin sulfate </ANSWER>\n\nBased on the observation that the Skin sensitization test is a sensitizer, we can rule out Neomycin sulfate from the list of possible compounds since it is known to be a skin sensitizer. This leaves us with the compounds Cisapride, Penicillin, and Amiodarone."], "consumed_tokens": 2446, "observations": [null, {"action": "Skin sensitization test", "observation": "Sensitizer"}], "successful": false, "parse_error": false}, {"actions": ["Immunogenicity testing", "Skin sensitization test", "hERG channel inhibition assay", "Amiodarone", {"predicted_truth": "Amiodarone"}], "generated_text": ["<ANSWER> Immunogenicity testing </ANSWER>\n\nReason: Since Penicillin is known to be non-immunogenic, performing an immunogenicity test will help us rule out Penicillin quickly. If the test shows a non-immunogenic response, we can confidently eliminate Penicillin from our list of possible compounds.", "<ANSWER> Neomycin sulfate </ANSWER>\n\nReason: Since the immunogenicity test showed a non-immunogenic response, we can rule out Penicillin. This leaves us with 'Neomycin sulfate', 'Cisapride', and 'Amiodarone'. Next, we should perform a skin sensitization test to further narrow down the options. If the test shows skin sensitization, we can rule out Neomycin sulfate. If not, we will need to perform additional tests to distinguish between Cisapride and Amiodarone.\n\n<ANSWER> Skin sensitization test </ANSWER>", "<ANSWER> Neomycin sulfate </ANSWER>\n\nReason: Since the skin sensitization test showed that the compound is a sensitizer, we can rule out Neomycin sulfate. This leaves us with 'Cisapride' and 'Amiodarone'. Next, we should perform an hERG channel inhibition assay to further narrow down the options. If the assay shows inhibition, we can rule out Amiodarone. If not, Cisapride is the remaining plausible compound.\n\n<ANSWER> hERG channel inhibition assay </ANSWER>", "<ANSWER> Amiodarone </ANSWER>\n\nReason: The hERG channel inhibition assay showed an inhibition level of 13.747809594463698, which falls outside the range that would rule out Amiodarone (0% to 10%). Since Cisapride is known to have hERG channel inhibition in the range of 0% to 10%, and the observed inhibition level is higher, Cisapride can be ruled out. This leaves us with Amiodarone as the remaining plausible compound."], "consumed_tokens": 5869, "observations": [null, {"action": "Immunogenicity testing", "observation": "Non-immunogenic"}, {"action": "Skin sensitization test", "observation": "Sensitizer"}, {"action": "hERG channel inhibition assay", "observation": 13.747809594463698}], "successful": false, "parse_error": false}, {"actions": ["Skin sensitization test", "Neomycin sulfate", {"predicted_truth": "Neomycin sulfate"}], "generated_text": ["<ANSWER> Skin sensitization test </ANSWER>\n\nReason: Since Neomycin Sulfate is known to be a skin sensitizer, performing a skin sensitization test would help us quickly eliminate it from the list of possible compounds if a positive result is observed. This will provide a clear step in ruling out one of the options.", "<ANSWER> Neomycin sulfate </ANSWER>\n\nReason: Since the skin sensitization test resulted in a sensitizer, we can confidently rule out Neomycin sulfate. This leaves us with the following compounds: ['Cisapride', 'Penicillin', 'Amiodarone']."], "consumed_tokens": 2548, "observations": [null, {"action": "Skin sensitization test", "observation": "Sensitizer"}], "successful": false, "parse_error": false}], "seed": 42, "average_actions": 3.4, "average_tokens": 3167.6, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["Blood-brain barrier permeability test", "Oxidative stress assay", "Glutathione depletion assay", "Animal behavioral study", "Animal toxicity test", "Micronucleus test", "Sertraline", {"predicted_truth": "Sertraline"}], "generated_text": ["<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Oxidative stress assay </ANSWER>", "<ANSWER> Glutathione depletion assay </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>", "<ANSWER> Animal toxicity test </ANSWER>", "<ANSWER> Micronucleus test </ANSWER>", "<ANSWER> Sertraline </ANSWER>\n\nGiven the observations:\n- The compound does not penetrate the blood-brain barrier, ruling out Zolpidem.\n- The compound induces oxidative stress, ruling out Cisplatin.\n- The compound does not deplete glutathione, ruling out Paracetamol.\n- The compound has moderate toxicity, which does not further rule out Sertraline.\n- The micronucleus test was negative, and since none of the other compounds match all the observations, Sertraline remains the only plausible compound."], "consumed_tokens": 9298, "observations": [null, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "Oxidative stress assay", "observation": "Induces ROS"}, {"action": "Glutathione depletion assay", "observation": "Does not deplete glutathione"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "Animal toxicity test", "observation": "Moderate toxicity"}, {"action": "Micronucleus test", "observation": "Negative"}], "successful": false, "parse_error": false}, {"actions": ["Oxidative stress assay", "Sertraline", {"predicted_truth": "Sertraline"}], "generated_text": ["<ANSWER> Oxidative stress assay </ANSWER>\n\nReason: Since Cisplatin is already ruled out by the fact that it does not penetrate the blood-brain barrier, we can rule out another compound by performing an Oxidative stress assay. If the compound induces ROS, then Cisplatin can be further confirmed as ruled out, and if it does not induce ROS, we can rule out Paracetamol. This assay provides a clear and decisive step in narrowing down the possibilities.", "<ANSWER> Sertraline </ANSWER>\n\nReason: Since the Oxidative stress assay indicates that the compound induces ROS, Cisplatin is further confirmed as ruled out. This leaves us with Sertraline, Paracetamol, and Zolpidem. Zolpidem does not induce ROS, so it can be ruled out. Between Paracetamol and Sertraline, Sertraline is the likely candidate as it fits the observed outcomes."], "consumed_tokens": 2648, "observations": [null, {"action": "Oxidative stress assay", "observation": "Induces ROS"}], "successful": false, "parse_error": false}, {"actions": ["Blood-brain barrier permeability test", "Oxidative stress assay", "Cisplatin", {"predicted_truth": "Cisplatin"}], "generated_text": ["<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Oxidative stress assay </ANSWER>", "<ANSWER> Cisplatin </ANSWER>"], "consumed_tokens": 3653, "observations": [null, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "Oxidative stress assay", "observation": "Induces ROS"}], "successful": false, "parse_error": false}, {"actions": ["Blood-brain barrier permeability test", "Oxidative stress assay", "Animal behavioral study", "Glutathione depletion assay", "Animal toxicity test", "Micronucleus test", "Sertraline", {"predicted_truth": "Sertraline"}], "generated_text": ["<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Oxidative stress assay </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>", "<ANSWER> Glutathione depletion assay </ANSWER>", "<ANSWER> Animal toxicity test </ANSWER>", "<ANSWER> Micronucleus test </ANSWER>", "<ANSWER> Sertraline </ANSWER>\n\nBased on the observations from the clinical trials and bioassays, we have ruled out:\n- Zolpidem (does not penetrate the BBB)\n- Cisplatin (induces ROS)\n- Paracetamol (does not penetrate the BBB, does not induce ROS, does not deplete glutathione, shows moderate toxicity, and is negative in the micronucleus test)\n\nThe only compound left that fits all the observed outcomes is Sertraline. Therefore, Sertraline is the correct pharmaceutical compound."], "consumed_tokens": 9291, "observations": [null, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "Oxidative stress assay", "observation": "Induces ROS"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "Glutathione depletion assay", "observation": "Does not deplete glutathione"}, {"action": "Animal toxicity test", "observation": "Moderate toxicity"}, {"action": "Micronucleus test", "observation": "Negative"}], "successful": false, "parse_error": false}, {"actions": ["Blood-brain barrier permeability test", "Oxidative stress assay", "Oxidative stress assay", "Animal behavioral study", "Glutathione depletion assay", "Animal toxicity test", "Micronucleus test", "Cisplatin", {"predicted_truth": "Cisplatin"}], "generated_text": ["<ANSWER> Blood-brain barrier permeability test </ANSWER>", "<ANSWER> Oxidative stress assay </ANSWER>", "<ANSWER> Oxidative stress assay </ANSWER>", "<ANSWER> Animal behavioral study </ANSWER>", "<ANSWER> Glutathione depletion assay </ANSWER>", "<ANSWER> Animal toxicity test </ANSWER>", "<ANSWER> Micronucleus test </ANSWER>", "<ANSWER> Cisplatin </ANSWER>"], "consumed_tokens": 10692, "observations": [null, {"action": "Blood-brain barrier permeability test", "observation": "Does not penetrate BBB"}, {"action": "Oxidative stress assay", "observation": "Induces ROS"}, {"action": "Oxidative stress assay", "observation": "Induces ROS"}, {"action": "Animal behavioral study", "observation": "No behavioral changes"}, {"action": "Glutathione depletion assay", "observation": "Does not deplete glutathione"}, {"action": "Animal toxicity test", "observation": "Moderate toxicity"}, {"action": "Micronucleus test", "observation": "Negative"}], "successful": false, "parse_error": false}], "seed": 43, "average_actions": 6.4, "average_tokens": 7116.4, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["CYP450 metabolism assay", "Saline solution", {"predicted_truth": "Saline solution"}], "generated_text": ["<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> Saline solution </ANSWER>\n\nGiven the outcome of the CYP450 metabolism assay showing \"No inhibition,\" we can eliminate Erythromycin. Now, we need to choose another assay to further narrow down the possibilities. Since Saline solution and Formaldehyde are non-inhibitors, we can test them in other assays. However, based on the current information, Saline solution is a neutral compound with no specific inhibitory effect, making it a strong candidate. We will now select the Skin sensitization test to further rule out the remaining compounds."], "consumed_tokens": 2547, "observations": [null, {"action": "CYP450 metabolism assay", "observation": "No inhibition"}], "successful": true, "parse_error": false}, {"actions": ["Skin sensitization test", "Erythromycin", {"predicted_truth": "Erythromycin"}], "generated_text": ["<ANSWER> Skin sensitization test </ANSWER>", "<ANSWER> Erythromycin </ANSWER>\n\nGiven the observation that Formaldehyde is a sensitizer, we can rule out Formaldehyde from our list of possible compounds. This leaves us with Erythromycin, Saline solution, and Neomycin sulfate. Since the skin sensitization test ruled out Formaldehyde, we can now focus on the remaining compounds. Next, we can perform the CYP450 metabolism assay to further narrow down the possibilities. However, based on the provided information and the process of elimination, Erythromycin stands out as the most likely candidate since it is the only antibiotic in the list and does not fit the criteria for formaldehyde (sensitizer and irritant)."], "consumed_tokens": 2569, "observations": [null, {"action": "Skin sensitization test", "observation": "Sensitizer"}], "successful": false, "parse_error": false}, {"actions": ["Skin sensitization test", "CYP450 metabolism assay", "Eye irritation test", "Saline solution", {"predicted_truth": "Saline solution"}], "generated_text": ["<ANSWER> Skin sensitization test </ANSWER>\n\nReason: Since Neomycin sulfate is known to cause skin sensitization, we can use the skin sensitization test to rule it out. This test will help us eliminate one of the compounds from the list, bringing us closer to identifying the correct pharmaceutical compound.", "<ANSWER> CYP450 metabolism assay </ANSWER>\n\nReason: Since the skin sensitization test has ruled out Neomycin sulfate, we can now use the CYP450 metabolism assay to further narrow down the possibilities. Erythromycin is known to not inhibit CYP450 enzymes, so if the assay shows no inhibition, it will help us confirm that Erythromycin is the likely candidate.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: Since the CYP450 metabolism assay has ruled out Erythromycin, we are left with Saline solution and Formaldehyde. Formaldehyde is known to be an irritant to the eyes, so the eye irritation test will help us rule it out. If the test shows that the compound is not an irritant, then it must be Saline solution.", "<ANSWER> Saline solution </ANSWER>\n\nReason: The eye irritation test ruled out Formaldehyde as it is an irritant. This leaves us with Saline solution as the only remaining option. Since the CYP450 metabolism assay and skin sensitization test have already ruled out Erythromycin and Neomycin sulfate respectively, and Formaldehyde has been ruled out by the eye irritation test, Saline solution is the correct pharmaceutical compound."], "consumed_tokens": 5731, "observations": [null, {"action": "Skin sensitization test", "observation": "Sensitizer"}, {"action": "CYP450 metabolism assay", "observation": "No inhibition"}, {"action": "Eye irritation test", "observation": "Irritant"}], "successful": true, "parse_error": false}, {"actions": ["Skin sensitization test", "CYP450 metabolism assay", "Eye irritation test", "Formaldehyde", {"predicted_truth": "Formaldehyde"}], "generated_text": ["<ANSWER> Skin sensitization test </ANSWER>\n\nReason: Since Neomycin sulfate is known to cause skin sensitization, performing a skin sensitization test will help us rule it out. This is a direct way to eliminate one of the compounds from the list based on the given information.", "<ANSWER> CYP450 metabolism assay </ANSWER>\n\nReason: Since the skin sensitization test has ruled out Neomycin sulfate, we can now focus on the remaining compounds: Erythromycin, Saline solution, and Formaldehyde. The CYP450 metabolism assay will help us rule out Erythromycin because it does not inhibit the CYP450 enzymes. This will leave us with either Saline solution or Formaldehyde, which we can further investigate with subsequent tests.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: Since the CYP450 metabolism assay has ruled out Erythromycin, we are left with Saline solution, Formaldehyde, and Neomycin sulfate. However, Neomycin sulfate has already been ruled out by the skin sensitization test. The next logical step is to perform an eye irritation test on Saline solution and Formaldehyde. Saline solution is known to be non-irritating to the eyes, so if Formaldehyde is irritating, it will be the remaining compound.", "<ANSWER> Formaldehyde </ANSWER>\n\nReason: The eye irritation test has confirmed that Formaldehyde is an irritant, while Saline solution is known to be non-irritating. Since Saline solution has been ruled out by the skin sensitization test and Formaldehyde has been confirmed as irritant by the eye irritation test, Formaldehyde is the remaining compound."], "consumed_tokens": 5800, "observations": [null, {"action": "Skin sensitization test", "observation": "Sensitizer"}, {"action": "CYP450 metabolism assay", "observation": "No inhibition"}, {"action": "Eye irritation test", "observation": "Irritant"}], "successful": false, "parse_error": false}, {"actions": ["Skin sensitization test", "CYP450 metabolism assay", "Eye irritation test", "Saline solution", {"predicted_truth": "Saline solution"}], "generated_text": ["<ANSWER> Skin sensitization test </ANSWER>\n\nReason: The skin sensitization test is the most straightforward and direct way to rule out Neomycin sulfate, as it is known to be a sensitizer. By performing this test, we can confidently eliminate Neomycin sulfate from our list of potential compounds. This will help us narrow down the possibilities and move closer to identifying the correct compound.", "<ANSWER> CYP450 metabolism assay </ANSWER>\n\nReason: Since Neomycin sulfate has been ruled out by the skin sensitization test, we now need to determine which of the remaining compounds (Erythromycin, Saline solution, and Formaldehyde) is the correct one. The CYP450 metabolism assay is a good choice because Erythromycin is known to be a CYP450 inhibitor, which will help us eliminate Erythromycin if it does not show inhibition. This will leave us with either Saline solution or Formaldehyde as potential candidates, and we can further narrow it down based on the next test.", "<ANSWER> Eye irritation test </ANSWER>\n\nReason: Since the CYP450 metabolism assay ruled out Erythromycin, we are left with Saline solution and Formaldehyde. The next best test to differentiate between these two is the eye irritation test. Formaldehyde is known to be an irritant to the eyes, while Saline solution is not. Therefore, performing the eye irritation test will help us eliminate one of these compounds.", "<ANSWER> Saline solution </ANSWER>\n\nReason: The eye irritation test ruled out Formaldehyde as it is an irritant. This leaves us with Saline solution as the only remaining option. Since Saline solution is known to be non-irritating to the eyes, and all other tests have been performed and their outcomes have helped us eliminate the other compounds, Saline solution is the correct pharmaceutical compound."], "consumed_tokens": 5943, "observations": [null, {"action": "Skin sensitization test", "observation": "Sensitizer"}, {"action": "CYP450 metabolism assay", "observation": "No inhibition"}, {"action": "Eye irritation test", "observation": "Irritant"}], "successful": true, "parse_error": false}], "seed": 44, "average_actions": 4.2, "average_tokens": 4518.0, "average_correct": 0.6, "average_parse_error": 0.0, "average_successful_action_num": 4.333333333333333, "average_successful_tokens": 4740.333333333333}
{"trajectories": [{"actions": ["Ames mutagenicity test", "Acyclovir", {"predicted_truth": "Acyclovir"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>\n\nReason: The Ames mutagenicity test can help us rule out Acyclovir, as it is known to be a mutagen. By performing this test, we can quickly eliminate one of the four compounds from our list.", "<ANSWER> Acyclovir </ANSWER>\n\nReason: The Ames mutagenicity test resulted in a positive outcome, which rules out Acyclovir. Therefore, we can confidently eliminate Acyclovir from our list of possible compounds."], "consumed_tokens": 2258, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Positive"}], "successful": false, "parse_error": false}, {"actions": ["Ames mutagenicity test", "Solubility test", "Off-target activity screening", "Dose-response study", "In vitro enzyme inhibition assay", "Acyclovir", {"predicted_truth": "Acyclovir"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>", "<ANSWER> Solubility test </ANSWER>", "<ANSWER> Off-target activity screening </ANSWER>", "<ANSWER> Dose-response study </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Acyclovir </ANSWER>"], "consumed_tokens": 6947, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "Solubility test", "observation": "Poorly soluble"}, {"action": "Off-target activity screening", "observation": "High off-target activity"}, {"action": "Dose-response study", "observation": "Linear response"}, {"action": "In vitro enzyme inhibition assay", "observation": 11.48381775904468}], "successful": false, "parse_error": false}, {"actions": ["Ames mutagenicity test", "Solubility test", "Off-target activity screening", "Dose-response study", "High-throughput screening assay", "Acyclovir", {"predicted_truth": "Acyclovir"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>", "<ANSWER> Solubility test </ANSWER>", "<ANSWER> Off-target activity screening </ANSWER>", "<ANSWER> Dose-response study </ANSWER>", "<ANSWER> High-throughput screening assay </ANSWER>", "<ANSWER> Acyclovir </ANSWER>"], "consumed_tokens": 6931, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "Solubility test", "observation": "Poorly soluble"}, {"action": "Off-target activity screening", "observation": "High off-target activity"}, {"action": "Dose-response study", "observation": "Linear response"}, {"action": "High-throughput screening assay", "observation": "Inactive"}], "successful": false, "parse_error": false}, {"actions": ["Ames mutagenicity test", "Solubility test", "Off-target activity screening", "Dose-response study", "High-throughput screening assay", "In vitro enzyme inhibition assay", "Acyclovir", {"predicted_truth": "Acyclovir"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>", "<ANSWER> Solubility test </ANSWER>", "<ANSWER> Off-target activity screening </ANSWER>", "<ANSWER> Dose-response study </ANSWER>", "<ANSWER> High-throughput screening assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Acyclovir </ANSWER>"], "consumed_tokens": 8261, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "Solubility test", "observation": "Poorly soluble"}, {"action": "Off-target activity screening", "observation": "High off-target activity"}, {"action": "Dose-response study", "observation": "Linear response"}, {"action": "High-throughput screening assay", "observation": "Inactive"}, {"action": "In vitro enzyme inhibition assay", "observation": 11.48381775904468}], "successful": false, "parse_error": false}, {"actions": ["Ames mutagenicity test", "Solubility test", "Off-target activity screening", "Dose-response study", "High-throughput screening assay", "In vitro enzyme inhibition assay", "Acyclovir", {"predicted_truth": "Acyclovir"}], "generated_text": ["<ANSWER> Ames mutagenicity test </ANSWER>", "<ANSWER> Solubility test </ANSWER>", "<ANSWER> Off-target activity screening </ANSWER>", "<ANSWER> Dose-response study </ANSWER>", "<ANSWER> High-throughput screening assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> Acyclovir </ANSWER>"], "consumed_tokens": 8261, "observations": [null, {"action": "Ames mutagenicity test", "observation": "Positive"}, {"action": "Solubility test", "observation": "Poorly soluble"}, {"action": "Off-target activity screening", "observation": "High off-target activity"}, {"action": "Dose-response study", "observation": "Linear response"}, {"action": "High-throughput screening assay", "observation": "Inactive"}, {"action": "In vitro enzyme inhibition assay", "observation": 11.48381775904468}], "successful": false, "parse_error": false}], "seed": 45, "average_actions": 6.6, "average_tokens": 6531.6, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["CYP450 metabolism assay", "Ketoconazole", {"predicted_truth": "Ketoconazole"}], "generated_text": ["<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> Ketoconazole </ANSWER>\n\nGiven the observation of \"No inhibition\" from the CYP450 metabolism assay, we can rule out Ketoconazole. This leaves us with the compounds Isotretinoin, Furosemide, and Prednisone as potential candidates."], "consumed_tokens": 2213, "observations": [null, {"action": "CYP450 metabolism assay", "observation": "No inhibition"}], "successful": false, "parse_error": false}, {"actions": ["CYP450 metabolism assay", "Pharmacokinetics profiling", "Teratogenicity assessment", "Isotretinoin", {"predicted_truth": "Isotretinoin"}], "generated_text": ["<ANSWER> CYP450 metabolism assay </ANSWER>\n\nBy choosing the CYP450 metabolism assay, we can start by eliminating Ketoconazole if the outcome is \"No inhibition,\" as this assay is a key determinant for ruling out certain compounds based on their interaction with the cytochrome P450 enzyme system. This step will help narrow down the list of potential compounds.", "<ANSWER> Pharmacokinetics profiling </ANSWER>\n\nGiven the observation from the CYP450 metabolism assay was \"No inhibition,\" we can rule out Ketoconazole. Now, let's choose the Pharmacokinetics profiling to further narrow down the possibilities. If the outcome is \"Short half-life,\" we can rule out Furosemide. This step will help us identify the correct compound more accurately.", "<ANSWER> Teratogenicity assessment </ANSWER>\n\nGiven the previous observations, we have ruled out Ketoconazole and Furosemide. The remaining compounds are Isotretinoin and Prednisone. The next step is to choose the Teratogenicity assessment. If the outcome is \"Non-teratogenic,\" we can rule out Isotretinoin, leaving Prednisone as the correct compound.", "<ANSWER> Isotretinoin </ANSWER>\n\nGiven the observations:\n1. The CYP450 metabolism assay showed \"No inhibition,\" ruling out Ketoconazole.\n2. The Pharmacokinetics profiling showed a \"Short half-life,\" ruling out Furosemide.\n3. The Teratogenicity assessment showed \"Teratogenic,\" ruling out Isotretinoin.\n\nThis leaves us with Prednisone as the correct compound."], "consumed_tokens": 5232, "observations": [null, {"action": "CYP450 metabolism assay", "observation": "No inhibition"}, {"action": "Pharmacokinetics profiling", "observation": "Short half-life"}, {"action": "Teratogenicity assessment", "observation": "Teratogenic"}], "successful": true, "parse_error": false}, {"actions": ["CYP450 metabolism assay", "Isotretinoin", {"predicted_truth": "Isotretinoin"}], "generated_text": ["<ANSWER> CYP450 metabolism assay </ANSWER>\n\nI choose the CYP450 metabolism assay because it provides specific information that can help us rule out certain compounds based on the outcome. For instance, if the outcome is \"No inhibition,\" we can rule out Ketoconazole. This assay is particularly useful for identifying metabolic interactions and clearance, which are important characteristics of pharmaceutical compounds.", "<ANSWER> Isotretinoin </ANSWER>\n\nGiven the outcome of 'No inhibition' from the CYP450 metabolism assay, we can rule out Ketoconazole. This leaves us with the compounds Isotretinoin, Furosemide, and Prednisone. Since Isotretinoin is known to be metabolized by CYP450 enzymes and would typically show some form of inhibition, the 'No inhibition' result helps us rule it out. Therefore, the remaining plausible compound is Isotretinoin."], "consumed_tokens": 2399, "observations": [null, {"action": "CYP450 metabolism assay", "observation": "No inhibition"}], "successful": true, "parse_error": false}, {"actions": ["CYP450 metabolism assay", "Ketoconazole", {"predicted_truth": "Ketoconazole"}], "generated_text": ["<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> Ketoconazole </ANSWER>\n\nBased on the 'No inhibition' outcome from the CYP450 metabolism assay, we can rule out Ketoconazole. This leaves us with the compounds Isotretinoin, Furosemide, and Prednisone. Next, we can perform another assay to further narrow down the possibilities."], "consumed_tokens": 2224, "observations": [null, {"action": "CYP450 metabolism assay", "observation": "No inhibition"}], "successful": false, "parse_error": false}, {"actions": ["CYP450 metabolism assay", "Pharmacokinetics profiling", "Teratogenicity assessment", "Isotretinoin", {"predicted_truth": "Isotretinoin"}], "generated_text": ["<ANSWER> CYP450 metabolism assay </ANSWER>\n\nReason: Since Ketoconazole is known to inhibit CYP450 enzymes, performing this assay will help us quickly rule out Ketoconazole as a potential candidate. This is because if the outcome is \"No inhibition,\" we can definitively rule out Ketoconazole, which will help narrow down the list of possible compounds.", "<ANSWER> Pharmacokinetics profiling </ANSWER>\n\nReason: Since the CYP450 metabolism assay did not show inhibition with Ketoconazole, we can rule out Ketoconazole. Now, we have three compounds left: Isotretinoin, Furosemide, and Prednisone. The next step is to use a trial that will help us differentiate between these compounds. Pharmacokinetics profiling can help us by ruling out Furosemide if the outcome is \"Short half-life,\" as Furosemide is known to have a short half-life compared to the other compounds.", "<ANSWER> Teratogenicity assessment </ANSWER>\n\nReason: The observed short half-life from the Pharmacokinetics profiling rules out Furosemide. Now we are left with Isotretinoin and Prednisone. The Teratogenicity assessment will help us rule out Isotretinoin since it is known to be teratogenic (can cause birth defects), while Prednisone is not. If the outcome is \"Teratogenic,\" we can rule out Isotretinoin, leaving Prednisone as the remaining compound.", "<ANSWER> Isotretinoin </ANSWER>\n\nReason: The Teratogenicity assessment outcome is \"Teratogenic,\" which rules out Isotretinoin. This leaves us with Prednisone as the only remaining compound. Therefore, we can confidently identify the compound as Prednisone."], "consumed_tokens": 5367, "observations": [null, {"action": "CYP450 metabolism assay", "observation": "No inhibition"}, {"action": "Pharmacokinetics profiling", "observation": "Short half-life"}, {"action": "Teratogenicity assessment", "observation": "Teratogenic"}], "successful": true, "parse_error": false}], "seed": 46, "average_actions": 3.8, "average_tokens": 3487.0, "average_correct": 0.6, "average_parse_error": 0.0, "average_successful_action_num": 4.333333333333333, "average_successful_tokens": 4332.666666666667}
{"trajectories": [{"actions": ["In vitro enzyme inhibition assay", "Human clinical trial Phase I", "Placebo", {"predicted_truth": "Placebo"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay provides specific outcomes that can rule out certain compounds. For instance, it shows that Codeine and Lisinopril can be ruled out based on enzyme activity levels. This makes it a good starting point to narrow down the possibilities.", "Reasoning: Given the observation from the In vitro enzyme inhibition assay (79.50827212522373), we can use the guidebook to determine which compounds can be ruled out. The observation falls within the range where no compounds are ruled out, but we can use the specific ranges provided to make an informed decision.\n\nSince the observation is 79.50827212522373, which is between 0 and 100 units, we can rule out Codeine (as it is ruled out for enzyme activity above 1000 units) and Lisinopril (as it is ruled out for enzyme activity above 1000 units). This leaves us with Verapamil and Placebo.\n\nTo further narrow it down, we can choose the Human clinical trial Phase I as our next action, as it provides a clear outcome that can rule out Placebo.\n\n<ANSWER> Human clinical trial Phase I </ANSWER>", "Reasoning: Given the observation from the Human clinical trial Phase I (No adverse effects), we can use the guidebook to determine which compounds can be ruled out. The guidebook states that Placebo is ruled out if there are no adverse effects. Since there are no adverse effects, we can rule out Placebo.\n\n<ANSWER> Placebo </ANSWER>"], "consumed_tokens": 4336, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 79.50827212522373}, {"action": "Human clinical trial Phase I", "observation": "No adverse effects"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Human clinical trial Phase I", "Placebo", {"predicted_truth": "Placebo"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay provides clear outcomes that can help rule out certain compounds based on their effect on enzyme activity. Specifically, it indicates that Codeine and Lisinopril can be ruled out based on their enzyme activity levels. This makes it a strategic choice to narrow down the possibilities early in the process.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Since the In vitro enzyme inhibition assay ruled out Codeine and Lisinopril based on enzyme activity levels, we now know that the remaining compounds are Verapamil and Placebo. The next step is to use a clinical trial that can help us rule out one of these compounds. A Human clinical trial Phase I is suitable because it can provide information on safety and adverse effects, which can help us rule out Placebo as it has no active intervention.", "<ANSWER> Placebo </ANSWER>\n\nReason: Since the Human clinical trial Phase I showed no adverse effects, we can rule out Placebo as it is an inactive substance and should not have any therapeutic effects. This leaves us with Verapamil as the only remaining compound."], "consumed_tokens": 4142, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 79.50827212522373}, {"action": "Human clinical trial Phase I", "observation": "No adverse effects"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Human clinical trial Phase I", "P-glycoprotein interaction assay", "Lisinopril", {"predicted_truth": "Lisinopril"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay is a good starting point because it can directly provide information about enzyme activity, which can help us rule out certain compounds. From the guidebook, we know that in this assay:\n- Enzyme activity (0-100 units): Rule Out: Codeine\n- Enzyme activity (100-1000 units): No compounds are ruled out.\n- Enzyme activity (1000-10,000 units): Rule Out: Lisinopril\n\nBy performing this assay, we can quickly rule out Codeine and Lisinopril, which will simplify our remaining options.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: Based on the observation from the in vitro enzyme inhibition assay (79.50827212522373 units), which falls within the range of 0-100 units, we can rule out Codeine. Now, we have three compounds left: Verapamil, Placebo, and Lisinopril. \n\nNext, we can perform a human clinical trial Phase I to further narrow down the possibilities. From the guidebook, this trial can help us rule out Placebo since it states that if there are no adverse effects, Placebo can be ruled out. This will leave us with Verapamil and Lisinopril, and we can then proceed with further tests to determine the correct compound.", "<ANSWER> Placebo </ANSWER>\n\nReason: Since the human clinical trial Phase I observed no adverse effects, we can rule out Placebo. This leaves us with the compounds Verapamil and Lisinopril. Next, we can perform the p-glycoprotein interaction assay to further narrow down the possibilities. From the guidebook, the p-glycoprotein interaction assay can help us rule out Verapamil if there is an inhibitor interaction.\n\n<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> Lisinopril </ANSWER>\n\nReason: The p-glycoprotein interaction assay observed an inhibitor interaction, which rules out Verapamil. This leaves us with Lisinopril as the only remaining compound."], "consumed_tokens": 6295, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 79.50827212522373}, {"action": "Human clinical trial Phase I", "observation": "No adverse effects"}, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Human clinical trial Phase I", "P-glycoprotein interaction assay", "Pharmacogenomics analysis", "Lisinopril", {"predicted_truth": "Lisinopril"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay is a good starting point because it provides clear outcomes that can rule out specific compounds. For instance, if the enzyme activity is in the range of 1000-10,000 units, Verapamil is ruled out. Similarly, if the enzyme activity is in the range of 0-100 units, Codeine is ruled out. This assay can quickly narrow down the possibilities and help identify the correct compound.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: The observation from the In vitro enzyme inhibition assay shows an enzyme activity of 79.50827212522373, which does not fall into the ranges that would rule out specific compounds. Therefore, we should move to another type of trial to gather more information. The Human clinical trial Phase I can provide insights into the safety profile of the remaining compounds, helping us to rule out Placebo (as it shows no adverse effects).", "<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: Since the Human clinical trial Phase I showed no adverse effects, we can rule out Placebo. Now we are left with Verapamil, Codeine, and Lisinopril. The next best step is to perform the P-glycoprotein interaction assay, as it can rule out Verapamil based on the outcome.", "<ANSWER> Pharmacogenomics analysis </ANSWER>\n\nReason: The P-glycoprotein interaction assay ruled out Verapamil as it showed an inhibitor interaction. Now we are left with Codeine and Lisinopril. The next best step is to perform the Pharmacogenomics analysis, as it can rule out Codeine based on the observed genetic impact.", "<ANSWER> Lisinopril </ANSWER>\n\nReason: The Pharmacogenomics analysis ruled out Codeine since there was no genetic impact. This leaves us with Lisinopril and Placebo. Since Placebo was already ruled out in the Human clinical trial Phase I, the remaining compound is Lisinopril."], "consumed_tokens": 7709, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 79.50827212522373}, {"action": "Human clinical trial Phase I", "observation": "No adverse effects"}, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}, {"action": "Pharmacogenomics analysis", "observation": "No genetic impact"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "P-glycoprotein interaction assay", "Human clinical trial Phase I", "Codeine", {"predicted_truth": "Codeine"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay can provide immediate information that rules out certain compounds based on their effect on enzyme activity. Specifically, it can rule out Codeine and Lisinopril, which makes it an effective first step in narrowing down the possibilities.", "<ANSWER> P-glycoprotein interaction assay </ANSWER>\n\nReason: Since the in vitro enzyme inhibition assay has ruled out Codeine and Lisinopril, we now have Verapamil and Placebo as potential candidates. The P-glycoprotein interaction assay can rule out Verapamil, leaving us with Placebo as the most likely compound. However, since we are not yet ready to predict the truth, we will choose another relevant assay to further narrow down the options. The P-glycoprotein interaction assay is a good choice as it can rule out Verapamil.", "<ANSWER> Human clinical trial Phase I </ANSWER>\n\nReason: The P-glycoprotein interaction assay has ruled out Verapamil. Now we are left with Codeine and Placebo. The human clinical trial Phase I can rule out Placebo since it has no adverse effects. By performing this trial, we can confidently identify the remaining compound.", "<ANSWER> Codeine </ANSWER>\n\nReason: The human clinical trial Phase I ruled out Placebo due to the absence of adverse effects. Since Placebo was eliminated and the P-glycoprotein interaction assay ruled out Verapamil, the remaining compounds are Codeine and Lisinopril. The cardiac function test can help rule out Lisinopril, but since there is no further information needed to distinguish between Codeine and Lisinopril after the previous steps, we can predict that the remaining compound is Codeine."], "consumed_tokens": 5806, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 79.50827212522373}, {"action": "P-glycoprotein interaction assay", "observation": "Inhibitor"}, {"action": "Human clinical trial Phase I", "observation": "No adverse effects"}], "successful": false, "parse_error": false}], "seed": 47, "average_actions": 4.8, "average_tokens": 5657.6, "average_correct": 0.4, "average_parse_error": 0.0, "average_successful_action_num": 5.5, "average_successful_tokens": 7002.0}
{"trajectories": [{"actions": ["In vitro enzyme inhibition assay", "Lisinopril", {"predicted_truth": "Lisinopril"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay can help us rule out Lisinopril based on its inhibition range. This will help us narrow down the list of possible compounds and move closer to identifying the correct one.", "Observation from previous action: The in vitro enzyme inhibition assay yielded an inhibition range of 5437.7227041412 nM, which falls within the range of 1,000 to 10,000 nM. According to the guidebook, this range specifically rules out Lisinopril.\n\n<ANSWER> Lisinopril </ANSWER>"], "consumed_tokens": 2485, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 5437.7227041412}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "CYP450 metabolism assay", "P-glycoprotein interaction assay", "Cardiac function test", "Metabolic stability assay", "Dose-response study", "Lisinopril", {"predicted_truth": "Lisinopril"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> P-glycoprotein interaction assay </ANSWER>", "<ANSWER> Cardiac function test </ANSWER>", "<ANSWER> Metabolic stability assay </ANSWER>", "<ANSWER> Dose-response study </ANSWER>", "<ANSWER> Lisinopril </ANSWER>\n\nBased on the observations from the clinical trials:\n\n1. The in vitro enzyme inhibition assay showed an inhibition range of 5437.72 nM, which did not rule out any compounds directly.\n2. The CYP450 metabolism assay showed Clarithromycin is a strong inhibitor, ruling it out.\n3. The P-glycoprotein interaction assay showed no interaction, ruling out Diltiazem.\n4. The cardiac function test showed cardiotoxic effects, ruling out Lisinopril.\n5. The metabolic stability assay showed stability, which did not rule out any compounds (since Lisinopril is known to be unstable, this observation aligns with our exclusion of Lisinopril).\n6. The dose-response study showed a non-linear response, ruling out Phenytoin.\n\nThus, the only remaining compound is Clarithromycin."], "consumed_tokens": 9190, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 5437.7227041412}, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "P-glycoprotein interaction assay", "observation": "No interaction"}, {"action": "Cardiac function test", "observation": "Cardiotoxic"}, {"action": "Metabolic stability assay", "observation": "Stable"}, {"action": "Dose-response study", "observation": "Non-linear response"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "CYP450 metabolism assay", "P-glycoprotein interaction assay", "Cardiac function test", "Phenytoin", {"predicted_truth": "Phenytoin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay provides specific outcome observations that can rule out certain compounds based on their enzyme inhibition range. This trial can help us eliminate Lisinopril, which does not fit within the inhibition range of 1,000 to 10,000 nM. By performing this assay, we can narrow down the list of potential compounds more effectively.", "Reasoning: Given the observation of 5437.7227041412 nM from the in vitro enzyme inhibition assay, we can see that this value falls within the range of 1,000 to 10,000 nM. According to the guidebook, this range rules out Lisinopril. Now we need to further narrow down the possibilities by selecting another relevant trial.\n\n<ANSWER> CYP450 metabolism assay </ANSWER>", "Reasoning: Since the CYP450 metabolism assay observation is 'Strong inhibitor', Clarithromycin is ruled out as it is confirmed to be a strong inhibitor of CYP450 enzymes. This leaves us with three potential compounds: Lisinopril, Diltiazem, and Phenytoin. The next logical step is to perform another trial to further narrow down the possibilities. The P-glycoprotein interaction assay is a good choice because it can help rule out Diltiazem based on its interaction with P-glycoprotein.\n\n<ANSWER> P-glycoprotein interaction assay </ANSWER>", "Reasoning: The observation from the P-glycoprotein interaction assay shows 'No interaction', which rules out Diltiazem. Now, we are left with only two potential compounds: Lisinopril and Phenytoin. The next logical step is to perform the cardiac function test to further narrow down the possibilities. Since Lisinopril does not cause cardiotoxic effects, a negative cardiac function test will rule out Lisinopril and confirm Phenytoin.\n\n<ANSWER> Cardiac function test </ANSWER>", "Reasoning: The observation from the cardiac function test shows 'Cardiotoxic', which rules out Lisinopril. However, since we need to identify the remaining compound and we have already ruled out Lisinopril and Diltiazem, the only remaining compound is Phenytoin. Therefore, we can conclude that the correct pharmaceutical compound is Phenytoin.\n\n<ANSWER> Phenytoin </ANSWER>"], "consumed_tokens": 7578, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 5437.7227041412}, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "P-glycoprotein interaction assay", "observation": "No interaction"}, {"action": "Cardiac function test", "observation": "Cardiotoxic"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Diltiazem", {"predicted_truth": "Diltiazem"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The in vitro enzyme inhibition assay provides specific outcomes that can help rule out certain compounds based on their inhibition range. Since the assay outcome can definitively rule out Lisinopril, it is a good starting point to narrow down the list of possible compounds.", "Reasoning: Given the observation of 5437.7227041412 nM from the in vitro enzyme inhibition assay, this value falls within the range of 1,000 to 10,000 nM, which specifically rules out Lisinopril. Therefore, we can now focus on the remaining compounds: Diltiazem, Phenytoin, and Clarithromycin.\n\n<ANSWER> Diltiazem </ANSWER>"], "consumed_tokens": 2523, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 5437.7227041412}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "CYP450 metabolism assay", "P-glycoprotein interaction assay", "Phenytoin", {"predicted_truth": "Phenytoin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: Starting with the in vitro enzyme inhibition assay can provide initial insights into the potential enzyme inhibition range of the compounds. This assay can help rule out Lisinopril, which has an inhibition range of 1,000 to 10,000 nM, thus narrowing down the list of potential compounds.", "Reasoning: The observation of 5437.7227041412 nM from the in vitro enzyme inhibition assay indicates that the compound inhibits the enzyme within the range of 1,000 to 10,000 nM, which rules out Lisinopril. This leaves us with Diltiazem, Phenytoin, and Clarithromycin as potential compounds. To further narrow down the options, we can perform the CYP450 metabolism assay, as Clarithromycin is known to be a strong inhibitor of CYP450 enzymes.\n\n<ANSWER> CYP450 metabolism assay </ANSWER>", "Reasoning: The observation that the compound is a strong inhibitor of CYP450 enzymes rules out Clarithromycin. This leaves us with Diltiazem and Phenytoin. To further narrow down the options, we can perform the P-glycoprotein interaction assay. If there is no interaction observed, Diltiazem is ruled out, and Phenytoin remains as the most likely candidate.\n\n<ANSWER> P-glycoprotein interaction assay </ANSWER>", "Reasoning: Since there is no interaction observed in the P-glycoprotein interaction assay, Diltiazem is ruled out. This leaves us with Phenytoin as the most likely candidate. We can now predict the truth based on the remaining compound.\n\n<ANSWER> Phenytoin </ANSWER>"], "consumed_tokens": 5749, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 5437.7227041412}, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "P-glycoprotein interaction assay", "observation": "No interaction"}], "successful": true, "parse_error": false}], "seed": 48, "average_actions": 5.0, "average_tokens": 5505.0, "average_correct": 0.4, "average_parse_error": 0.0, "average_successful_action_num": 5.5, "average_successful_tokens": 6663.5}
{"trajectories": [{"actions": ["In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "CYP450 metabolism assay", "Omeprazole", {"predicted_truth": "Omeprazole"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nBased on the observation from the In vitro enzyme inhibition assay (outcome: 73.3744889835985), we can rule out Codeine since the outcome falls within the range that indicates enzyme inhibition. Codeine is ruled out because the result is not in the range of 0-100, which would confirm it as an inhibitor. Now, we need to narrow down between Omeprazole, Erythromycin, and Neomycin sulfate. Next, we can perform another assay to further eliminate one of these compounds.", "<ANSWER> CYP450 metabolism assay </ANSWER>\n\nGiven the initial observation from the In vitro enzyme inhibition assay, we have ruled out Codeine. Next, we can use the CYP450 metabolism assay to further narrow down the possibilities. Omeprazole is known to be a strong inhibitor of CYP450 enzymes, so if the assay indicates strong inhibition, we can rule it out. Erythromycin and Neomycin sulfate are less likely to show strong inhibition in this assay.\n\n<ANSWER> CYP450 metabolism assay </ANSWER>", "<ANSWER> Omeprazole </ANSWER>\n\nBased on the observation from the CYP450 metabolism assay, which indicated that the compound is a strong inhibitor, we can rule out Omeprazole. Now, we are left with Erythromycin and Neomycin sulfate. Since the CYP450 metabolism assay did not rule out Erythromycin (as it is not a strong inhibitor in this assay), and there is no other strong evidence against Neomycin sulfate from the previous assays, we can predict that the remaining compound is Erythromycin."], "consumed_tokens": 5495, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 73.3744889835985}, {"action": "In vitro enzyme inhibition assay", "observation": 73.3744889835985}, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}], "successful": false, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "In vitro enzyme inhibition assay", "CYP450 metabolism assay", "Erythromycin", {"predicted_truth": "Erythromycin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay can help us eliminate Codeine if its results fall within the specified range (0-100). This will provide us with an early indication of which compounds can be ruled out based on their enzyme inhibitory effects.", "<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: Since the In vitro enzyme inhibition assay result is 73.3744889835985, which falls within the range (0-100), Codeine can be ruled out. This step helps us narrow down the potential compounds and brings us closer to identifying the correct pharmaceutical compound.", "<ANSWER> CYP450 metabolism assay </ANSWER>\n\nReason: Since Codeine has been ruled out, we can now focus on the remaining compounds: Omeprazole, Erythromycin, and Neomycin sulfate. The CYP450 metabolism assay can help us rule out Omeprazole if it shows strong inhibition, as Omeprazole is a known CYP450 inhibitor. This will further narrow down our options.", "<ANSWER> Erythromycin </ANSWER>\n\nReason: Since Omeprazole has been ruled out as a strong CYP450 inhibitor, we are left with Erythromycin, Neomycin sulfate. The next step is to use the Skin sensitization test to rule out Neomycin sulfate, as it is known to cause skin sensitization. However, since the options are limited, we can infer that the remaining compound is Erythromycin."], "consumed_tokens": 5475, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 73.3744889835985}, {"action": "In vitro enzyme inhibition assay", "observation": 73.3744889835985}, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "Skin sensitization test", "CYP450 metabolism assay", "Pharmacogenomics analysis", "Cytokine release assay", "Erythromycin", {"predicted_truth": "Erythromycin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay can help us rule out compounds that have a certain level of enzyme inhibition. This assay is particularly useful for eliminating Codeine and Omeprazole, as their outcomes in this assay fall into specific ranges provided in the guidebook. By performing this assay, we can quickly eliminate at least two compounds and narrow down our options.", "<ANSWER> Skin sensitization test </ANSWER>\n\nReason: Given the observation from the In vitro enzyme inhibition assay (73.3744889835985), which falls within the range that does not rule out any compounds directly, the next best step is to perform the Skin sensitization test. This test will help us eliminate Neomycin sulfate if it causes skin sensitization, further narrowing down our options.", "<ANSWER> CYP450 metabolism assay </ANSWER>\n\nReason: The observation from the Skin sensitization test indicates that Neomycin sulfate is a sensitizer. Since Neomycin sulfate is now ruled out, we are left with Codeine, Omeprazole, and Erythromycin. The CYP450 metabolism assay can help us rule out Omeprazole since it is a known CYP450 inhibitor. If Omeprazole is ruled out, we will be left with Codeine and Erythromycin, and we can further test with the Cytokine release assay or QT prolongation assessment to identify the remaining compound. However, the CYP450 metabolism assay is a more direct step to rule out Omeprazole.", "<ANSWER> Pharmacogenomics analysis </ANSWER>\n\nReason: Since Omeprazole has been ruled out as a strong CYP450 inhibitor, we are left with Codeine and Erythromycin. The next step is to perform the Pharmacogenomics analysis to determine if there is any genetic impact. Codeine is known to show no genetic impact, which would rule it out, leaving Erythromycin as the remaining compound.", "<ANSWER> Cytokine release assay </ANSWER>\n\nReason: Since the Pharmacogenomics analysis has ruled out Codeine, we are left with Erythromycin and Neomycin sulfate. The Cytokine release assay can help us determine if Erythromycin causes high cytokine release, which would confirm Erythromycin as the compound. If it does not cause high cytokine release, Neomycin sulfate would be ruled out, and Erythromycin would be the remaining compound.", "<ANSWER> Erythromycin </ANSWER>"], "consumed_tokens": 9332, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 73.3744889835985}, {"action": "Skin sensitization test", "observation": "Sensitizer"}, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "Pharmacogenomics analysis", "observation": "No genetic impact"}, {"action": "Cytokine release assay", "observation": "High cytokine release"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "CYP450 metabolism assay", "Skin sensitization test", "Pharmacogenomics analysis", "Cytokine release assay", "Erythromycin", {"predicted_truth": "Erythromycin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay can help us rule out certain compounds based on their effect on enzyme activity. This assay is a good starting point to eliminate compounds that do not match the observed outcomes.", "<ANSWER> CYP450 metabolism assay </ANSWER>\n\nReason: Since the In vitro enzyme inhibition assay ruled out Codeine (as the result is within the range that would identify it as an inhibitor), we can proceed to the next assay. The CYP450 metabolism assay can help us rule out Omeprazole, as it is a strong inhibitor of CYP450 enzymes.", "<ANSWER> Skin sensitization test </ANSWER>\n\nReason: Since Omeprazole is ruled out as a strong inhibitor in the CYP450 metabolism assay, we can now rule out Neomycin sulfate using the Skin sensitization test. Neomycin sulfate is known to cause skin sensitization, so if the test indicates sensitization, Neomycin sulfate can be ruled out.", "<ANSWER> Pharmacogenomics analysis </ANSWER>\n\nReason: Since Neomycin sulfate has been ruled out by the Skin sensitization test, the only remaining compounds are Codeine and Erythromycin. The Pharmacogenomics analysis can help us determine if either of these compounds have any genetic impact, which would rule out Codeine.", "<ANSWER> Cytokine release assay </ANSWER>\n\nReason: Since both Codeine and Erythromycin have shown no genetic impact, we need to further differentiate between them. The Cytokine release assay can help us determine if Codeine causes high cytokine release, which would rule it out.", "<ANSWER> Erythromycin </ANSWER>\n\nReason: The observation from the Cytokine release assay shows high cytokine release, which rules out Codeine. Since all other compounds have been ruled out, the remaining compound must be Erythromycin."], "consumed_tokens": 8659, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 73.3744889835985}, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "Skin sensitization test", "observation": "Sensitizer"}, {"action": "Pharmacogenomics analysis", "observation": "No genetic impact"}, {"action": "Cytokine release assay", "observation": "High cytokine release"}], "successful": true, "parse_error": false}, {"actions": ["In vitro enzyme inhibition assay", "CYP450 metabolism assay", "Skin sensitization test", "Pharmacogenomics analysis", "QT prolongation assessment", "Erythromycin", {"predicted_truth": "Erythromycin"}], "generated_text": ["<ANSWER> In vitro enzyme inhibition assay </ANSWER>\n\nReason: The In vitro enzyme inhibition assay can help us rule out Codeine if the results fall within the specified range (0-100). This assay is a good starting point to eliminate one of the compounds based on the provided outcomes.", "<ANSWER> CYP450 metabolism assay </ANSWER>\n\nReason: Since the In vitro enzyme inhibition assay ruled out Codeine (as the observed value 73.3744889835985 falls within the range of 0-100), we can now use the CYP450 metabolism assay to rule out Omeprazole. If Omeprazole is a strong inhibitor, it will be ruled out based on the outcome.", "<ANSWER> Skin sensitization test </ANSWER>\n\nReason: Since Omeprazole has been ruled out as a strong inhibitor in the CYP450 metabolism assay, we can now use the Skin sensitization test to rule out Neomycin sulfate. If Neomycin sulfate causes skin sensitization, it will be ruled out based on the outcome.", "<ANSWER> Pharmacogenomics analysis </ANSWER>\n\nReason: Since Neomycin sulfate has been ruled out as a sensitizer in the Skin sensitization test, the only compound left is Erythromycin. We can use the Pharmacogenomics analysis to confirm that Erythromycin does not show any genetic impact, thereby identifying Erythromycin as the correct compound.", "<ANSWER> QT prolongation assessment </ANSWER>\n\nReason: Since all other possibilities have been ruled out, we can now use the QT prolongation assessment to confirm that Erythromycin does not prolong the QT interval. If it does not prolong the QT interval, Erythromycin is the correct compound.", "<ANSWER> Erythromycin </ANSWER>\n\nReason: Based on the observations from all the clinical trials and bioassays, we have ruled out Codeine, Omeprazole, and Neomycin sulfate. The only remaining compound is Erythromycin. The QT prolongation assessment showed no effect on QT, which confirms that Erythromycin is the correct compound."], "consumed_tokens": 8822, "observations": [null, {"action": "In vitro enzyme inhibition assay", "observation": 73.3744889835985}, {"action": "CYP450 metabolism assay", "observation": "Strong inhibitor"}, {"action": "Skin sensitization test", "observation": "Sensitizer"}, {"action": "Pharmacogenomics analysis", "observation": "No genetic impact"}, {"action": "QT prolongation assessment", "observation": "No effect on QT"}], "successful": true, "parse_error": false}], "seed": 49, "average_actions": 6.2, "average_tokens": 7556.6, "average_correct": 0.8, "average_parse_error": 0.0, "average_successful_action_num": 6.5, "average_successful_tokens": 8072.0}
